TW201806596A - Antiviral agents - Google Patents

Abstract

Described herein are substituted phenyl-heteroaryl-aryl compounds, and corresponding methods, pharmaceutical compositions, and kits directed to antiviral therapy. The antiviral activity of the compounds is tolerant of a wide diversity of viral serotypes and species, being effective against Zika virus; Japanese encephalitis virus; dengue virus strains: DENV1 Hawaii, DENV2 PL046, DENV3 H087, and DENV4 H241; and influenza H1N1. Further, the antiviral activity of the compounds may be independent on the type of infected host cell. Accordingly, the antiviral activity of the described compounds, methods, pharmaceutical compositions, and kits may be generally applicable to a wide range of human and animal viral pathogens.

Description

Antiviral agent

The present application claims priority to U.S. Provisional Patent Application No. 62/369,550, filed on Aug. 1, the entire disclosure of which is hereby incorporated by reference.

Human dengue virus (DENV) infection can cause a broad spectrum of diseases including mild dengue fever, severe dengue hemorrhagic fever and life-threatening dengue shock syndrome. DENV may be transmitted by Aedes mosquitoes, and more than 40% of the population living in tropical and subtropical regions are at risk of DENV infection. The World Health Organization estimates the prevalence of between 50 million and 100 million cases of DENV infection each year; however, recent studies have shown 390 million cases of DENV infection each year. Although efforts have been made to reduce mortality in recent years, the recurrence and increased prevalence of dengue fever has been a major socio-economic impact in epidemic countries.

This application understands that effective treatment of viral infections can be a challenging task.

In one embodiment, a method of antiviral therapy is provided. The method can include providing a subject who may be at risk of or at risk of infection with the virus. The method can comprise administering to the subject a compound in an amount effective to reduce viral infection in the subject, the compound being represented by Structural Formula (I) : (I) And pharmaceutically acceptable salts thereof. R ¹ may be H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. R ² may be H, and R ³ may be: sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl, β-aminocarbonyl, γ-amino group Carbonyl, α-β-unsaturated carbonyl, hydrazine or urea. Alternatively, the aniline nitrogen, R ² and R ^{3 of} formula (I) may together form an optionally substituted heterocyclic group. Ar may be an optionally substituted aryl or heteroaryl group consisting of 1, 2, 3 or 4 rings which may be one or more of a linked ring and a fused ring. Het may be a heteroaryl group including a first ring which may be a nitrogen-containing five- or six-membered heteroaryl group. The first ring may be fused to one or more of the second ring and the third ring to form a characteristic that the first ring, the second ring, and the third ring are present in 8, 9, 10, 11 , a 12 or 13 ring atom of a bicyclic or tricyclic heteroaryl group. R ¹ and benzene ring A may be bonded to the first ring, and Ar may be bonded to the first ring, the second ring or the third ring. In some embodiments, when the compound is 2-amino- N- [4-[5-phenanthr-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide The virus is not one of the following: Ebola, Marburg, Reisar fever, Hepatitis A, Hepatitis B, serotype 5 adenovirus, Coxsackie virus B4, euthania, mumps, measles, Rubella, respiratory fusion virus a, respiratory fusion virus b, cytomegalovirus, influenza A and influenza B.

In another embodiment, a compound is provided. A compound can be represented by structural formula (I) : (I) And pharmaceutically acceptable salts thereof. R ¹ may be H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. R ² may be H, and R ³ may be: sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl, β-aminocarbonyl, γ-amino group a carbonyl group, an α-β-unsaturated carbonyl group, a hydrazine or a urea; or an aniline nitrogen of the formula (I) , R ² and R ³ may together form an optionally substituted heterocyclic group; Ar may be 1, 2, 3 Or an optionally substituted aryl or heteroaryl group of 4 rings which may be one or more of a linked ring and a fused ring; Het may comprise a heteroaryl group of the first ring, The heteroaryl group may be a nitrogen-containing five- or six-membered heteroaryl group, and the first ring is optionally fused to one or more of the second ring and the third ring to form 8, 9, 10, 11 a bicyclic or tricyclic heteroaryl group consisting of 12 or 13 ring atoms, wherein R ¹ and benzene ring A may be bonded to the first ring, and Ar may be bonded to the first ring, the second ring or The third ring. When the compound is represented by: (I') One or more of the following: R ¹ ' may be H, cycloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro; Ar' may be optionally substituted and may be as follows One of them: thick tetraphenyl, propylene naphthalene, sulfhydryl, Phenyl, morphinyl, acridinyl, phenanthrene Base, carbazolyl, dibenzofuranyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, bipyridyl, pyridyl, pyridyl , pyrimidinyl, fluorenyl, benzimidazolyl, benzoxazolyl, benzofuranyl and fluorenyl; R ² ' may be H, and R ³ ' may be sulfonamide, sulfinamide, An alkylamino hydrazine, an alkylamino hydrazide, an α-aminocarbonyl group other than glycine, a β-aminocarbonyl group, a γ-aminocarbonyl group, or an α-β-unsaturated carbonyl group; or R ² , R ³ and the aniline nitrogen of formula (I') may together form an optionally substituted heterocyclic group.

In one embodiment, a pharmaceutical composition is provided. The pharmaceutical composition can include a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition may include a compound represented by the formula (I) : (I) And pharmaceutically acceptable salts thereof. R ¹ may be H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. R ² may be H, and R ³ may be: sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl, β-aminocarbonyl, γ-amino group A carbonyl group, an α-β-unsaturated carbonyl group, a hydrazine or a urea; or R ² , R ³ and an aniline nitrogen of the formula (I) may together form an optionally substituted heterocyclic group. Ar may be an optionally substituted aryl or heteroaryl group consisting of 1, 2, 3 or 4 rings which may be one or more of a linked ring and a fused ring. Het may be a heteroaryl group including a first ring which may be a nitrogen-containing five- or six-membered heteroaryl group. The first ring may optionally be fused to one or more of the second ring and the third ring to form a bicyclic or tricyclic heteroaryl group characterized by 8, 9, 10, 11, 12 or 13 ring atoms. . R ¹ and benzene ring A may be bonded to the first ring, and Ar may be bonded to the first ring, the second ring or the third ring. When the compound is represented by the structural formula (I') : (I') There may be one or more of the following items. R ¹ ' may be H, cycloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. Ar' may be substituted as appropriate, and may be one of the following: fused tetraphenyl, propylene naphthalene, fluorenyl, Phenyl, morphinyl, acridinyl, phenanthrene Base, carbazolyl, dibenzofuranyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, bipyridyl, pyridyl, pyridyl A group, a pyrimidinyl group, a fluorenyl group, a benzimidazolyl group, a benzoxazolyl group, a benzofuranyl group and a fluorenyl group. R ² ' may be H, and R ³ ' may be sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazine, α-aminocarbonyl other than glycine, β-amine A carbonyl group, a γ-aminocarbonyl group or an α-β-unsaturated carbonyl group. Alternatively, the aniline nitrogen, R ² and R ^{3 of} formula (I') may together form an optionally substituted heterocyclic group.

In another embodiment, a kit is provided. The kit can include compounds and instructions. This specification can guide the user to provide a subject who may be at risk of or at risk of infection with the virus. The instructions can direct the user to administer the compound to the subject in an amount effective to reduce viral infection. A compound can be represented by structural formula (I) : (I) And pharmaceutically acceptable salts thereof. R ¹ may be H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. R ² may be H, and R ³ may be: sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl, β-aminocarbonyl, γ-amino group A carbonyl group, an α-β-unsaturated carbonyl group, a hydrazine or a urea; or R ² , R ³ and an aniline nitrogen of the formula (I) may together form an optionally substituted heterocyclic group. Ar may be an optionally substituted aryl or heteroaryl group consisting of 1, 2, 3 or 4 rings which may be one or more of a linked ring and a fused ring. Het may be a heteroaryl group including a first ring which may be a nitrogen-containing five- or six-membered heteroaryl group. The first ring may optionally be fused to one or more of the second ring and the third ring to form a bicyclic or tricyclic heteroaryl group characterized by 8, 9, 10, 11, 12 or 13 ring atoms. . R ¹ and benzene ring A may be bonded to the first ring, and Ar may be bonded to the first ring, the second ring or the third ring. When the compound is represented by the structural formula (I') : (I') There may be one or more of the following items. R ¹ ' may be H, cycloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. Ar' may be substituted as appropriate, and may be one of the following: fused tetraphenyl, propylene naphthalene, fluorenyl, Phenyl, morphinyl, acridinyl, phenanthrene Base, carbazolyl, dibenzofuranyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, bipyridyl, pyridyl, pyridyl A group, a pyrimidinyl group, a fluorenyl group, a benzimidazolyl group, a benzoxazolyl group, a benzofuranyl group and a fluorenyl group. R ² ' may be H, and R ³ ' may be sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazine, α-aminocarbonyl other than glycine, β-amine A carbonyl group, a γ-aminocarbonyl group or an α-β-unsaturated carbonyl group. Alternatively, the aniline nitrogen, R ² and R ^{3 of} formula (I') may together form an optionally substituted heterocyclic group.

Described herein are compounds, methods, pharmaceutical compositions, and kits for antiviral therapies. Without wishing to be bound by theory, it is believed that the compounds are targeted to infected or infectible host cells rather than viruses. Such compounds may act to inhibit enzymes that promote viral replication in infected cells such as GRP78, BiP and HSPA5 or the like. These compounds can destroy viral receptors on some host cells and block the entry of viruses into such cells. As shown by the examples and the data in the figures , the antiviral activity of these compounds can be used for a wide variety of viral serotypes and species, against Zika virus; Japanese encephalitis virus; following dengue virus strains: DENV1 Hawaii, DENV2 PL046, DENV3 H087 and DENV4 H241; and influenza virus H1N1 are effective. Moreover, the antiviral activity of such compounds is independent of the type of infected host cell. Thus, the antiviral activity of the compounds, methods, pharmaceutical compositions and kits is generally applicable to most or all human and animal viral pathogens.

In various embodiments, a method of antiviral therapy is provided. The method can include providing a subject who may be at risk of or at risk of infection with the virus. The method can comprise administering to the subject a compound in an amount effective to reduce viral infection in the subject, the compound being represented by Structural Formula (I) : (I) And pharmaceutically acceptable salts thereof. R ¹ may be H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. R ² may be H, and R ³ may be: sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl, β-aminocarbonyl, γ-amino group Carbonyl, α-β-unsaturated carbonyl, hydrazine or urea. Alternatively, the aniline nitrogen, R ² and R ^{3 of} formula (I) may together form an optionally substituted heterocyclic group. Ar may be an optionally substituted aryl or heteroaryl group consisting of 1, 2, 3 or 4 rings which may be one or more of a linked ring and a fused ring. Het may be a heteroaryl group including a first ring which may be a nitrogen-containing five- or six-membered heteroaryl group. The first ring may be fused to one or more of the second ring and the third ring to form a characteristic that the first ring, the second ring, and the third ring are present in 8, 9, 10, 11 , a 12 or 13 ring atom of a bicyclic or tricyclic heteroaryl group. R ¹ and benzene ring A may be bonded to the first ring, and Ar may be bonded to the first ring, the second ring or the third ring. In some embodiments, when the compound is 2-amino- N- [4-[5-phenanthr-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide The virus is not one of the following: Ebola, Marburg, Reisar fever, Hepatitis A, Hepatitis B, serotype 5 adenovirus, Coxsackie virus B4, euthania, mumps, measles, Rubella, respiratory fusion virus a, respiratory fusion virus b, cytomegalovirus, influenza A and influenza B.

In several embodiments, the subject may be infected with a virus. The method can include administering to the subject an amount of the compound in an amount effective to reduce one or more symptoms of the viral infection in the subject. The subject may be at risk of a viral infection. The method can include administering a compound to the subject in an amount effective to reduce viral infection in the subject.

In various embodiments, the subject can include cells capable of exhibiting one of: GRP78, BiP, and HSPA5. These cells may be infected by or at risk of viral infection. The compound can effectively modulate one of the following: GRP78, BiP and HSPA5, which effectively alleviate viral infection of such cells.

In several embodiments, the amount of the composition administered to the subject can be directed to the amount of the compound (eg, active ingredient) administered by the subject. The amount of the composition or compound can include about 2.5 mg per kg body weight of the subject. The amount of the composition or compound administered to the subject can include less than about 5 mg per kg of body weight of the subject. The amount of the composition administered to the subject may include at least about one or more of the following items in mg/kg: 0.01, 0.05, 0.1, 0.3, 0.5, 0.7, 1.0, 1.25, 1.5, 1.8, 2.0, 2.3, 2.5, 3.0, 5.0, 10, 15, 20, 25, 50, 75 and 100, or any value or range between any of the foregoing values, for example about 2.75; between about 0.5 and about 2.5 Between, between about 3 and about 10 and the like. For example, the amount of the composition administered to the subject can include a range between about one or more of the following items in mg/kg: 1 and 5, 1 and 10, 1 and 15, 5 With 10, 5 and 15, and 5 and 20.

In some embodiments, the amount of the composition administered to the subject can include any of the amounts described herein and can be administered as a single dose. In some embodiments, the amount of the composition can be administered in a dosage of one or more of the following: a single dose, a daily dose, a weekly dose, a biweekly dose, a monthly dose, an annual dose, and the like. One or more of the amount and dose of the composition administered to the subject can be determined in one or more of the following: the stage of infection, the stage of progression of infection, and the stage of treatment response to the composition. One or more of the infection phase, the stage of infection progression, and the phase of the therapeutic response to the composition can be analyzed or monitored, for example, by IFA via cell and/or tissue extraction.

Compounds can be administered by one or more of the following: oral administration, intraperitoneal administration, intravenous administration, and intranasal administration. The amount of the composition or compound administered to the subject can be between about 1 mg and about 100 mg per kg body weight of the subject. The amount of the composition administered to the subject may be in the range of one or more of about the following items in mg/kg: 1 and 5, 1 and 10, 1 and 15, 5 with 10, 5 and 15, and 5 and 20. The subject can administer the compound at a dose of one or more of the following: a single dose, a daily dose, a weekly dose, a monthly dose, and an annual dose.

In several embodiments, the virus can belong to any taxonomic group including human or animal pathogens. For example, the virus can be tied by one of the following items: adenovirus family (Adenoviridae); Arenaviridae (Arenaviridae); arteritis virus family (Arteriviridae); asfarviridae (Asfarviridae); Astroviridae (Astroviridae ); Jan this virus family (Bunyaviridae); calicivirus Branch (Caliciviridae); circovirus Branch (Circoviridae); coronavirus family (Coronaviridae); filamentous virus family (Filoviridae); yellow fever virus family (Flaviviridae); liver Branch virus deoxyribonucleic acid (Hepadnaviridae); orthohepevirus (Hepeviridae); herpes virus family (Herpesviridae); orthomyxoviridae (Orthomyxoviridae); papillomavirus Branch (Papillomaviridae); Paramyxoviridae (Paramyxoviridae); small DNA virus family (Parvoviridae); Picornaviridae (Picornaviridae); polyomaviridae (Polyomaviridae); pox virus family (poxviridae); reoviridae (Reoviridae); retrovirus family (Retroviridae); rod Rhabdoviridae ; Togaviridae and the like. In some embodiments, the virus may belong to one of the following: adenoviridae; genus, genus, hepatic deoxyribonucleic acid; herpesviridae; paramyxoviridae; picornavirus; Clothing virus family; and filamentous virus family.

In various embodiments, the virus can be any virus known to be a human or animal pathogen. For example, the virus may belong to one of the following: an adenoviridae, such as an adenovirus; an adenine-thymidine-rich Atadenovirus , such as an adenine-thymidine-enriched adenovirus D; avian adenovirus Aviadenovirus , such as poultry adenovirus A; Ichtadenovirus , such as salmon adenovirus A; mammalian adenovirus ( Mastadenovirus ), such as human adenovirus species A, B, C, D, E, F and G; and salivary adenoviruses, such as frog salivary adenovirus A; arenaviruses, such as Reese fever virus; arteritis virus, such as equine arteritis virus, porcine reproductive and respiratory syndrome virus, elevated lactate dehydrogenase Virus and hemorrhagic fever virus; African swine fever virus family, such as African swine fever virus; Astrovirus family, such as human astrovirus; Bentoviridae, such as Crimean-Congo hemorrhagic fever virus and Hantavirus; Calicivirus family, such as Novak virus; circoviridae, such as gyrovirus, such as chicken anemia virus; and circovirus, such as type 1 and type 2 porcine ring disease , parrot feather disease virus, pigeon circovirus, canary ring virus, goose circovirus and postweaning multisystemic wasting syndrome; coronavirus family, such as severe acute respiratory syndrome virus; Torovirinae , such as Berne virus and Breda virus; human coronaviruses such as 229E, OC43, NL63 and HKU1; SARS-CoV; Middle Eastern respiratory syndrome coronavirus; avian infectious Bronchitis virus; porcine infectious gastroenteritis coronavirus; porcine epidemic diarrhea virus; bovine coronavirus; feline coronavirus; canine coronavirus; turkey coronavirus; sputum coronavirus; ferrets systemic coronavirus; Tropical canine coronavirus; filamentous virus family, such as Ebola virus and Marburg virus; yellow fever virus family, such as Zika virus, dengue virus, Japanese encephalitis virus, St. Louis encephalitis, West Nile virus, tick-borne encephalitis virus , hepatitis C virus, yellow fever virus, Israeli turkey meningoencephalitis virus, Sitiawan virus, Wesselsbron virus, louping ill virus and prions, such as bovine viral diarrhea virus 1; hepatic deoxyribonucleic acid family, such as hepatitis B virus; hepatitis virus family, for example Hepatitis E virus; herpesvirus family, such as herpes simplex virus type 1, herpes simplex virus type 2, varicella zoster virus, Epstein-Barr virus, cytomegalovirus, rose Rash virus, herpes lymphoblastic virus and human herpesvirus type 8; positive mucinous virus family, such as influenza A, such as serotypes H1N1, H1N2, H2N2, H3N2, H5N1, H7N2, H7N3, H7N7, H7N9, H9N2 and H10N7; influenza B, influenza C, avian influenza, swine influenza; papillomavirus family, such as human papillomavirus; paramyxoviridae, such as measles virus, mumps virus, parainfluenza virus, respiratory fusion virus; small DNA virus family, such as small DNA virus B19; picornavirus family, such as Coxsackie virus, hepatitis A virus, polio virus, rhinovirus and hand, foot and mouth disease virus; polyomavirus family, such as BK disease And JC virus; poxvirus family, such as smallpox; reoviridae, such as rotavirus; orbivirus, such as bluetongue virus; Colorado tick fever virus; and Banna virus; retroviridae, For example, human immunodeficiency virus, feline leukemia virus and feline immunodeficiency virus; baculovirus family, such as rabies virus and vesicular stomatitis virus; chlamydia family, such as typhus and rubella virus; and the like.

In some embodiments, the virus can be one of: adenovirus; rysal fever virus; hepatitis B virus; cytomegalovirus; influenza A virus; measles virus; rubella virus; mumps virus; Sexual virus; Coxsackie virus; Hepatitis A virus; Qugong disease; and Rubella virus.

In several embodiments, the virus may belong to the yellow fever virus family. For example, the virus can be one of the following: Zika virus, dengue virus, and Japanese encephalitis virus. The dengue virus can be one of the following serotypes: DENV1, DENV2, DENV3, DENV4, and DENV5. The dengue virus can be one of the following lines: DENV1 Hawaii, DENV2 PL046, DENV3 H087, and DENV4 H241. In various embodiments, the virus may belong to the family of the Orthomyxoviridae. For example, the virus can be an influenza virus, such as influenza H1N1.

In some embodiments, a method can include co-administering an antiviral agent to a subject. Antiviral drugs may include, for example, one or more of the following: abacavir; aciclovir; acyclovir; adefovir; amantadine (amantadine);ampranavir;ampligen;arbidol; atazanavir; atripla; balavir; Cidofovir; combivir; dolutegravir; darunavir; delavirdine; didanosine; docosane Alcohol (docosanol); edoxudine; efavirenz; emtricitabine; enfuvirtide; entecavir; ecoliever; famciclovir; Fomivirsen; fosamprenavir; foscarnet; fosfonet; fusion inhibitor; ganciclovir; ibacitabine; isoproterenol (imunovir); idoxuridine; imiquimod; indinavir; inosine; integrase inhibition Interferon, such as type I, II or III; lamivudine; lopinavir; loviride; maraviroc; moroxydine; Methisazone; nelfinavir; nevirapine; nexavir; nitazoxanide; nucleoside analogue; novir; oseltamivir Peginterferon alfa-2a; penciclovir; peramivir; pleconaril; podophyllotoxin; Protease inhibitor; raltegravir; reverse transcriptase inhibitor; ribavirin; rimantadine; ritonavir; pyramididine; saquinavir (saquinavir); sofosbuvir; stavudine; telaprevir; tenofovir; tenofovir disoproxil; Tipranavir; trifluridine; trizivir; tromantadine; Truvada Truvada); valaciclovir; valganciclovir; vicriviroc; vidarabine; viramidine; zalcitabine ); zanamivir; zidovudine; and the like.

In several embodiments, a method can include co-administering a phosphodiesterase inhibitor to a subject. The phosphodiesterase inhibitor may include, for example, one or more of a phosphodiesterase 3 inhibitor and a phosphodiesterase 5 inhibitor. The phosphodiesterase 5 inhibitor may include, for example, one or more of the following: sildenafil, tadalafil, vardenafil, udenafil (udenafil) , avanafil, dipyridamole, icariin and the like. The phosphodiesterase 3 inhibitor may include, for example, one or more of the following: inamrinone, cilostazol, milrinone, enoximone, Anagrelide, pimobendane, theophylline, meribendan, trequinsin, 4,5-dihydro-6-(4-(imidazole-1) -yl)phenyl)-5-methyl-3(2H)-oxime Ketone, N-{2-[(2E)-2-(ylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimidine[6,1- a] Isoquinoline-3(4H)-yl]ethyl}urea and the like.

In various embodiments of the method, the compound can be represented by structural formula (II) : (II) Wherein: R ¹ may be C ₁ -C ₄ alkyl or C ₁ -C ₄ haloalkyl; Ar may be phenanthryl, fluorenyl, biphenyl, phenyl or naphthyl, and Ar may be as follows: One or more of the substitutions: halogen, C ₁ -C ₄ haloalkyl, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy, nitrile and nitro; R ² may be H, and R ³ Can be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O) C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C (=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C( =O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N( CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (II) may be formed together: Wherein R ⁴ and R ⁵ may each independently be: H, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl or C ₁ -C ₆ haloalkyl; and n may be an integer from 1 to 6 .

In some embodiments of the method, the compound can be represented by structural formula (III) : (III) . Wherein: R ¹ may be CF ₃ ; Ar may be phenanthryl, anthracenyl, biphenylyl, phenyl or naphthyl; and Ar may be optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ - C ₄ alkoxy or C ₁ -C ₄ haloalkyl; Ar can be 2-phenanthryl, 3-phenanthryl, 9-fluorenyl, 4-biphenyl, 4-(4'-CF ₃ )-linked Phenyl, 4-(3',5'-dimethyl)-biphenyl, 4-(3',5'-dimethoxy)-biphenyl, phenyl, 1-(4-CF ₃ -phenyl, 1-naphthyl or 2-naphthyl; and R ² may be H, and R ³ may be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N (CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH( CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O) CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (III) may be formed together: .

For example, the compound of the method may be one of the compounds III-1 to III-39 ( Figs. 1A , 1B , 1C and 1D ): 2-amino- N- (4-(2-(phenanthr-2-yl)) 4-(Trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-1 ); 2-amino- N- (4-(2-(phenanthr-3-yl)) -4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-2 ); 2-amino- N- (4-(2-(naphthalene-2-) 4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-3 ); 2-amino- N- (4-(2-(naphthalene-1) -yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-4 ); 2-amino- N- (4-(4-(trifluoro) Methyl)-2-(4-(trifluoromethyl)phenyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-5 ); N -(4-(2-([ 1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2-aminoacetamide ( III-6 ); 2-Amino- N- (4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-7 ); 2-amino- N- (4-(2-(3',5'-dimethyl-[1,1'-- Biphenyl]-4-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-8 ); 2-amino- N- (4- (2-(3',5'-Dimethoxy-[1,1'-biphenyl]-4-yl)- 4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-9); 2- (methylamino) - N - (4- (2- ( Philippines - 2- yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-10); 2- (methylamino) - N - (4- ( 2-(naphthalen-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-11 ); 2-(methylamino) -N -(4-(2-(naphthalen-1-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-12 ); N -(4- (2-([1,1'-Biphenyl]-4-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2-(methylamino) Acetamide ( III-13 ); N- (4-(2-(3',5'-dimethyl-[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl) -1 H -pyrrol-1-yl)phenyl)-2-(methylamino)acetamide ( III-14 ); N- (4-(2-(3',5'-dimethyl Oxy-[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2-(methylamino)B Amides (III-15); 2- (dimethylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - pyrrole-1- yl) phenyl) acetyl amine (III-16); 2- (dimethylamino) - N - (4- (2- ( naphthalen-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-17); (S ) -2- amino - N - (4- (2- (phenanthren-2 ) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) -3-phenyl-propan-acyl amines (III-18); (S ) -2- ( methylamino) - N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-3-phenylpropanamide ( III-19 ) ; (S) -2- (methylamino) - N - (4- (2- ( naphthalen-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl ) -3-phenyl-propan-acyl amines (III-20); (R ) -2- ( dimethylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl Methyl)-1 H -pyrrol-1-yl)phenyl)-3-phenylpropanamide ( III-21 ); ( R )-2-amino-4-methyl- N- (4-( 2-(phenan-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)pentanylamine ( III-22 ); ( R )-4-methyl-2 - (methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) pentyl Amides (III -23); (S) -4- methyl-2- (methylamino) - N - (4- (2- ( naphthalen-2-yl) -4- (trifluoromethyl) -1 H - Pyrrol-1-yl)phenyl)pentanylamine ( III-24 ); ( R )-2-amino-3-methyl- N- (4-(2-(phenanthr-2-yl)-4- (trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)butanamine ( III-25 ); ( R )-2-amino-3-methyl- N- (4-(2- (naphthalen-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)butanamine ( III-26 ); (R & lt) -2- (methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) Propylamine ( III-27 ); 2-amino-2-methyl- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrole-1 -yl)phenyl)propanamide ( III-28 ); 2-amino-2-methyl- N- (4-(2-(naphthalen-2-yl)-4-(trifluoromethyl)- 1 H -pyrrol-1-yl)phenyl)propanamine ( III-29) ; 1-amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)) -1 H -pyrrol-1-yl)phenyl)cyclopropane-1-carboxamide ( III-30 ); 1-amino- N- (4-(4-(trifluoromethyl)-2-() 4'-(Trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)cyclopropane-1-carboxamide ( III-31 N- (4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrole) -1-yl)phenyl)propynylamine ( III-32 ); N,N -dimethyl-1-(1-(4-(2-(phenanthr-2-yl)-4-)trifluoro Methyl)-1 H -pyrrol-1-yl)phenyl)-1 H -1,2,3-triazol-4-yl)methylamine ( III-33 ); 1-(1-(4-( 2-(indol-9-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-1 H -1,2,3-triazol-4-yl) -N , N -dimethylmethylamine ( III-34 ); N,N -dimethyl-1-(1-(4-(4-(trifluoromethyl))-2-(4'-(trifluoromethyl) Base)-[1,1' -biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)-1 H -1,2,3-triazol-4-yl)methylamine ( III-35 ); N - (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-36 ); N -(4 -(2-(phenanthr-3-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-37) ; N -(4-( 2-(indol-9-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-38 ); or N- (4-(4) -(Trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)amine Sulfosamine ( III-39 ).

In various embodiments of the method, the compound can be represented by structural formula (IV) : (IV) Wherein: R ¹ may be C ₁ -C ₄ alkyl or C ₁ -C ₄ haloalkyl; Ar may be phenanthryl, fluorenyl, biphenyl, phenyl, naphthyl, pyridyl or pyrrolyl, and Ar optionally substituted with the following: halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkyl, nitrile or SO ₂ -C ₁ -C ₄ alkyl; R ² may be H, and R ³ may be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl) NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ ) CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ ) NH(CH ₃ ), C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O) CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (IV) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. For example, a compound can be represented by structural formula (V) : (V) Wherein: R ¹ may be C ₁ -C ₄ alkyl or C ₁ -C ₄ haloalkyl; Ar may be 1-(4-CF ₃ )-phenyl, 1-(4-CN)-phenyl, 1-(4-Me)-phenyl, 5-(2-CF ₃ )-pyridyl, 1-(4-SO ₂ Me)-phenyl, 9-fluorenyl, 1-(4-OMe)-benzene , 1-(4-F)-phenyl, 1-(4- t Bu)-phenyl, 1-(4-Et)-phenyl, 1-(4- i Pr)-phenyl or N- Me-3-pyrrolyl; R ² may be H, and R ³ may be C(=O)CH ₂ NH ₂ , SO ₂ NH ₂ , C(=O)C(CH ₃ ) ₂ NH ₂ , C(= O) C (cyclopropyl) NH ₂ , C(=O)(CH ₂ ) ₂ NH ₂ , C(=O)CH(NH ₂ )(4-imidazole), SO ₂ N(CH ₃ ) ₂ , C (=O)CH ₂ NH(CH ₃ ); or R ² , R ³ and the nitrogen of formula (V) may be formed together: .

For example, the compound of the method can be one of the compounds V-1 to V-22 ( Figs. 2A , 2B and 2C ): 2-amino- N- (4-(3-isopropyl-6-(4-) (trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)acetamidamine ( V-1 ); 2-amino- N- (4-(3-isopropyl-6) -(4-(methylsulfonyl)phenyl)-1 H -indol-1-yl)phenyl)acetamidamine ( V-2 ); 3-(1-(4-(2-amino) Ethylamino)phenyl)-6-(4-(trifluoromethyl)phenyl)-1 H -indol-3-yl) -N -methylpropanamide ( V-3 ); N - (4-(3-Isopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)-2-(methylamino)acetamide (V-4); (S ) -2- amino -2- (1 H - imidazol-4-yl) - N - (4- (3- isopropyl-6- (4- (trifluoromethyl Phenyl)-1 H -indol-1-yl)phenyl)acetamidamine ( V-5 ); 2-amino- N- (4-(3-isopropyl-6-(4-() Trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)-2-methylpropanamide ( V-6 ); 1-amino- N- (4-(3-iso) Propyl-6-(4-(trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)cyclopropane-1-carboxamide ( V-7 ); 3-amino- N- (4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)propanamine ( V-8 ); -(1-(4-(3-isopropyl-6-(4-(trifluoromethyl)) Phenyl)-1 H -indol-1-yl)phenyl)-1 H -1,2,3-triazol-4-yl)- N,N -dimethylmethylamine ( V-9 ) ; N -(4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-10) N- (4-(6-(4-Cyanophenyl)-3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-11 ); N -(4-(3-isopropyl-6-(p-tolyl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-12 ); N -(4-(3 -isopropyl-6-(p-tolyl)-1 H -indol-1-yl)phenyl)dimethylaminosulfonamide ( V-13 ); N -(4-(6-(4) -(t-butyl)phenyl)-3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-14 ); N -(4-(6-( 4-ethylphenyl)-3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-15 ); N- (4-(3-isopropyl)- 6-(4-isopropylphenyl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-16 ); N -(4-(3-isopropyl-6-) (4-methoxyphenyl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-17 ); N -(4-(6-(4-fluorophenyl)- 3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-18) ; N- (4-(3-isopropyl-6-(4-(methyl)) Sulfhydryl)phenyl)-1 H -indol-1-yl)phenyl) Aminosulfonamide ( V-19 ); N- (4-(6-(蒽-9-yl)-3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonate Amine ( V-20 ); N- (4-(3-isopropyl-6-(6-(trifluoromethyl)pyridin-3-yl)-1 H -indol-1-yl)phenyl) Aminosulfonamide ( V-21 ); and N- (4-(3-isopropyl-6-(1-methyl-1 H -pyrrol-3-yl)-1 H -吲哚-1- Phenyl)aminosulfonamide ( V-22 ).

In various embodiments of the method, the compound can be represented by structural formula (VI) : (V) Wherein: R ¹ may be C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl or C ₁ -C ₄ haloalkyl; Ar may be phenanthryl, fluorenyl, biphenyl, phenyl or naphthalene a group, and Ar may be optionally substituted by an alkyl group; R ² may be H, and R ³ may be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (V) may be formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. For example, a compound can be represented by structural formula (VII) : (VII) Wherein: R ¹ may be CF ₃ or cyclopropyl; Ar may be CF ₃ -phenyl; and R ² may be H, and R ³ may be C(=O)CH ₂ NH ₂ or SO ₂ NH ₂ .

For example, the compound can be one of the compounds VII-1 to VII-4 ( Fig. 3 ): 2-amino- N- (4-(3-(trifluoromethyl)-6-(4-(trifluoro)) Methyl)phenyl)-1 H -indazol-1-yl)phenyl)acetamidamine ( VII-1 ); 2-amino- N- (4-(3-cyclopropyl-6-(4) -(Trifluoromethyl)phenyl)-1 H -carbazol-1-yl)phenyl)acetamidamine ( VII-2 ); N -(4-(3-cyclopropyl-6-(4- (trifluoromethyl)phenyl)-1 H -indazol-1-yl)phenyl)aminosulfonamide ( VII-3 ); or N- (4-(3-(trifluoromethyl)-) 6-(4-(Trifluoromethyl)phenyl)-1 H -indazol-1-yl)phenyl)aminosulfonamide ( VII-4 ).

In various embodiments of the method, the compound can be represented by structural formula (VIII) : (VIII) Wherein: R ¹ may be C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl or C ₁ -C ₄ haloalkyl; Ar may be phenanthryl, fluorenyl, biphenyl, phenyl or naphthalene And Ar can be optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ haloalkyl; R ² can be H, and R ³ can be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)C( CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(= O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH _{3 ) 2} ; or R ² , R ³ and the aniline nitrogen of formula (VIII) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. For example, a compound can be represented by structural formula (IX) : (IX) Wherein: R ¹ may be CF ₃ ; Ar may be phenanthryl; and R ² may be H, and R ³ may be C(=O)CH ₂ NH ₂ or SO ₂ NH ₂ . For example, the compound can be ( Fig. 3 ) 2-amino-N-(4-(6-(phenanthr-2-yl)-4-(trifluoromethyl)pyridin-2-yl)phenyl)acetamide ( IX-1) or N- (4-(6-(phenanthr-2-yl)-4-(trifluoromethyl)pyridin-2-yl)phenyl)aminosulfonamide ( IX-2) .

In various embodiments of the method, the compound can be represented by structural formula (X) : (X) Wherein: R ¹ may be C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl or C ₁ -C ₄ haloalkyl; Ar may be phenanthryl, fluorenyl, biphenyl, phenyl or naphthalene And Ar may be optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ haloalkyl; and R ² may be H, and R ³ may be Is SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)C (CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C( =O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(= O) CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (X) may be formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. For example, a compound can be represented by structural formula (XI) : (XI) Wherein: R ¹ may be CF ₃ ; Ar may be fluorenyl, phenanthryl, CF ₃ -biphenyl, CF ₃ -phenyl or Br-phenyl; R ² may be H, and R ³ may be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ NH(CH ₃ ), C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)CH[CH ₂ CH (CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH[CH(CH ₃ ) ₂ ]NH(CH ₃ ); or, or R ² , R ³ and the aniline nitrogen of formula (XI) Formed together: .

For example, the compound of the method may be one of the compounds XI-1 to XI-21 ( Figs. 4A , 4B , 4C and 2C ): 2-amino- N- (4-(2-(phenanthr-2-yl)) -4-(Trifluoromethyl)-1 H -imidazol-1-yl)phenyl)acetamidamine ( XI-1 ); 2-amino- N- (4-(4-(trifluoromethyl)) -2-(4'-(Trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -imidazol-1-yl)phenyl)acetamidamine ( XI-2 ) 2-amino- N- (4-(2-(4-bromophenyl)-4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)acetamidamine ( XI-3 2-amino- N- (4-(4-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)-1 H -imidazol-1-yl)phenyl) Amides (XI-4); 2- (dimethylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - imidazol-1 yl) phenyl) acetyl amine (XI-5); 2- (methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - imidazol-1-yl) phenyl) acetyl amine (XI-6); (S ) -4- methyl-2- (methylamino) - N - (4- (2- ( phenanthren-2 (4-)(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)pentanylamine ( XI-7 ); ( R )-3-methyl-2-(methylamino) - N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)butanamine ( XI-8 ); N,N -Dimethyl-1-(1-(4-(2-(phenanthr-2-yl)-4-)trifluoro Methyl)-1 H -imidazol-1-yl)phenyl)-1 H -1,2,3-triazol-4-yl)methylamine ( XI-9 ); N -(4-(2-(蒽-9-yl)-4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-10 ); N -(4-(2-(phenanthrene)- 2-yl)-4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-11 ); N -(4-(4-(trifluoromethyl) -2-(4-(Trifluoromethyl)phenyl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-12 ); N -(4-(4-(3) Fluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -imidazol-1-yl)phenyl)aminosulfonyl Amine ( XI-13 ); ( S )-2-amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)benzene 3-phenylpropanamide ( XI-14 ); N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)benzene Propynylamine ( XI-15 ); 2-amino- N- (4-(2-(3',5'-dimethyl-[1,1'-biphenyl]-4-yl) -4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)acetamidamine ( XI-16 ); 2-amino- N- (4-(2-(3',5') -dimethoxy-[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)acetamide ( XI-17 ) ; 2-amino - N - (4- (2- (naphthalen-2-yl) -4- (trifluoromethyl) lH-imidazol-1-yl) phenyl) acetyl (XI-18); 2- amino - N - (4- (2- (naphthalen-1-yl) -4- (trifluoromethyl) lH-imidazol-1-yl) phenyl) acetyl amine ( XI-19 ); 2-amino- N- (4-(2-(3',5'-bis(trifluoromethyl)-[1,1'-biphenyl]-4-yl)- 4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)acetamidamine ( XI-20 ); or N- (4-(2-(3',5'-bis(trifluoromethyl)) -[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)-2-(methylamino)acetamidine Amine ( XI-21 ).

In various embodiments of the method, the compound can be represented by structural formula (XII) : (XII) Wherein R ¹ may be C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl, C ₁ -C ₄ haloalkyl or alkylalkylamine optionally alkylated; Ar may be phenanthryl, anthracene Or a biphenyl group, a phenyl group or a naphthyl group, and Ar may be optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ haloalkyl; R ² may be H, and R ³ R ² ' may be H, and R ³ ' may be sulfonamide, sulfinamide, alkylamino hydrazine, alkylaminopyrene, except glycine. An α-aminocarbonyl group, a β-aminocarbonyl group, a γ-aminocarbonyl group or an α-β-unsaturated carbonyl group; or R ² , R ³ and an aniline nitrogen of the formula (XII) may be formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. For example, a compound can be represented by structural formula (XIII) : (XIII) Wherein: R ¹ may be CH ₂ CH ₂ C(=O)NHCH ₃ ; Ar may be biphenyl substituted by halogen or C ₁ -C ₄ haloalkyl as appropriate; and R ² may be H, and R ³ may be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ NH(CH ₃ ), C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O) CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ) or C(=O)CH[CH(CH ₃ ) ₂ ]NH(CH ₃ ). For example, the compound can be 3-(1-(4-(2-aminoethylamino)phenyl)-5-(4'-(trifluoromethyl)-[1,1'-biphenyl] 4-yl)-1 H -pyrazol-3-yl) -N -methylpropanamide: XIII-1 .

In various embodiments of the method, Het can be one of the following: pyrrole, imidazole, triazole, tetrazole, oxazole, thiazole, hydrazine, oxazole, benzimidazole, benzoxazole, benzo Thiazole, carbazole, quinoline, isoquinoline, quin Porphyrin, quinazoline, pyridine, pyridyl , pyrimidine and three .

In some embodiments of the method, R ¹ may be H, C ₁ -C ₄ alkyl, C ₃ -C ₆ cycloalkyl, C ₁ -C ₄ haloalkyl, C ₃ -C ₆ halocycloalkyl, Halogen, nitrile, alkylguanamine or nitro. For example, R ¹ may be CF ₃ , isopropyl, cyclopropyl or —(CH ₂ ) ₂ C(O)NH(CH ₃ ).

In several embodiments of the method, R ² can be H. R ³ may be, for example, SO ₂ NH ₂ , SO ₂ NH(CH ₃ ), SO ₂ N(CH ₃ ) ₂ , S(=O)-C ₁ -C ₄ alkylamine, SO ₂ -C ₁ -C ₄ Alkylamine, C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)CH ₂ NH(CH ₃ ), C(=O)(CH ₂ ) ₂ NH ₂ , C(=O)(CH ₂ ) ₃ NH ₂ , C(=O)C(CH ₃ ) ₂ NH ₂ , C(=O)CH(NH ₂ )(4-imidazole), C(= O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH (CH ₃ ), C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)C(cyclopropyl)NH ₂ , C(=O)C≡CH or C(=O)CHCH ₂ . Additionally or alternatively, the aniline nitrogen of formula (I) wherein R ³ and R ³ may be bonded together may represent a guanamine-bonded: glycine, alanine, serine, threonine, cysteamine Acid, valine, leucine, isoleucine, methionine, valine, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspartame, valley Amine amide, histidine, lysine or arginine.

In various embodiments of the method, the compound can be represented by structural formula (XIV) : (XIV) Wherein: R ⁴ and R ⁵ may each independently be: H, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl or C ₁ -C ₆ haloalkyl; and n may be from 1 to 6 Integer.

In several embodiments of the method, R ² , R ³ and the aniline nitrogen of formula (I) may together form an optionally substituted triazole or tetrazole. The triazole can be substituted with an alkylamine group.

In some embodiments of the method, Ar may be substituted as appropriate: phenyl, pyridyl, pyr Base, pyrimidinyl, naphthyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, biphenyl, bipyridyl, phenanthryl, morpholinyl, fluorenyl, fused tetraphenyl, propylene naphthyl, anthracenyl, Base, acridine group, pheno , carbazolyl, fluorenyl, dibenzofuran, fluorenyl, oxazolyl, benzimidazolyl, benzoxazolyl, benzofuranyl, fluorenyl, pyrrolyl, imidazolyl, pyrazolyl , triazolyl or tetrazolyl. Ar may optionally be substituted by, for example, one or more of the following: C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, C ₁ -C ₆ haloalkyl, C ₃ -C ₆ halocycloalkyl , nitrile, C ₁ -C ₆ alkyl hydrazine, alkyl hydrazine, C ₁ -C ₆ O-alkyl, O-phenyl, C ₁ -C ₆ NH-alkyl, C ₂ -C ₁₂ N-alkane Base ₂ , hydroxy, NH ₂ , halogen, meta-dioxole, dioxolane, NO ₂ , aldehyde, C ₂ -C ₇ alkyl or aryl ketone, C ₂ -C ₇ alkyl or Aryl esters, C ₂ -C ₇ alkyl or aryl decylamine, hydrazine, hydrazine, N-OH hydrazine, urea, quinone imine, hydrazine, hydrazine and hydrazine. Ar optionally substituted with one or more of the following: methyl, ethyl, isopropyl, t-butyl, CF _3, CN, _{methoxy, S (O) 2 -C 1} -C 4 alkyl Base, Br and F.

In various embodiments of the method, when the compound is represented by structural formula (I') : (I') Wherein R ¹ ' may be a trifluoromethyl group; Ar' may be a 2-phenanthryl group; R ² ' may be H, and R ³ ' may be one of the following: CONH ₂ , C(=NH)NH ₂ , C(=O)CH ₂ NH ₂ , CH ₂ C(=O)NH ₂ , C(=O)-(p-phenylene)-SO ₂ NH ₂ , C(=O)CH ₂ NHC(=NH NH ₂ and C(=O)CH ₂ NHCO-phenyl, and the virus is not one of the following: Ebola, Marburg, Reisar fever, Hepatitis A, Hepatitis B, serotype 5 adenovirus , Coxsackie virus B4, typhus, mumps, measles, rubella, respiratory fusion virus a, respiratory fusion virus b, cytomegalovirus, influenza A and influenza B.

In some embodiments of the method, when the virus is one of the following: Ebola, Marburg, Reisar fever, Hepatitis A, Hepatitis B, serotype 5 adenovirus, Coxsackie virus B4, Public disease, mumps, measles, rubella, respiratory fusion virus a, respiratory fusion virus b, cytomegalovirus, influenza A and influenza B, this compound can be represented by structural formula (I') : (I') Wherein: R ¹ ' may be H, cycloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro; Ar' may be substituted as appropriate, and may be one of the following: fused tetraphenyl , propylene naphthalene, sulfhydryl, Phenyl, morphinyl, acridinyl, phenanthrene Base, carbazolyl, dibenzofuranyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, bipyridyl, pyridyl, pyridyl , pyrimidinyl, fluorenyl, benzimidazolyl, benzoxazolyl, benzofuranyl and fluorenyl; R ² ' may be H, and R ³ ' may be sulfonamide, sulfinamide, Alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl other than glycine, β-aminocarbonyl, γ-aminocarbonyl, or α-β-unsaturated carbonyl; or R ² ' And R ³ ' and the aniline nitrogen of formula (I') together form an optionally substituted heterocyclic group.

In some embodiments of the method, when the compound is represented by structural formula (I') : (I') , the virus is not one of the following: Ebola, Marburg, Reisar fever, Hepatitis A, Hepatitis B, serotype 5 adenovirus, Coxsackie virus B4, euthania, mumps, measles , rubella, respiratory fusion virus a, respiratory fusion virus b, cytomegalovirus, influenza A and influenza B. For example, R ¹ ' may be a trifluoromethyl group; Ar' may be a 2-phenanthryl group; R ² ' may be H, and R ³ ' may be one of the following: CONH ₂ , C(=NH)NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)-(p-phenylene)-SO ₂ NH ₂ , C(=O)CH ₂ NHC(=NH)NH ₂ , CH ₂ C(= O) NH ₂ and C(=O)CH ₂ NHCO-phenyl. Additionally or alternatively, wherein R ¹ ' may be a trihalomethyl group; Ar' may be a 2-phenanthryl group; R ² ' may be H, and R ³ ' may be one of the following: CONH ₂ , C (=NH)NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)-(p-phenylene)-SO ₂ NH ₂ , C(=O)CH ₂ NHC(=NH)NH ₂ , CH ₂ C(=O)NH ₂ and C(=O)CH ₂ NHCO-phenyl. Additionally or alternatively, wherein R ¹ ' may be trihalomethyl, H, methyl, ethyl or halo; Ar' may be 2-phenanthryl; R ² ' may be H, and R ³ ' may be One of the following: CONH ₂ , C(=NH)NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)-(p-phenylene)-SO ₂ NH ₂ , C(=O CH ₂ NHC(=NH)NH ₂ , CH ₂ C(=O)NH ₂ and C(=O)CH ₂ NHCO-phenyl. Additionally or alternatively, wherein R ¹ ' may be trifluoromethyl; Ar' may be phenanthryl; R ² ' may be H, and R ³ ' may be one of the following: CONH ₂ , C (= NH)NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)-(p-phenylene)-SO ₂ NH ₂ , C(=O)CH ₂ NHC(=NH)NH ₂ ,CH ₂ C(=O)NH ₂ and C(=O)CH ₂ NHCO-phenyl. Additionally or alternatively, wherein R ¹ ' may be trifluoromethyl; Ar' may be phenyl, biphenyl, naphthyl, anthracenyl, phenanthryl or anthryl; R ² ' may be H, and R ³ ' Can be one of the following: CONH ₂ , C(=NH)NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)-(p-phenylene)-SO ₂ NH ₂ , C (=O) CH ₂ NHC(=NH)NH ₂ , CH ₂ C(=O)NH ₂ and C(=O)CH ₂ NHCO-phenyl. Additionally or alternatively, wherein R ¹ ' may be trifluoromethyl; Ar' may be 2-phenanthryl; R ² ' may be H, methyl or ethyl, and R ³ ' may be one of the following : CONH ₂ , C(=NH)NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)-(p-phenylene)-SO ₂ NH ₂ , C(=O)CH ₂ NHC( =NH)NH ₂ , CH ₂ C(=O)NH ₂ and C(=O)CH ₂ NHCO-phenyl. Additionally or alternatively, wherein R ¹ ' may be trifluoromethyl; Ar' may be 2-phenanthryl; R ² ' may be H, and R ³ ' may be one of the following: CONH ₂ , C (=NH)NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)-(p-phenylene)-SO ₂ NH ₂ , C(=O)CH ₂ NHC(=NH)NH ₂ , CH ₂ C(=O)NH ₂ and C(=O)CH ₂ NHCO-phenyl; wherein each H position in R ³ ' may be optionally substituted by methyl or ethyl. Additionally or alternatively, R ¹ ' may be one of an alkyl group or a haloalkyl group; Ar may be one of the following: phenyl, biphenyl, naphthyl, anthryl, phenanthryl and anthracenyl Wherein Ar can be optionally substituted by one or more of the following: halo, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, azido, C ₁ -C ₄ azidoalkyl , aryl, alkylaryl, haloaryl, haloalkylaryl, and combinations thereof; R ² ' may be H; and R ³ ' may be one of the following: N -formamide, N -脒, N -acetamidine, N -aminoacetamide, N -indole and N -urea. In some embodiments, R ² ' may be H, methyl or ethyl, and each H of the nitrogen bonded to R ³ ' may be methyl or ethyl, as appropriate.

In some embodiments of the methods, the compound can be represented by structural formula (I') . R ¹ ' may be H, cycloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. Ar' may be substituted as appropriate, and may be one of the following: fused tetraphenyl, propylene naphthalene, fluorenyl, Phenyl, morphinyl, acridinyl, phenanthrene Base, carbazolyl, dibenzofuranyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, bipyridyl, pyridyl, pyridyl A group, a pyrimidinyl group, a fluorenyl group, a benzimidazolyl group, a benzoxazolyl group, a benzofuranyl group and a fluorenyl group. R ^{2 "} may be H, and R ³ ' may be sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazine, α-aminocarbonyl other than glycine, β- Aminocarbonyl, γ-aminocarbonyl or α-β-unsaturated carbonyl. Alternatively, R ² ' , R ³ ' and the aniline nitrogen of formula (I') may together form an optionally substituted heterocyclic group. The virus can be any of the viruses described herein. In some embodiments, the virus can be one of: Ebola, Marburg, Reisar fever, Hepatitis A, Hepatitis B, serotype 5 adenovirus, Coxsackie virus B4, Phytophthora, Mumps, measles, rubella, respiratory fusion virus a, respiratory fusion virus b, cytomegalovirus, influenza A and influenza B.

In various embodiments, a compound is provided. A compound can be represented by structural formula (I) : (I) And pharmaceutically acceptable salts thereof. R ¹ may be H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. R ² may be H, and R ³ may be: sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl, β-aminocarbonyl, γ-amino group a carbonyl group, an α-β-unsaturated carbonyl group, a hydrazine or a urea; or an aniline nitrogen of the formula (I) , R ² and R ³ may together form an optionally substituted heterocyclic group; Ar may be 1, 2, 3 Or an optionally substituted aryl or heteroaryl group of 4 rings which may be one or more of a linked ring and a fused ring; Het may comprise a heteroaryl group of the first ring, The heteroaryl group may be a nitrogen-containing five- or six-membered heteroaryl group, and the first ring is optionally fused to one or more of the second ring and the third ring to form 8, 9, 10, 11 a bicyclic or tricyclic heteroaryl group consisting of 12 or 13 ring atoms, wherein R ¹ and benzene ring A may be bonded to the first ring, and Ar may be bonded to the first ring, the second ring or The third ring.

In several embodiments, when the compound is represented by: (I') One or more of the following: R ¹ ' may be H, cycloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro; Ar' may be optionally substituted and may be as follows One of them: thick tetraphenyl, propylene naphthalene, sulfhydryl, Phenyl, morphinyl, acridinyl, phenanthrene Base, carbazolyl, dibenzofuranyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, bipyridyl, pyridyl, pyridyl , pyrimidinyl, fluorenyl, benzimidazolyl, benzoxazolyl, benzofuranyl and fluorenyl; R ² ' may be H, and R ³ ' may be sulfonamide, sulfinamide, An alkylamino hydrazine, an alkylamino hydrazide, an α-aminocarbonyl group other than glycine, a β-aminocarbonyl group, a γ-aminocarbonyl group, or an α-β-unsaturated carbonyl group; or R ² , R ³ and the aniline nitrogen of formula (I') may together form an optionally substituted heterocyclic group.

In various embodiments, a compound can include any aspect of a compound as described in the methods herein. For example, the compound can be represented by the formula (II) , wherein: R ¹ can be a C ₁ -C ₄ alkyl group or a C ₁ -C ₄ haloalkyl group; Ar can be a phenanthryl group, a fluorenyl group, a biphenyl group, a phenyl group or Naphthyl, and Ar may be optionally substituted by one or more of the following: halogen, C ₁ -C ₄ haloalkyl, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy, nitrile and nitro ; R ² may be H, and R ³ may be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl) Base) NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ ) CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ ) NH(CH ₃ ), C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(= O) CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (II) may be formed together: Wherein R ⁴ and R ⁵ may each independently be: H, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl or C ₁ -C ₆ haloalkyl; and n may be an integer from 1 to 6 .

In some embodiments, the compound can be represented by structural formula (III) , wherein: R ¹ can be CF ₃ ; Ar can be phenanthryl, fluorenyl, biphenyl, phenyl or naphthyl; and Ar can be visually observed as follows Substitution: halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ haloalkyl; Ar can be 2-phenanthryl, 3-phenanthryl, 9-fluorenyl, 4- Biphenyl, 4-(4'-CF ₃ )-biphenyl, 4-(3',5'-dimethyl)-biphenyl, 4-(3',5'-dimethoxy) -biphenyl, phenyl, 1-(4-CF ₃ )-phenyl, 1-naphthyl or 2-naphthyl; and R ² may be H, and R ³ may be SO ₂ NH ₂ , C(= O) CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (III) can be formed together: .

For example, the compound can be one of the compounds III-1 to III-39 ( Figs. 1A , 1B , 1C and 1D ).

In various embodiments, the compound can be represented by structural formula (IV) wherein: R ¹ can be C ₁ -C ₄ alkyl or C ₁ -C ₄ haloalkyl; Ar can be phenanthryl, fluorenyl, biphenyl , phenyl, naphthyl, pyridyl or pyrrolyl, and Ar may be optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkyl, Nitrile or SO ₂ -C ₁ -C ₄ alkyl; R ² may be H, and R ³ may be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH _{3 2} , C(=O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH( CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH) ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (IV) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. For example, the compound can be represented by the formula (V) wherein: R ¹ can be a C ₁ -C ₄ alkyl group or a C ₁ -C ₄ haloalkyl group; Ar can be a 1-(4-CF ₃ )-phenyl group, 1 -(4-CN)-phenyl, 1-(4-Me)-phenyl, 5-(2-CF ₃ )-pyridyl, 1-(4-SO ₂ Me)-phenyl, 9-fluorenyl , 1-(4-OMe)-phenyl, 1-(4-F)-phenyl, 1-(4- t Bu)-phenyl, 1-(4-Et)-phenyl, 1-(4 - i Pr)-phenyl or N- Me-3-pyrrolyl; R ² may be H, and R ³ may be C(=O)CH ₂ NH ₂ , SO ₂ NH ₂ , C(=O)C ( CH ₃ ) ₂ NH ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)(CH ₂ ) ₂ NH ₂ , C(=O)CH(NH ₂ )(4-imidazole), SO ₂ N(CH ₃ ) ₂ , C(=O)CH ₂ NH(CH ₃ ); or R ² , R ³ and the nitrogen of formula (V) may be formed together: .

For example, the compound can be one of compounds V-1 to V-22 ( Figs. 2A , 2B, and 2C ).

In various embodiments, the compound may be of formula (VI) represents, wherein: R ¹ can be C ₁ -C ₄ alkyl-based, C ₂ -C ₆ cycloalkyl or C ₁ -C ₄ haloalkyl; Ar can be based Fenyl, fluorenyl, biphenyl, phenyl or naphthyl, and Ar optionally substituted by alkyl; R ² may be H, and R ³ may be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C ≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH( CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and structural formula (V) ) the aniline nitrogen can together form: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. For example, the compound can be represented by structural formula (VII) wherein: R ¹ can be CF ₃ or cyclopropyl; Ar can be CF ₃ -phenyl; and R ² can be H, and R ³ can be C(=O) CH ₂ NH ₂ or SO ₂ NH ₂ . For example, the compound can be one of the compounds VII-1 to VII-4 ( Fig. 3 ).

In various embodiments, the compound may be of formula (VIII) represents, wherein: R ¹ can be C ₁ -C ₄ alkyl-based, C ₂ -C ₆ cycloalkyl or C ₁ -C ₄ haloalkyl; Ar can be based Fenyl, fluorenyl, biphenyl, phenyl or naphthyl, and Ar may be optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ halo Alkyl; R ² may be H, and R ³ may be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C( Cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH (NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH (CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C (=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (VIII) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. For example, the compound can be represented by structural formula (IX) wherein: R ¹ can be CF ₃ ; Ar can be phenanthryl; and R ² can be H, and R ³ can be C(=O)CH ₂ NH ₂ or SO ₂ NH ₂ . For example, the compound can be ( Fig. 3 ) 2-amino-N-(4-(6-(phenanthr-2-yl)-4-(trifluoromethyl)pyridin-2-yl)phenyl)acetamide ( IX-1) or N- (4-(6-(phenanthr-2-yl)-4-(trifluoromethyl)pyridin-2-yl)phenyl)aminosulfonamide ( IX-2) .

In various embodiments, the compound may be of formula (X) represented, wherein: R ¹ can be C ₁ -C ₄ alkyl-based, C ₂ -C ₆ cycloalkyl or C ₁ -C ₄ haloalkyl; Ar can be based Fenyl, fluorenyl, biphenyl, phenyl or naphthyl, and Ar may be optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ halo Alkyl; and R ² may be H, and R ³ may be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C (cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O) CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O) CH(CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (X) may be formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. For example, the compound may be structural formula (XI) represented, wherein: R ¹ may be based CF _3; Ar may be based anthryl, phenanthryl, CF ₃ - biphenyl, CF ₃ - phenyl Br- or phenyl; R ² may be H, and R ³ may be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ NH(CH ₃ ), C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH[CH(CH ₃ ) ₂ ]NH(CH ₃ ); or, or R ² , R ³ And the aniline nitrogen of formula (XI) can be formed together: .

For example, the compound can be one of the compounds XI-1 to XI-21 ( Figs. 4A , 4B , 4C and 2C ).

In various embodiments, the compound can be represented by structural formula (XII) , wherein R ¹ can be C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl, C ₁ -C ₄ haloalkyl or, optionally, alkyl Alkyl decylamine; Ar may be phenanthryl, fluorenyl, biphenylyl, phenyl or naphthyl, and Ar may be substituted by the following: halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ Alkoxy or C ₁ -C ₄ haloalkyl; and R ² may be H, and R ³ R ² ' may be H, and R ³ ' may be sulfonamide, sulfinamide, alkylamine hydrazine , alkylamino hydrazide, α-aminocarbonyl other than glycine, β-aminocarbonyl, γ-aminocarbonyl or α-β-unsaturated carbonyl; or R ² , R ³ and structural formula ( The aniline nitrogen of XII) can be formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. For example, the compound can be represented by the formula (XIII) wherein: R ¹ can be CH ₂ CH ₂ C(=O)NHCH ₃ ; Ar can be biphenyl substituted by halogen or C ₁ -C ₄ haloalkyl as appropriate And R ² may be H, and R ³ may be SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ NH(CH ₃ ), C(=O)CH ₂ N ( CH ₃ ) ₂ , C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ) or C(=O)CH[CH(CH ₃ ) ₂ ]NH(CH ₃ ). For example, the compound can be 3-(1-(4-(2-aminoethylamino)phenyl)-5-(4'-(trifluoromethyl)-[1,1'-biphenyl] 4-yl)-1 H -pyrazol-3-yl) -N -methylpropanamide (compound XIII-1 ).

In various embodiments of the compounds, Het can be one of the following: pyrrole, imidazole, triazole, tetrazole, oxazole, thiazole, hydrazine, oxazole, benzimidazole, benzoxazole, benzo Thiazole, carbazole, quinoline, isoquinoline, quin Porphyrin, quinazoline, pyridine, pyridyl , pyrimidine and three .

In some embodiments of compounds, R ¹ is based can be H, C ₁ -C ₄ alkyl, C ₃ -C ₆ cycloalkyl, C ₁ -C ₄ haloalkyl, C ₃ -C ₆ halocycloalkyl, Halogen, nitrile, alkylguanamine or nitro. For example, R ¹ may be CF ₃ , isopropyl, cyclopropyl or —(CH ₂ ) ₂ C(O)NH(CH ₃ ).

In several embodiments of the compound, R ² can be H. R ³ may be, for example, SO ₂ NH ₂ , SO ₂ NH(CH ₃ ), SO ₂ N(CH ₃ ) ₂ , S(=O)-C ₁ -C ₄ alkylamine, SO ₂ -C ₁ -C ₄ Alkylamine, C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)CH ₂ NH(CH ₃ ), C(=O)(CH ₂ ) ₂ NH ₂ , C(=O)(CH ₂ ) ₃ NH ₂ , C(=O)C(CH ₃ ) ₂ NH ₂ , C(=O)CH(NH ₂ )(4-imidazole), C(= O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH (CH ₃ ), C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)C(cyclopropyl)NH ₂ , C(=O)C≡CH or C(=O)CHCH ₂ . Additionally or alternatively, the aniline nitrogen of formula (I) wherein R ³ and R ³ may be bonded together may represent a guanamine-bonded: glycine, alanine, serine, threonine, cysteamine Acid, valine, leucine, isoleucine, methionine, valine, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspartame, valley Amine amide, histidine, lysine or arginine.

In various embodiments, the compound can be represented by structural formula (XIV) wherein: R ⁴ and R ⁵ can each independently be: H, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl or C ₁ - C ₆ haloalkyl; and n may be an integer from 1 to 6.

In several embodiments of the compounds, R ² , R ³ and the aniline nitrogen of formula (I) may together form an optionally substituted triazole or tetrazole. The triazole can be substituted with an alkylamine group.

In some embodiments of the compound, Ar may be substituted as appropriate: phenyl, pyridyl, pyridyl Base, pyrimidinyl, naphthyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, biphenyl, bipyridyl, phenanthryl, morpholinyl, fluorenyl, fused tetraphenyl, propylene naphthyl, anthracenyl, Base, acridine group, pheno , carbazolyl, fluorenyl, dibenzofuran, fluorenyl, oxazolyl, benzimidazolyl, benzoxazolyl, benzofuranyl, fluorenyl, pyrrolyl, imidazolyl, pyrazolyl , triazolyl or tetrazolyl. Ar may optionally be substituted by, for example, one or more of the following: C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, C ₁ -C ₆ haloalkyl, C ₃ -C ₆ halocycloalkyl , nitrile, C ₁ -C ₆ alkyl hydrazine, alkyl hydrazine, C ₁ -C ₆ O-alkyl, O-phenyl, C ₁ -C ₆ NH-alkyl, C ₂ -C ₁₂ N-alkane Base ₂ , hydroxy, NH ₂ , halogen, meta-dioxole, dioxolane, NO ₂ , aldehyde, C ₂ -C ₇ alkyl or aryl ketone, C ₂ -C ₇ alkyl or Aryl esters, C ₂ -C ₇ alkyl or aryl decylamine, hydrazine, hydrazine, N-OH hydrazine, urea, quinone imine, hydrazine, hydrazine and hydrazine. Ar optionally substituted with one or more of the following: methyl, ethyl, isopropyl, t-butyl, CF _3, CN, _{methoxy, S (O) 2 -C 1} -C 4 alkyl Base, Br and F.

In various embodiments, a pharmaceutical composition is provided. The pharmaceutical composition can include a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition may include a compound represented by the formula (I) : (I) And pharmaceutically acceptable salts thereof. R ¹ may be H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. R ² may be H, and R ³ may be: sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl, β-aminocarbonyl, γ-amino group A carbonyl group, an α-β-unsaturated carbonyl group, a hydrazine or a urea; or R ² , R ³ and an aniline nitrogen of the formula (I) may together form an optionally substituted heterocyclic group. Ar may be an optionally substituted aryl or heteroaryl group consisting of 1, 2, 3 or 4 rings which may be one or more of a linked ring and a fused ring. Het may be a heteroaryl group including a first ring which may be a nitrogen-containing five- or six-membered heteroaryl group. The first ring may optionally be fused to one or more of the second ring and the third ring to form a bicyclic or tricyclic heteroaryl group characterized by 8, 9, 10, 11, 12 or 13 ring atoms. . R ¹ and benzene ring A may be bonded to the first ring, and Ar may be bonded to the first ring, the second ring or the third ring. When the compound is represented by the structural formula (I') : (I') There may be one or more of the following items. R ¹ ' may be H, cycloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. Ar' may be substituted as appropriate, and may be one of the following: fused tetraphenyl, propylene naphthalene, fluorenyl, Phenyl, morphinyl, acridinyl, phenanthrene Base, carbazolyl, dibenzofuranyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, bipyridyl, pyridyl, pyridyl A group, a pyrimidinyl group, a fluorenyl group, a benzimidazolyl group, a benzoxazolyl group, a benzofuranyl group and a fluorenyl group. R ² ' may be H, and R ³ ' may be sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazine, α-aminocarbonyl other than glycine, β-amine A carbonyl group, a γ-aminocarbonyl group or an α-β-unsaturated carbonyl group. Alternatively, the aniline nitrogen, R ² and R ^{3 of} formula (I') may together form an optionally substituted heterocyclic group.

In several embodiments, the pharmaceutical composition can further comprise an antiviral agent, such as the antiviral drugs described herein for use in the method. The pharmaceutical composition can further comprise a phosphodiesterase inhibitor, such as the phosphodiesterase inhibitors described herein for use in the method.

In some embodiments of the pharmaceutical composition, the compound can include any aspect of a compound of the compound or method as described herein. For example, the compound of the pharmaceutical composition may be compounds III-1 to III-39 ( Figs. 1A , 1B , 1C and 1D ), V-1 to V-22 ( Figs. 2A , 2B and 2C ), VII-1 to VII- One of 4 ( Fig. 3 ), IX-1 and IX-2 ( Fig. 3 ), XI-1 to XI-21 ( Figs. 4A , 4B , 4C and 2C ) or XIII-1 .

In various embodiments, a kit is provided. The kit can include compounds and instructions. This specification can guide the user to provide a subject who may be at risk of or at risk of infection with the virus. The instructions can direct the user to administer the compound to the subject in an amount effective to reduce viral infection. A compound can be represented by structural formula (I) : (I) And pharmaceutically acceptable salts thereof. R ¹ may be H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. R ² may be H, and R ³ may be: sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl, β-aminocarbonyl, γ-amino group A carbonyl group, an α-β-unsaturated carbonyl group, a hydrazine or a urea; or R ² , R ³ and an aniline nitrogen of the formula (I) may together form an optionally substituted heterocyclic group. Ar may be an optionally substituted aryl or heteroaryl group consisting of 1, 2, 3 or 4 rings which may be one or more of a linked ring and a fused ring. Het may be a heteroaryl group including a first ring which may be a nitrogen-containing five- or six-membered heteroaryl group. The first ring may optionally be fused to one or more of the second ring and the third ring to form a bicyclic or tricyclic heteroaryl group characterized by 8, 9, 10, 11, 12 or 13 ring atoms. . R ¹ and benzene ring A may be bonded to the first ring, and Ar may be bonded to the first ring, the second ring or the third ring. When the compound is represented by the structural formula (I') : (I') There may be one or more of the following items. R ¹ ' may be H, cycloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro. Ar' may be substituted as appropriate, and may be one of the following: fused tetraphenyl, propylene naphthalene, fluorenyl, Phenyl, morphinyl, acridinyl, phenanthrene Base, carbazolyl, dibenzofuranyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, bipyridyl, pyridyl, pyridyl A group, a pyrimidinyl group, a fluorenyl group, a benzimidazolyl group, a benzoxazolyl group, a benzofuranyl group and a fluorenyl group. R ² ' may be H, and R ³ ' may be sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazine, α-aminocarbonyl other than glycine, β-amine A carbonyl group, a γ-aminocarbonyl group or an α-β-unsaturated carbonyl group. Alternatively, the aniline nitrogen, R ² and R ^{3 of} formula (I') may together form an optionally substituted heterocyclic group.

In several embodiments, the kit can further comprise an antiviral agent, such as the antiviral drugs described herein for use in the method. The kit may further comprise a phosphodiesterase inhibitor, such as the phosphodiesterase inhibitors described herein for use in the method.

In various embodiments of the kit, the compound can include any of the compounds, compounds of the methods, or compounds of the pharmaceutical compositions as described herein. For example, the compound of the pharmaceutical composition may be compounds III-1 to III-39 ( Figs. 1A , 1B , 1C and 1D ), V-1 to V-22 ( Figs. 2A , 2B and 2C ), VII-1 to VII- One of 4 ( Fig. 3 ), IX-1 and IX-2 ( Fig. 3 ), XI-1 to XI-21 ( Figs. 4A , 4B , 4C and 2C ) or XIII-1 . Alternatively, the compounds in the kit may be provided in the form of a pharmaceutical composition. The instructions in the kit can direct the user to perform any aspect of the method as described herein. Instance

The following examples and results are shown in FIGS. 5 A to FIG. 15. All commercially available reagents were used without further purification unless otherwise stated. Anhydrous tetrahydrofuran (THF) was obtained by distillation of a commercial reagent with CaH ₂ , and anhydrous dimethylformamide (DMF) was obtained by distillation under reduced pressure of P ₂ O ₅ under reduced pressure. Tannins for column chromatography from 230 to 400 mesh were purchased from Fisher Scientific, Pittsburg, PA. Conventional ¹ H and ¹³ C NMR spectra were recorded on a DPX 300 or Ascend 400 (Bruker, Billerica, MA). The sample was dissolved in deuterated chloroform (CDCl ₃ ) or dimethyl hydrazine (DMSOd ₆ ), and tetramethyl decane (TMS) was used as a reference. Electrospray ionization mass spectrometry analysis was performed using a maXis 4G mass spectrometer (Bruker, Billerica, MA). All compounds used in the bioassay were identified by ¹ H NMR, ¹³ C NMR and HRMS, and the purity was confirmed to be higher than 95%. The purity of all test compounds was determined by the Hitachi Elite LaChrom HPLC system including the Versa Grad Prep 36 pump, the L-2400 UV detector, the L-2200 autosampler and the 250 x 4.6 mm Phenomenex Luna 5μ C18. Column (Hitachi High-Technologies Science America, Inc., Northridge, CA). Example 1 : 2- Amino - N- (4-(2-( phenanthr -2- yl )-4-( trifluoromethyl )-1 H - pyrrol- 1 -yl ) phenyl ) acetamide (III -1)

The synthetic sequence described below is shown in Figure 5A . The derivative of compound III-1 was prepared from the precursor ( 1 g) by various " step h " methods (A to E). As depicted in FIG. 5A, compounds such as III-1, III-2 and III-10 A Method of preparation. Method B prepares a compound such as III-16 as described below. Method C prepares a compound such as III-36 as described below. Method D prepares a compound such as III-3 3 as described below. Method E prepares compounds such as III-28 , III-26 , III-22 , III-18 , III-27 , III-24 , III-30 and III-20 as described below. 2-(1,1 -diethoxyethyl ) phenanthrene (1a)

See Figure 5A , step a . Add N -bromosuccinimide (0.121 g, 0.68 mmol) to 2-ethenylphenanthrene (5.0 g, 22.69 mmol), triethyl orthoformate (6.72 g, 45.39 mmol) and anhydrous EtOH (50 mL) In the solution. The resulting solution was stirred at room temperature for 5 to 6 h. The reaction was monitored by TLC. Upon completion, the addition of cold aqueous NaOH solution (10%, 15 mL), and the mixture (3 × 50 mL) and extracted with Et ₂ O. The organic extracts (3 × 25 mL) and washed with water, and dried over anhydrous Na ₂ SO _4. The solvent was removed under reduced pressure. The crude product was purified by flash chromatography eluting with EtOAc EtOAc EtOAc (EtOAc) 4-( ethoxy -1,1,1- trifluoro- 4-( phenanthr -2- yl ) but- 3 -en -2- one (1b)

See Figure 5A , step b . Pyridine (3.76 g, 47.55 mmol) was added to a solution of 2-(1,1-diethoxyethyl)phenanthrene ( 1a) (7.0 g, 23.77 mmol) in chloroform (50 mL). Stir at 0 ° C for 5 min. A solution of trifluoroacetic anhydride (9.98 g, 47.55 mmol) in 20 mL of chloroform was added dropwise over 15 min. The resulting solution was stirred at room temperature for 5 to 6 h. The reaction was monitored by TLC. Upon completion of the reaction, ice-cold water was added and the mixture was extracted with DCM. The organic layer was washed with 2 N HCl solution to 10% Na ₂ CO ₃ aqueous solution was washed, and dried over anhydrous Na ₂ SO _4. The solvent was removed under reduced pressure. Purification by flash chromatography of crude product afforded (Z)-4-ethoxy-1,1,1-trifluoro-4-(phenanthr-2-yl)but-3-en-2-one (1b) (6.95 g), the yield was 85%. 4- Ethoxy- 4-( phenanthr -2- yl )-2-( trifluoromethyl )-2-(( trimethylcarbinyl ) oxy ) but- 3 -enenitrile (1c)

See Figure 5A , step c . Add (Z)-4-Ethoxygen to a solution of trimethylmethanesulfonyl cyanide (5.0 g, 14.5 mmol) and triethylamine (0.073 g, 0.726 mmol) in acetonitrile (20 mL) at 0 °C A solution of benzyl-1,1,1-trifluoro-4-(phenanthr-2-yl)but-3-en-2-one (1b) in acetonitrile (20 mL). The resulting solution was stirred for 16 h and then concentrated under reduced pressure. The crude product was purified by flash chromatography to give (Z)-4-ethoxy-4-(phenan-2-yl)-2-(trifluoromethyl)-2-((trimethylmethyl) Oxy)but-3-enenitrile (1c) (4.89 g), yield 76%. 2-( Aminomethyl )-4- ethoxy -1,1,1- trifluoro- 4-( phenanthr -2- yl ) but- 3 -en -2- ol (1d)

See Figure 5A , step d . LiAlH ₄ (0.753 g, 19.0 mmol) was suspended in dry diethyl ether (50 mL) under an inert atmosphere and cooled to 0 to 5 °. (Z)-4-Ethoxy-4-(phenanthr-2-yl)-2-(trifluoromethyl)-2-((trimethylcarbalenyl) was added dropwise at 0 to 5 °C over 30 min. A solution of oxy)but-3-enenitrile ( 1c) (8.0 g, 18.0 mmol) in dry diethyl ether (30 mL). The mixture was allowed to reach room temperature and stirred overnight. The mixture was cooled to 0 to 5 ℃, and added to a cold 30% NaOH (10 mL) was added to quench the excess LiAlH _4. The mixture was filtered and the solid was washed with EtOAc (3 &lt The filtrate was dried over Na ₂ SO ₄ and concentrated under reduced pressure to give (Z)-2-(aminomethyl)-4-ethoxy-1,1,1-trifluoro-4-(phen-2- Butyl-3-en-3-ol ( 1d ) (5.28 g), yield 78%. 2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- pyrrole (1e)

See Figure 5A , step e . To (Z)-2-(aminomethyl)-4-ethoxy-1,1,1-trifluoro-4-(phenanthr-2-yl)but-3-en-2-ol ( 1d ) ( A solution of 3.0 g, 7.99 mmol), acetonitrile (20 mL) and water (1.5 mL) was added 5% aqueous HCl (1. The resulting solution was stirred at 80 ° C for 12 h and was monitored by TLC. Upon completion, water and 3% NaHCO ₃ (20 mL) were added. The solution (3 x 50 mL) extracted with EtOAc, and the combined organic layers were dried over anhydrous Na ₂ SO _4. The solvent was removed under reduced pressure and purified EtOAcqqqqqqqqq 1H-pyrrole ( 1e ) (2.13 g), yield 86%. 1-(4- nitrophenyl )-2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- pyrrole (1f)

See Figure 5A , step f . Add 4-fluoronitrobenzene to a solution of 2-(phenanthr-2-yl)-4-(trifluoromethyl)-1H-pyrrole ( 1e ) (2.0 g, 6.42 mmol) in DMF (20 mL) (1.35 g, 9.63 mmol) and K ₂ CO ₃ (1.77 g, 12.8 mmol). The resulting mixture was stirred at 120 ° C for 12 h. The reaction was monitored by TLC. Upon completion, ice cold water was added and the solution was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anhydrous Na ₂ SO _4. The solvent was removed under reduced pressure and purified EtOAcqqqqqqqq 4-(trifluoromethyl)-1 H -pyrrole ( 1f ) (1.80 g), yield 65%. 4-(2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- pyrrol- 1 -yl ) aniline (1 g)

See Figure 5A , step g . To 1-(4-Nitrophenyl)-2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrole ( 1f ) (1.0 g, 2.31 mmol) in EtOAc (20 ml And 10% Pd/C (122 mg, 1.15 mmol) was added to the solution in MeOH (10 mL). 70 PSI of H ₂ gas was applied to the mixture for 3 h using a Parr apparatus. The reaction mixture was filtered through diatomaceous earth to remove the catalyst, and the filtrate was concentrated under reduced pressure to afford pure 4- (2- (phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - pyrrole -1 Aniline aniline ( 1 g ) (725 mg), yield 78%. Method (A) : A representative amino acid derivative (2- amino -N-(4-(2-( phenanthr -2- yl ))-4-( trifluoromethyl )-1H- ) using a peptide coupling agent Pyrrol- 1 -yl ) phenyl ) acetamidine ) ( III-1 )

Method (A) . See Figure 5A , step h . To the third butoxycarbonyl ( t BOC) glycine (0.143 g, 0.82 mmol) and 4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrole-1 Add 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide to a solution of aniline ( 1 g ) (0.300 g, 0.75 mmol) in dry tetrahydrofuran (20 mL) Hydrochloride (0.162 g, 0.81 mmol). The resulting solution was stirred at 25 ° C for 12 h and then concentrated under reduced pressure. The resulting residue was suspended in water and extracted with EtOAc. The organic layer was dried over anhydrous Na ₂ SO _4, and solvent was removed under reduced pressure to give Boc protected intermediate, The crude boc protected intermediate (0.410 g, 0.73 mmol) was dissolved in containing concentrated HCl (1 mL) In EtOAc (9 mL). The resulting solution was stirred at room temperature for 2 h and concentrated under reduced pressure. By silica gel flash chromatography _{(DCM: MeOH: NH 4 OH} 96: 2: 2) Purification of the crude product was obtained as a white powder of the compound III-1 (308 mg), 90% yield. 2- Amino -N-(4-(2-( phenanthr- 3 -yl )-4-( trifluoromethyl )-1H- pyrrol- 1 -yl ) phenyl ) acetamidamine ( III-2 )

Compound III-2 was prepared from ( 1 g ) of the phenanthren-3-yl derivative according to method (A). The phenanthren-3-yl derivative was prepared starting from 1-(phenanthr-3-yl)ethan-1-one according to the scheme in Figure 5A . 2-( Methylamino )-N-(4-(2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- pyrrol- 1 -yl ) phenyl ) acetamide ( III -10 )

According to Method A , compound III-10 was prepared from 1 g using N- Boc, N -methylglycine. Process (B) : Representative amino acid derivative 2-( dimethylamino )-N-(4-(2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- pyrrole -1 -yl ) phenyl ) acetamidine ( III-16 )

Method (B) . Alternative step h . Dimethylglycine (76 mg, 0.74 mmol) was suspended in DCM (3 mL) EtOAc (EtOAc) After 1 h, the solution was warmed to room temperature and stirred for 1 h, then a solution of compound (1 g) (100 mg, 024 mmol) and triethylamine (0.150 g, 1.48 mmol) in THF was added and the suspension was stirred. Overnight. The solution was diluted with water and extracted with EtOAc (2 x 50 mL). The combined organic layers were dried over Na ₂ SO _4, filtered and concentrated. By flash column chromatography (DCM: MeOH 8: 2) The residue was purified to give Compound III-16 (99 mg), in 82% yield. Process (C) Representative thiodiamine derivative 2- amino -N-(4-(2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- pyrrol- 1 -yl ) Phenyl ) sulfonamide ( III-36 )

Method (C) . Alternative step h . Chlorosulfonium isocyanate (1.1 mmol) was added dropwise to a solution of t- BuOH (1.2 mmol) in anhydrous THF at 0 ° C, and the obtained solution was warmed to 25 ° C and stirred for 30 min. Then 4-(2-(phenanthryl-2-yl)-4-(trifluoromethyl)-1H-pyrrol-1-yl)phenylamine (1 g) (1.0 mmol) and pyridine (2.0 mmol) in THF Solution. The solution was stirred at 25 ° C for 4 h and then concentrated under reduced pressure. The resulting residue in DCM to 20% of trifluoroacetic acid at room temperature for 3 h, and then washed with 10% NaHCO _3, dried over Na ₂ SO _4, and concentrated under reduced pressure. The residue was purified by flash chromatography to afford compound III- 36 (83 mg). Process (D) : Representative Triazole Derivative 2- Amino -N-(4-(2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- pyrrol- 1 -yl ) benzene yl) acetyl amine (III-33)

Method (D) . Alternative step h . At 0 ℃ 4- (2- (phenanthrene-2-yl) -4- (trifluoromethyl) lH-pyrrol-1-yl) aniline (1g) (70 mg, 0.17 mmol), Nitrite tributyl (26 mg, 0.26 mmol) and trimethylsilyl azide silicon group (24 mg, 0.20 mmol) mixture (10 mL) was stirred in dry acetonitrile in the 2 h, and then concentrated under reduced pressure. The crude azide residue (70 mg, 0.16 mmol) and N,N -dimethylprop-2-yn-1-amine (27 mg, 0.32 mmol) were suspended in THF (2 mL) and t- BuOH ( In 1.0 mL), a solution of sodium ascorbate (19 mg, 0.096 mmol) in water (1 mL) and CuSO ₄ .5H ₂ O (12 mg, 0.048 mmol) was added. The resulting mixture was stirred overnight. The mixture was diluted with water and extracted with EtOAc (2 x 20 mL). The combined organic layers were dried over anhydrous Na ₂ SO _4, and concentrated under reduced pressure. By silica gel flash chromatography (DCM: MeOH 98: 2) Purification of the crude product was an off-white powder of Compound III-33 (64.0 mg), 72% yield. Method (E) : Representative amino acid derivative of PyBOP using the peptide coupling agent

Method (F) . Alternative step h . To a solution of Boc-protected amino acid (3.0 eq.) and triethylamine (3.0 eq.) in dry DMF was added PyBOP (3.2 eq.) at 0 °C. The reaction was warmed to room temperature and stirred for 1 h. The mixture was cooled to 0 ° C and amine (1 g) (1.0 eq.) and triethylamine (3.0 eq.). The resulting mixture was stirred at 25 ° C for 48 h. The reaction was monitored by TLC. The mixture was poured into ice cold water and then extracted with EtOAc (2 x 50 mL). The combined organic layers were dried via Na ₂ SO _4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography (EtOAc:EtOAc) toield Boc-protected decylamine (0.200 g) was dissolved in EtOAc (10 mL). The resulting solution was stirred at room temperature for 2 h and then concentrated under reduced pressure. The crude product was purified by silica gel flash chromatography (DCM: methanol: NH ₄ OH, 96:2:2) to give the corresponding compound III-18 , III-20 , III-22 , III-24 , III-26 , III -27 , III-28 and III-30 , the yield is 54% to 83%. Example 2 : N-(4-(4-( Trifluoromethyl )-2-(4'-( trifluoromethyl )-[1,1' -biphenyl ]-4 -yl )-1H- pyrrole -1 -yl ) phenyl ) propynylamine ( III-32 )

The synthetic sequences described below are shown in Figure 5B and are used to prepare such as III-6 , III-7 , III-8 , III-9 , III-13 , III-14 , III-15 , III-31 , III. Compounds of -32 , III-35 and III-39 . 1-(4'-( trifluoromethyl )-[1,1' -biphenyl ]-4 -yl ) ethanone

See Figure 5B , step a . 4-Bromoacetophenone (11.8 g, 59 mmol), 4-trifluoromethylphenylboronic acid (11.4 g, 60 mmol), palladium (II) acetate (250 mg, 2 mol%), potassium carbonate (20.3 g) , 147 mmol) and tetrabutylammonium bromide (20.1 g, 62 mmol) were flushed with argon. Water (500 mL) was introduced using a syringe. The resulting suspension was stirred and heated to 60 ℃, continued 2 h, then cooled to room temperature, diluted with water, extracted with ethyl acetate, filtered through diatomaceous earth, dried over Na ₂ SO _4, and concentrated in vacuo to Dry to give 1-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)ethanone (15.2 g), yield 97%. The product was used in step b without further purification. 4-(1,1 -diethoxyethyl )-4'-( trifluoromethyl )-1,1'- biphenyl

See Figure 5B , step b . Add N -bromosuccinimide (0.094 g, 0.52 mmol) to 1-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)ethanone (7.0 g , 26.44 mmol), a solution of triethyl orthoformate (7.70 g, 52.88 mmol) and anhydrous EtOH (70 mL). The resulting solution was stirred at room temperature for 6 h. The reaction was monitored by TLC. Upon completion, the addition of cold aqueous NaOH solution (10%, 15 mL), and the mixture (3 × 50 mL) and extracted with Et ₂ O. The organic extracts (3 × 25 mL) and washed with water, and dried over anhydrous Na ₂ SO _4. The solvent was removed under reduced pressure. The crude product was purified by flash chromatography of TEA-coated cerium oxide to give 4-(1,1-diethoxyethyl)-4'-(trifluoromethyl)-1,1'-biphenyl ( 7.33 g), yield 82%. (Z)-4- ethoxy -1,1,1- trifluoro- 4-(4'-( trifluoromethyl )-[1,1' -biphenyl ]-4 -yl ) butene- 3 - en-2-one

See Figure 5B , step c . To a solution of 4-(1,1-diethoxyethyl)-4'-(trifluoromethyl)-1,1'-biphenyl (9.36 g, 27.66 mmol) in chloroform (50 mL) Pyridine (4.35 g, 55.32 mmol) was added and the resulting solution was stirred at 0 ° C for 5 min. A solution of trifluoroacetic anhydride (11.63 g, 55.32 mmol) in 30 mL of chloroform was added dropwise over 15 min. The resulting solution was stirred at room temperature for 5 to 6 h. The reaction was monitored by TLC. Upon completion of the reaction, ice-cold water (50 mL) was added and the mixture was extracted with DCM (3×60 mL). The organic layer was washed with 2 N HCl solution to 10% Na ₂ CO ₃ aqueous solution was washed, and dried over anhydrous Na ₂ SO _4. The solvent was removed under reduced pressure. The crude product was purified by flash chromatography to give ( Z )-4-ethoxy-1,1,1-trifluoro-4-(4'-(trifluoromethyl)-[1,1'-biphenyl 4-yl)but-3-en-2-one (9.12 g), yield 85%. (Z)-4- ethoxy -2-( trifluoromethyl )-4-(4'-( trifluoromethyl )-[1,1' -biphenyl ]-4 -yl )-2- (( trimethylcarbinyl ) oxy ) but- 3 -enenitrile

See Figure 5B , step d . Add ( Z )-4-Ethoxygen to a solution of trimethylmethanesulfonyl cyanide (2.49 g, 25.10 mmol) and triethylamine (0.095 g, 0.965 mmol) in acetonitrile (20 mL) at 0 °C Base-1,1,1-trifluoro-4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)but-3-en-2-one (7.50 g, 19.31 mmol) in acetonitrile (20 mL). The resulting solution was stirred for 16 h and then concentrated under reduced pressure to give (Z)-4-ethoxy-2-(trifluoromethyl)-4-(4'-(trifluoromethyl)-[1 , 1'-biphenyl]-4-yl)-2-((trimethylcarbinyl)oxy)but-3-enenitrile (7.90 g), yield 84%. The product was used in Step 5 without further purification. (Z)-2-( Aminomethyl )-4- ethoxy -1,1,1- trifluoro- 4-(4'-( trifluoromethyl )-[1,1' -biphenyl ] -4 -yl ) but- 3 -en -2- ol

See Figure 5B , step e . LiAlH ₄ (0.857 g, 22.56 mmol) was suspended in dry diethyl ether (40 mL) under EtOAc. (Z)-4-Ethoxy-2-(trifluoromethyl)-4-(4'-(trifluoromethyl)-[1,1'-linked by 30 min at 0 to 5 °C A solution of phenyl]-4-yl)-2-((trimethylcarbinyl)oxy)but-3-enenitrile (10.0 g, 20.51 mmol) in dry diethyl ether (60 mL). The mixture was allowed to reach room temperature and stirred overnight. The mixture was cooled to 0 to 5 ℃, and added to a cold 30% NaOH (10 mL) \ solution to quench excess LiAlH _4. The mixture was filtered and the solid was washed with EtOAc (3 &lt The filtrate was dried over Na ₂ SO ₄ and concentrated under reduced pressure to give (Z)-2-(aminomethyl)-4-ethoxy-1,1,1-trifluoro-4-(4'-( Trifluoromethyl)-[1,1'-biphenyl]-4-yl)but-3-en-2-ol (6.70 g), yield 78%. 4-( Trifluoromethyl )-2-(4'-( trifluoromethyl )-[1,1' -biphenyl ]-4 -yl )-1H- pyrrole

See Figure 5B , step f . To (Z)-2-(Aminomethyl)-4-ethoxy-1,1,1-trifluoro-4-(4'-(trifluoromethyl)-[1,1'-biphenyl To a solution of -4-yl)but-3-en-2-ol (3.0 g, 7.15 mmol) in EtOAc (EtOAc) (EtOAc) The resulting solution was stirred at 80 ° C for 12 h and was monitored by TLC. Upon completion, water and saturated NaHCO ₃ (20 mL). The solution (3 x 50 mL) extracted with EtOAc, and the combined organic layers were dried over anhydrous Na ₂ SO _4. The solvent was removed under reduced pressure and EtOAcqqqqqqqqqq Base]-[1,1'-biphenyl]-4-yl)-1H-pyrrole (2.18 g), yield 86%). 1-(4- Nitrophenyl )-4-( trifluoromethyl )-2-(4'-( trifluoromethyl )-[1,1' -biphenyl ]-4 -yl )-1H - pyrrole

See Figure 5B , step g . To 4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1H-pyrrole (2.0 g, 5.62 mmol) 4-Fluoronitrobenzene (1.19 g, 8.44 mmol) and K ₂ CO ₃ (1.55 g, 11.25 mmol) were added to a solution in DMF (20 mL). The resulting mixture was stirred at 120 ° C for 12 h. Upon completion, ice cold water was added and the solution was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anhydrous Na ₂ SO _4. The solvent was removed under reduced pressure and EtOAcqqqqqqqqqq 2-(4'-(Trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1H-pyrrole (1.74 g), yield 65%. 4-(4-( Trifluoromethyl )-2-(4'-( trifluoromethyl )-[1,1' -biphenyl ]-4 -yl )-1H- pyrrol- 1 -yl ) aniline

See Figure 5B , step h . To 1-(4-nitrophenyl)-4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)- To a solution of 1H-pyrrole (1.0 g, 2.1 mmol) EtOAc (20 mL) 70 PSI of H ₂ gas was applied to the mixture for 3 h using a Parr apparatus. The reaction mixture was filtered through celite to remove the catalyst, and the filtrate was concentrated under reduced pressure to give purified 4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1, 1'-biphenyl]-4-yl)-1H-pyrrol-1-yl)aniline (0.730 g), yield 78%

Peptide coupling agent TBTU Representative Michael Receptor derivatives: N-(4-(4-( Trifluoromethyl )-2-(4'-( Trifluoromethyl )-[1,1'- Biphenyl ]-4- base )-1H- Pyrrole -1- base ) Phenyl ) Propargylamine ( III-32 )

See Figure 5B , step i . 4-(4-(Trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl Aniline (1.0 equivalents), propiolic acid (1.2 equivalents) and 2-(1i-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) ( The mixture was stirred at room temperature for 48 h (monitored by TLC; DCM:MeOH). The resulting mixture was diluted with DCM and washed with water and brine. The organic phase was dried over Na ₂ SO _4, filtered, and concentrated under reduced pressure. By flash chromatography (DCM: MeOH) The residue was purified to give Compound III-32 (82 mg), in 74% yield. Example 3 : 2- Amino -N-(4-(2-( phenanthr -2- yl )-4-( trifluoromethyl )-1 H - imidazol- 1 -yl ) phenyl ) acetamide (XI -1)

The synthetic sequence described below is shown in Figure 6 . As shown in Figure 6, post-modified by various methods (the AF), was prepared from compound XI-1 derivatives of 2c. As shown in Figure 6, was prepared using method A and XI-1 XI-6. Method B was used to prepare XI-5 as described above. Method XI was used to prepare XI-9 as described above. Method F was used to prepare XI-14 , XI-15 and XI-16 as described above. 2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- imidazole (2a)

Dissolve 3,3-dibromo-1,1,1-trifluoropropan-2-one (2.0 g, 7.40 mmol) and sodium acetate (600 mg, 7.40 mmol) in water (2 mL) and heat to 100 ° C for 1 h. The mixture was then cooled to room temperature and a solution of phenanthrene-2-carbaldehyde (1.52 g, 7.40 mmol) and ammonium hydroxide (15 mL) in methanol (40 mL). The resulting mixture was stirred at room temperature for 1 h, heated to reflux for 2 h and then stirred at room temperature overnight. The mixture was concentrated under reduced pressure and the residue was crystallisjjjjjjjj The combined organic extracts were dried over anhydrous Na ₂ SO _4, filtered and concentrated. By flash chromatography (Hex: EtOAc6: 4) Purification of the crude product was an off-white solid 2- (phenanthrene-2-yl) -4- (trifluoromethyl) lH-imidazole (2a) (1.75 g ), the yield was 76%. 1-(4- Nitrophenyl )-2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- imidazole (2b)

Add 4-fluoronitro to a solution of 2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -imidazole ( 2a ) (1.75 g, 5.60 mmol) in DMF (20 mL) Benzene (1.18 g, 8.41 mmol) and K ₂ CO ₃ (1.55 g, 11.2 mmol). The resulting mixture was stirred at 130 ° C for 12 h. The reaction was monitored by TLC. Upon completion, ice cold water was added and the solution was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anhydrous Na ₂ SO _4, filtered, and concentrated under reduced pressure. The crude product was purified by EtOAc EtOAc EtOAc (EtOAc) Base- 1H -imidazole (2b) (1.16 g), yield 67%. 4-(2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- imidazol- 1 -yl ) aniline (2c)

To 1-(4-Nitrophenyl)-2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -imidazole (2b) (1.0 g, 2.31 mmol) in EtOAc (20 ml And 10% palladium on carbon (122 mg, 1.15 mmol) was added to a solution in MeOH (10 mL). The resulting mixture was pressurized with H ₂ gas at 75 psi for 3 h on a Parr apparatus. The mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to give purified 4-(2-(phenan-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)aniline (2c) (763 mg), yield 82%. 2- Amino -N-(4-(2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- imidazol- 1 -yl ) phenyl ) acetamide (XI-1)

Method (A) : Boc-protected glycine (47 mg, 0.27 mmol) and 4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -imidazol-1-yl To a solution of aniline (2c) (0.100 g, 0.24 mmol) in dry THF (20 mL), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride Salt (71 mg, 0.36 mmol). The resulting mixture was stirred at 25 ° C for 12 h and then concentrated under reduced pressure. The residue was suspended in water and then extracted with EtOAc. The organic phase was dried over anhydrous Na ₂ SO _4, and concentrated under reduced pressure to give Boc protected intermediate. The intermediate was dissolved in EtOAc (9 mL) and concentrated EtOAc (1 mL). The resulting solution was stirred at room temperature for 2 h and then concentrated under reduced pressure. By silica gel flash chromatography _{(DCM: MeOH: NH 4 OH} 96: 2: 2) Purification of the crude product was obtained as a white powder of 2-amino - N - (4- (2- (phenanthrene-2-yl) 4-(Trifluoromethyl)-1 H -imidazol-1-yl)phenyl)acetamide (XI-1) (95 mg), yield 90%. 2-( Methylamino )-N-(4-(2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- imidazol- 1 -yl ) phenyl ) acetamidamine (XI -6)

According to Method A , compound XI-6 was prepared using N- Boc, N -methylglycine as described above. 2-( Dimethylamino )-N-(4-(2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- imidazol- 1 -yl ) phenyl ) acetamidamine ( XI-5)

Compound XI-5 was prepared according to Method B as described above. N,N -Dimethyl- 1-(1-(4-(2-( phenanthr -2- yl )-4-( trifluoromethyl )-1H- imidazol- 1 -yl ) phenyl )-1H- 1,2,3- triazol- 4 -yl ) methylamine (XI-9) Compound XI-9 was prepared according to Method D as described above. Compounds XI-14 , XI-15 and XI-16

Compounds XI-14 , XI-15 and XI-16 were prepared according to Method F as described above. Example 4 : 2- Amino - N- (4-(6-( phenanthr -2- yl )-4-( trifluoromethyl ) pyridin -2- yl ) phenyl ) acetamide (IX-1)

The synthetic sequence described below is shown in Figure 7A . As shown in 7A, a post-modified by various methods (AF), Compound 3d was prepared from the derivative of IX-1. 4,4,4- trifluoro- 1-(4- nitrophenyl ) butane- 1,3 -dione (3a)

NaH (871 mg, 36.3 mmol) was suspended in anhydrous THF (20 mL) and ethyl trifluoroacetate (5.16 g, 14.0 mmol). The resulting mixture was stirred at room temperature for 10 min. To the mixture was added dropwise a solution of 4-nitroacetophenone (5.0 g, 12.0 mmol) in THF (10 mL), and the mixture was allowed to stand at room temperature for 4 h. The mixture was then cooled to 0.degree. C. and quenched with 1 N EtOAc (0.5 mL). The solution was allowed to stir for 15 min before adding a saturated NaHCO ₃ solution. The resulting solution was extracted with EtOAc. The organic layer was dried over anhydrous Na ₂ SO _4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel to give 4,4,4-trifluoro-1-(4-nitrophenyl)butane-1,3-dione (3a) (5.51 g). The yield was 95%. 3- hydroxy- 1-(4- nitrophenyl )-5-( phenanthr -2- yl )-3-( trifluoromethyl ) pent- 4- yn- 1 -one (3b)

Was added dropwise n -BuLi (0.294 g 4.6 mmol) at -78 deg.] C to 2-ethynyl -one (935 mg, 4.6 mmol) in dry THF (7 mL) in the solution. After the addition of n- BuLi, the cooling bath was removed and the solution was allowed to warm to room temperature and stirred for 1.5 h. The solution was again cooled to -78 ° C, and 4,4,4-trifluoro-1-(4-nitrophenyl)butane-1,3-dione ( 3a ) (500 mg, 2.3 mmol) was added dropwise. A solution in anhydrous THF (3 mL). After the addition of 3a , the solution was allowed to warm to room temperature and stirred for 3 h. Saturated aqueous NH ₄ Cl (5 mL), and the mixture was stirred for 15 min. Water and EtOAc were added and the layers were separated. The aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water and dried over Na ₂ CH ₄ The residue was purified by flash chromatography to give 3-hydroxy-1-(4-nitrophenyl)-5-(phenanthr-2-yl)-3-(trifluoromethyl)pent-4-yne-1 - Ketone (3b) (911 mg) in 85% yield. 2-(4- Nitrophenyl )-6-( phenanthr -2- yl )-4-( trifluoromethyl ) pyridine (3c)

To 3-hydroxy-1-(4-nitrophenyl)-5-(phenanthr-2-yl)-3-(trifluoromethyl)pent-4-yn-1-one (3b) (200 mg, 0.43 mmol) Urea (34 mg, 0.51 mmol) and TFA (187 mg, 1.5 mmol) were added to a solution in toluene (4 mL). The resulting mixture was heated at reflux for 6 h and then was taken &lt Triethylamine (0.2 mL) was added, and the solution was concentrated under reduced pressure. The residue was purified by flash chromatography to give 2-(4-nitrophenyl)-6-(phenan-2-yl)-4-(trifluoromethyl)pyridine ( 3c ) (149 mg) It is 78%. 4-(6-( phenanthr -2- yl )-4-( trifluoromethyl ) pyridin -2- yl ) aniline (3d)

To 2-(4-Nitrophenyl)-6-(phenanthr-2-yl)-4-(trifluoromethyl)pyridine ( 3c ) (150 mg, 0.43 mmol) in EtOAc (10 mL) 10% palladium on carbon (46 mg, 0.43 mmol) was added to the solution in 5 mL). H ₂ gas was added to the resulting mixture at 75 psi using a Parr apparatus, and the reaction was allowed to stir for 2 h. The mixture was filtered through celite to remove the catalyst, and concentrated under reduced pressure to give 4-(6-(phenan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)aniline (3d) Compound (115 mg), yield 82%. 2- Amino -N-(4-(6-( phenanthr -2- yl )-4-( trifluoromethyl ) pyridin -2- yl ) phenyl ) acetamidamine (IX-1)

Compound IX-1 was prepared according to Method A as described above. To the third butoxycarbonyl ( ^t BOC) glycine (46 mg, 0.26 mmol) and 4-(6-(phenanthr-2-yl)-4-(trifluoromethyl)pyridin-2-ylaniline ( 3d ) (100 mg, 0.24 mmol) of 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (1%) in anhydrous THF (10 mL) 71 mg, 0.36 mmol). The resulting mixture was stirred at 25 ° C for 12 h and then concentrated under reduced pressure. The residue was suspended in water and extracted with EtOAc. The organic phase was dried over anhydrous Na ₂ SO _4, filtered, and concentrated under reduced pressure to give the Boc protected intermediate. The intermediate (0.110 g, 0.73 mmol) was dissolved in EtOAc (10 mL). The resulting solution was stirred at room temperature for 2 h and then concentrated under reduced pressure. By silica gel flash chromatography (DCM: _{methanol: NH 4 OH 96: 2:} 2) Purification of the crude product was obtained as a white powder corresponding 2-amino - N - (4- (6- (phenanthrene -2- 4-(trifluoromethyl)pyridin-2-yl)phenyl)acetamide (IX-1) (98.5 mg), yield 87%. Example 5 : 2- Amino -N-(4-(2-( naphthalen -2- yl )-4-( trifluoromethyl )-1H- pyrrol- 1 -yl ) phenyl ) acetamidamine (III- 3)

As shown, Compound III-3 was prepared 7B and derivatives thereof, such as III-4, III-11, III-12, III-17, III-19, III-24, III-26 and III-29. 4-(1,1 -diethoxyethyl )-4'-( trifluoromethyl )-1,1'- biphenyl

See Figure 7B , step a . N-Bromosuccinimide (0.168 g, 0.94 mmol) was added to 2-ethyldecylnaphthalene (8.0 g, 47.0 mmol), triethyl orthoformate (13.93 g, 94.00 mmol) and anhydrous EtOH (80 mL) In the solution. The resulting solution was stirred at room temperature for 6 h. The reaction was monitored by TLC. Upon completion, the addition of cold aqueous NaOH solution (10%, 15 mL), and the mixture (3 × 50 mL) and extracted with Et ₂ O. The organic extracts (3 × 25 mL) and washed with water, and dried over anhydrous Na ₂ SO _4. The solvent was removed under reduced pressure. The crude product was purified by flash chromatography eluting with EtOAc EtOAc EtOAc (EtOAc) (Z)-4- ethoxy -1,1,1- trifluoro- 4-( naphthalen -2- yl ) but- 3 -en -2- one

See Figure 7B , step b . Pyridine (9.7 g, 122.7 mmol) was added to a solution of 2-(1,1-diethoxyethyl)naphthalene (15.0 g, 61.39 mmol) in chloroform (60 mL). Stir for 5 min. A solution of trifluoroacetic anhydride (25.8 g, 122.7 mmol) in 40 mL of chloroform was added dropwise over 15 min. The resulting solution was stirred at room temperature for 5 to 6 h. The reaction was monitored by TLC. Upon completion of the reaction, ice-cold water (50 mL) was added and the mixture was extracted with DCM (3×60 mL). The organic layer was washed with 2 N HCl solution to 10% Na ₂ CO ₃ aqueous solution was washed, and dried over anhydrous Na ₂ SO _4. The solvent was removed under reduced pressure. Purification by flash chromatography to give (Z)-4-ethoxy-1,1,1-trifluoro-4-(naphthalen-2-yl)but-3-en-2-one (14.0 g) ), the yield was 78%. (Z)-4- ethoxy- 4-( naphthalen -2- yl )-2-( trifluoromethyl )-2-(( trimethylcarbinyl ) oxy ) but- 3 -enenitrile

See Figure 7B , step c . Add (Z)-4-Ethoxygen to a solution of trimethylmethanesulfonyl cyanide (6.13 g, 61.75 mmol) and triethylamine (0.240 g, 0.237 mmol) in acetonitrile (40 mL) at 0 °C A solution of benzyl-1,1,1-trifluoro-4-(naphthalen-2-yl)but-3-en-2-one (7.50 g, 19.31 mmol) in EtOAc (20 mL). The resulting solution was stirred for 16 h and then concentrated under reduced pressure to give ((Z)-4-ethoxy-4-(naphthalen-2-yl)-2-(trifluoromethyl)-2-( Trimethylmethanealkyl)oxy)but-3-enenitrile (6.96 g) in 85% yield. The product was used in the next step without further purification. (Z)-2-( Aminomethyl ) -4- ethoxy -1,1,1- trifluoro- 4-( naphthalen -2- yl ) but- 3 -en -2- ol

See Figure 7B , step d . LiAlH ₄ (2.0 g, 53.11 mmol) was suspended in dry diethyl ether (40 mL) and then cooled to 0 to 5 °C. ((Z)-4-Ethoxy-4-(naphthalen-2-yl)-2-(trifluoromethyl)-2-((trimethylmethane) was added dropwise at 0 to 5 °C over 30 min. a solution of benzyl)but-3-enenitrile (19.0 g, 48.28 mmol) in dry diethyl ether (60 mL). The mixture was taken to room temperature and stirred overnight. The mixture was cooled to 0 to 5 ° C and added cooled 30% NaOH (10 mL) was added to quench the excess LiAlH _4. the mixture was filtered, and the solids (3 x 50 mL) washed with EtOAc. the filtrate was dried over Na ₂ SO ₄ and concentrated under reduced pressure to give (Z)-2-(Aminomethyl)-4-ethoxy-1,1,1-trifluoro-4-(naphthalen-2-yl)but-3-en-3-ol (12.24 g), The yield was 78%. 2-( Naphthalen -2- yl )-4-( trifluoromethyl )-1H- pyrrole

See Figure 7B , step e . To (Z)-2-(aminomethyl)-4-ethoxy-1,1,1-trifluoro-4-(naphthalen-2-yl)but-3-en-2-ol (4.0 g, Concentrated HCl (1.5 mL) was added to a solution of 12.31 mmol), acetonitrile (20 mL) and water (1.5 mL). The resulting solution was stirred at 80 ° C for 12 h and was monitored by TLC. Upon completion, water and saturated NaHCO ₃ (20 mL). The solution (3 x 50 mL) extracted with EtOAc, and the combined organic layers were dried over anhydrous Na ₂ SO _4. The solvent was removed under reduced pressure and purified EtOAcqqqqqqqqq 1H-pyrrole (2.76 g), yield 86%. 2-( naphthalen -2- yl )-1-(4- nitrophenyl )-4-( trifluoromethyl )-1H- pyrrole

See Figure 7B , step f . Add 4-fluoronitrobenzene (0.809 g) to a solution of 2-(naphthalen-2-yl)-4-(trifluoromethyl)-1H-pyrrole (1.0 g, 3.82 mmol) in DMF (20 mL) , 5.74 mmol) and K ₂ CO ₃ (1.05 g, 7.52 mmol). The resulting mixture was stirred at 120 ° C for 12 h. Upon completion, ice cold water was added and the solution was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anhydrous Na ₂ SO _4. The solvent was removed under reduced pressure and purified EtOAcqqqqqqqq 4-(trifluoromethyl)-1H-pyrrole (1.05 g), yield 72%. 4-(4-( Trifluoromethyl )-2-(4'-( trifluoromethyl )-[1,1' -biphenyl ]-4 -yl )-1H- pyrrol- 1 -yl ) aniline

See Figure 7B , step g . To 2-(naphthalen-2-yl)-1-(4-nitrophenyl)-4-(trifluoromethyl)-1H-pyrrole (1.0 g, 2.84 mmol) in EtOAc (20 mL) 10% Pd/C (0.150 g, 1.41 mmol) was added to the solution in 10 mL), and 70 PSI of H ₂ gas was applied to the mixture for 3 h using a Parr apparatus. The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to give pure 4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'- Phenyl]-4-yl)-1H-pyrrol-1-yl)phenylamine (0.850 g), yield 92%. 2- Amino -N-(4-(2-( naphthalen -2- yl )-4-( trifluoromethyl )-1H- pyrrol- 1 -yl ) phenyl ) acetamide

See Figure 7B , step h . To the third butoxycarbonyl ( t BOC) glycine (0.054 g, 0.31 mmol) and 4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrole-1 Add 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride to a solution of phenylamine (0.100 g, 0.28 mmol) in dry EtOAc (20 mL) (0.083 g, 0.42 mmol). The resulting solution was stirred at 25 ° C for 12 h and then concentrated under reduced pressure. The resulting residue was suspended in water and extracted with EtOAc. The organic layer was dried over anhydrous Na ₂ SO _4, and solvent was removed under reduced pressure to give Boc protected intermediate, The crude Boc protected intermediate (0.140 g, 0.73 mmol) was dissolved in containing concentrated HCl (1 mL) In EtOAc (9 mL). The resulting solution was stirred at room temperature for 2 h and concentrated under reduced pressure. By silica gel flash chromatography _{(DCM: MeOH: NH 4 OH} 96: 2: 2) Purification of the crude product was obtained as a white powder of 2-amino -N- (4- (2- (naphthalen-2-yl) 4-(Trifluoromethyl)-1H-pyrrol-1-yl)phenyl)acetamide II-3 (0.101 g), yield 90%. ¹ H NMR (400 MHz, CDCl ₃ ) δ: 9.52 (s, 1H), 8.76 (dd, J = 5.9, 3.3 Hz, 1H), 7.72 ~ 7.69 (m, 2H), 7.66 (d, J = 8.6 Hz , 1H), 7.59 (d, J = 8.70 Hz, 2H), 7.44 (dd, J = 6.18, 3.2 Hz, 2H), 7.25 (s, 1H), 7.16 ~ 7.14 (m, 3H), 6.69 (s, 1H), 3.46 (s, 2H), 1.61 (s, 2H); ¹³ C NMR (100 MHz, CDCl ₃ ) δ: 170.8, 137.1, 135.1, 134.9, 133.1, 132.2, 129.0, 127.9, 127.7, 127.5, 127.3 , 126.3 (3 X CH), 126.1, 125.1, 123.0 (q, J = 4.8 Hz), 119.8, 115.5 (d, J = 37.3 Hz), 107.6 (d, J = 2.7 Hz), 44.9. Example 6 : 2- Amino -N-(4-(3- isopropyl- 6-(4-( trifluoromethyl ) phenyl )-1H- indol- 1 -yl ) phenyl ) acetamide (V-1):, a compound represented by the formula V was prepared from compound 3d as shown FIG. 7C, a compound such as V-1 to V-17. 3- isopropyl- 6- bromo 1H -indole

See Figure 7C , step a . A mixture of triethyldecane (8.90 g, 76.53 mmol), trichloroacetic acid (6.12 g, 38.26 mmol) was dissolved in toluene (40 mL) and the solution was heated to 70 ° C for 1 h, then 1 A solution of 6-bromoindole (5.0 g, 25.51 mmol) and acetone (4.35 g, 76.53 mmol) in toluene (15 mL) was added dropwise, and the mixture was stirred at 70 ° C for 2 h. the solution, and the organic layer was extracted with 10% aqueous sodium carbonate solution was quenched with ethyl acetate (2 X 50 mL), the dried over anhydrous Na ₂ SO _4, and concentrated under reduced pressure, and by flash column chromatography ( Purification afforded 3-isopropyl-6-bromo 1H -indole (3.09 g, 68%). 6- bromo- 3- isopropyl- 1-(4- nitrophenyl )-1H -indole

See Figure 7C , step b . 3-isopropyl-6-bromo 1 H -indole (3.0 g, 12.0 mmol), 4-iodonitrobenzene (6.29 g, 25.0 mmol), Cu ₂ O (858 mg, 6.0 mmol) and Cs ₂ CO ₃ (4.60 g, 24.0 mmol) in EtOAc (EtOAc) (EtOAc m. ₂ SO _{4 was} dried, filtered, EtOAcjjjjjjjjjjjjjjj -(4-Nitrophenyl)-1H-indole (3.0 g, 68%). 3- isopropyl- 1-(4- nitrophenyl )-6-(4-( trifluoromethyl ) phenyl )-1H -indole

See Figure 7C , step c . 6-Bromo-3-isopropyl-1-(4-nitrophenyl)-1H-indole (1.9 g, 5.2 mmol), (4-(trifluoromethyl)phenylboronic acid (1.2 g, 6.3 mmol) and 2M. Na ₂ CO ₃ (3 mL) in toluene:methanol (10:5 mL) was degassed with nitrogen, then Pd(PPh ₃ ) ₄ (0.180 g, 0.15 mmol) the reaction mixture was heated at 80 ℃ 24 hours, the reaction mixture was concentrated, water was added with ethyl acetate (3 X 50 mL), dried over anhydrous Na ₂ SO _4, and concentrated under reduced pressure, and by flash column chromatography (Hexane: EtOAc = 7:3) to give 3-isopropyl-1-(4-nitrophenyl)-6-(4-(trifluoromethyl)phenyl) as a brown solid. 1H-indole (1.8 g, 80%) 4-(3- isopropyl- 6-(4-( trifluoromethyl ) phenyl )-1H- indol- 1 -yl ) aniline

See Figure 7C , step d . To 3-isopropyl-1-(4-nitrophenyl)-6-(4-(trifluoromethyl)phenyl)-1H-indole (1.8 g, 4.24 mmol) in ethyl acetate (20) 10% palladium on carbon (0.225 g, 2.12 mmol) was added to a solution of ml) and methanol (10 mL), and the reaction was carried out on a Par apparatus at 70 PSI H ₂ for 3 h. After completion, the reaction was filtered through celite to remove the catalyst and concentrated to dryness in vacuo to afford pure 4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1H. -Indol-1-yl)aniline (1.28 g, 77% yield). 2- Amino -N-(4-(3- isopropyl- 6-(4-( trifluoromethyl ) phenyl )-1H- indol- 1 -yl ) phenyl ) acetamide

See Figure 7C , step e . To the third butoxycarbonyl ( t BOC) glycine (175 mg, 1.0 mmol) and 4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1H-indole 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride was added to a solution of -1-yl)aniline (0.360 g, 0.91 mmol) in 20 mL of anhydrous tetrahydrofuran ( 270 mg, 1.3 mmol), stirred at 25 ° C for 12 h and concentrated to dryness in vacuo. The residue was suspended in water and the product extracted with ethyl acetate (2 x 50 mL), dried over anhydrous Na ₂ SO _4, and concentrated to dryness in vacuo to give almost pure compound (2 - ((4- ( 3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1H-indol-1-yl)phenyl)amino)-2-oxoethyl)carbamic acid tert-butyl ester , the crude compound (2-((4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1H-indol-1-yl)phenyl)amino)- 2-Ethylethyl)carbamate (0.396 g, 0.71 mmol) was dissolved in EtOAc EtOAc EtOAc. The crude product was purified by silica gel column chromatography (DCM /MeOH / NH ₄ OH = 6/2/2 in H ₂ O) to give the corresponding 2-amino-N-(4-(3-isopropyl)- 6-(4-(Trifluoromethyl)phenyl)-1H-indol-1-yl)phenyl)acetamide as a white powder V-1 (0.300 g, 93%). ¹ H NMR (300 MHz, CDCl ₃ ) δ: 9.59 (s, 1H), 7.79 ~ 7.76 (m, 3H), 7.73 ~ 7.64 (m, 5H), 7.49 (d, J = 8.6 Hz, 2H), 7.41 (d, J = 7.7 Hz, 1H), 7.14 (s, 1H), 3.53 (s, 2H), 3.33 ~ 3.24 (m, 1H), 1.69 (s, 2H), 1.44 (d, J = 6.8 Hz, 6H); ¹³ C NMR (75 MHz, CDCl ₃ ) δ: 170.8, 145.8, 136.8, 135.9, 135.6, 134.2, 127.9, 127.5, 125.5 (d, J = 3.7 Hz), 124.9, 124.7, 124.6, 120.5, 119.6 (d, J = 69.9 Hz), 109.2, 45.0, 25.4, 23.3. Example 7 : 2- Amino -N-(4-(3-( trifluoromethyl )-6-(4-( trifluoromethyl ) phenyl )-1H- indazol- 1 -yl ) phenyl ) Acetamine (VI-2)

As shown, the compound represented by Formula VI prepared from compound 3d 7C, a compound such as V-1 to V-17. 1-(4- bromo -2- fluorophenyl )-2,2,2- trifluoroethyl- 1 -one

See Figure 7D , step a . Add 2-iododecylbenzene to a solution of 1-(4-bromo-2-fluorophenyl)-2,2,2-trifluoroethanol (1.09 g, 3.99 mmol) in ethyl acetate (30 mL) Formic acid (2.28 g, 7.97 mmol). The reaction was heated to reflux overnight. The reaction was cooled to room temperature and diluted with EtOAc (30 mL). The mixture was filtered through EtOAc (EtOAc)EtOAc. 95%). 6- bromo- 3-( trifluoromethyl )-1H -carbazole

See Figure 7D , step b . Hydrazine hydrate (3.5 mL, 45 mmol) and 1-(4-bromo-2-fluorophenyl)-2,2,2-trifluoroethyl ketone (1.00 g, 3.69 mmol) in 1-butanol (15 mL) Solution in the middle. The reaction was heated to reflux for 6 h then cooled to rt and then stirred overnight. The reaction was diluted with water (30 mL) andEtOAcEtOAc The combined organics were dried with sodium sulfate, filtered and evaporated. The crude product was purified by EtOAc EtOAc EtOAc (EtOAc:EtOAc 6- bromo- 1-(4- nitrophenyl )-3-( trifluoromethyl )-1H -carbazole

See Figure 7D , step c . 6-Bromo-3-(trifluoromethyl)-1H-indazole (1.0 g, 3.77 mmol), 4-fluoronitrobenzene (0.800 g, 5.66 mmol) and K ₂ CO ₃ (1.02 g, 7.54 mmol) The solution in DMF (10 mL) was stirred at 120 ° C for 12 h. The reaction was monitored by TLC. After the reaction was completed, iced water was added and the product was extracted with ethyl acetate (3×50 mL) and dried over anhydrous Na ₂ SO ₄ . After evaporating the solvent, EtOAcqqqqqqqq Methyl)-1H-indazole (0.947 g, 65% yield). 1-(4- nitrophenyl )-3-( trifluoromethyl )-6-(4-( trifluoromethyl ) phenyl )-1H -carbazole

See Figure 7D , step d . 6-Bromo-1-(4-nitrophenyl)-3-(trifluoromethyl)-1H-indole (300 mg, 0.77 mmol), (4-(trifluoromethyl)phenylboronic acid ((4-(trifluoromethyl)phenyl)) A mixture of 177 mg, 0.93 mmol) and 2M Na ₂ CO ₃ (2 mL) in toluene:methanol (10 mL: 5 mL) was degassed with nitrogen, then Pd(PPh ₃ ) ₄ (26 mg, 0.023 mmol) And the reaction mixture was heated at 80 ° C for 12 h, then the mixture was evaporated, mjjjjjjjjjjjjjjjj Purification by column chromatography (hexanes:EtOAc =EtOAc) (. 0.280 g, 85%) 4- (3- ( trifluoromethyl) -6- (4- (trifluoromethyl)) phenyl) lH-indazol-phenyl) lH-indazole - 1- yl ) aniline

See Figure 7D, step e. To 1-(4-nitrophenyl)-3-(trifluoromethyl)-6-(4-(trifluoromethyl)phenyl)-1H-indazole compound (0.280 g, 0.62 mmol) in acetic acid 10% palladium on carbon (0.035 g, 0.31 mmol) was added to a solution of ethyl acetate (10 ml) and methanol (5 mL), and the reaction was carried out on a Par apparatus at 70 PSI H ₂ for 2 h. After completion, the reaction was filtered through celite and concentrated to dryness in vacuo to give purified 4-(trifluoromethyl)-6-(4-(trifluoromethyl)phenyl)-1H-carbazole. -1-yl)aniline (0.250 g, 96% yield). 2- Amino -N-(4-(3-( trifluoromethyl )-6-(4-( trifluoromethyl ) phenyl )-1H- indazol- 1 -yl ) phenyl ) acetamide

See Figure 7D , step f . To the third butoxycarbonyl ( ^t BOC) glycine (0.035 g, 0.20 mmol) and 4-(3-(trifluoromethyl)-6-(4-(trifluoromethyl)phenyl)-1H 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide was added to a solution of oxazol-1-yl)aniline (0.080 g, 0.19 mmol) in 10 mL of dry tetrahydrofuran Hydrochloride (53 mg, 0.27 mmol) was stirred at 25 ° C for 12 h and concentrated to dryness on a rotary evaporator. The residue was suspended in water and extracted with ethyl acetate, dried over anhydrous Na ₂ SO _4, and concentrated to dryness in vacuo to give almost pure Boc protected intermediate. This crude Boc-protected intermediate (0.110 g, 0.20 mmol) was dissolved in EtOAc. The crude product was purified by silica gel column chromatography (DCM /MeOH / NH ₄ OH = 6/2/2 in H ₂ O) to give 2-amino-N-(4-(3-(trifluoromethyl)) -6-(4-Trifluoromethyl)phenyl)-1H-indazol-1-yl)phenyl)acetamide as a white powder VII-2 (0.081 g, 90%). ¹ H NMR (300 MHz, CDCl ₃ ) δ: 9.58 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.83 ~ 7.77 (m, 4H), 7.73 (s, 1H), 7.71 (s , 1H), 7.62 (d, J = 8.8 Hz, 2H), 7.47 (dd, J = 8.4, 1.3 Hz, 2H), 3.45 (s, 2H), 1.69 (s, 2H); ¹³ C NMR (75 MHz , CDCl ₃ ) δ: 169.8, 150.8, 144.2, 140.3, 136.0 (d, J = 32.7 Hz), 127.9, 125.7 (m, J = 3.7 Hz), 123.9, 123.4, 122.8, 121.1, 120.6, 120.3, 108.9 ( d, J = 3.4 Hz), 45.0. Example 8 : Bioassay for anti-dengue activity ≥ 1 μM

The DENV2-eGFP reporter virus was generated by the method reported in Proc. Natl. Acad. Sci. USA, 2012 , 109 , 14610-1415. Human A549 lung cancer cells were infected with DENV2-eGFP reporter virus at MOI 5 and treated with the indicated compounds at the indicated concentrations (1 μM, 2.5 μM and 5 μM). After 24 h of infection, cells were fixed, stained with 4',6-diamidino-2-phenylindole (DAPI), and analyzed by ImageXpress Micro XL High Content Imaging System (Molecular Devices, Sunnyvale CA). 8A to 8D as compared to the DMSO control system, depicted in the case of the pyrrole and pyridine compound is present in different amounts, DENV-2-GFP fluorescence infected human A549 cells of FIG. 9A and 9B as compared to the DMSO control system, in the presence of varying amounts of imidazole compound depicted, the fluorescent FIG DENV-2-GFP infection of human A549 cells. Example 9 : Anti-dengue activity of compounds ≤ 1 μM

8A to select 8D, 9A and further analysis of the most potent agents for the 13 kinds of 9B. Figure 10A shows immunofluorescence images of four representative pyrrole compounds ( III-18 , 22 , 26 and 28 ) of 0, 0.016, 0.031, 0.063, 0.125, 0.25, 0.5 and 1 μM against dengue fever. Fluorescence of DENV-2-GFP in human A549 cells. Figure 10B shows the relatives of selected pyrrole and imidazole compounds ( III-1 , 10 , 16 , 18 , 22 , 24 , 26 , 27 , 28 , 32 and 33 ; XI-1 , 5 ) for dengue viruses ≤ 1 μM Potency (% DENV positive cell percentage versus concentration (μM)). The percentage of DENV-eGFP positive rate was normalized to the solvent control. Example 10 : Anti-dengue activity of compounds is not affected by differences in host cell strains for bioassays

In addition to A549 cancer cells, anti-dengue effects of pyrrole compounds III-18 , 22 , 26 and 28 were explored in human microglial cells CHME3 cells and mononuclear THP-1 cells with DC-SIGN overexpression. Cells were infected with DENV2-eGFP and treated with individual compounds at indicated concentrations (0, 0.31, 0.5, 0.63, 1.0, 1.25, 2.5 μM). Cells were fixed 24 h after infection and analyzed by IFA. By flow cytometry analysis, pyrrole Compound III-18, 22, 26, and 28 effectively blocked the DENV2-eGFP CHME3 human microglial cells (as shown in FIG. 11A of the immune fluorescence image), and human monocytes THP-1 cells (as shown in FIG. 11B to 11E of FIG.). Example 11 : Compounds alleviate infection with four dengue serotypes

Human microglia CHME3 cells were infected with DENV-1 (Hawaii strain), DENV-2 (PL046 strain), DENV-3 (H087 strain) and DENV-4 (H241 strain) at MOI 2 to 5 for 24 h. Various concentrations of compound III-28 (0, 0.5 and 1 μM) were used during infection. Cells were fixed 24 h after infection and analyzed by IFA with anti-DENV antibody and DAPI. Antiviral activity is not limited to DENV2-eGFP reporter virus. Immunofluorescence images as shown in FIG. 12A (-DENV anti-antibody) and FIG. 12B (an anti-antibody -DENV / DAPI staining) of all four serotypes of DENV infected with the wild-type blocked from compound III-28. Example 12 : In vivo anti- DENV activity of compounds

Stat1-/- mouse group (n = 5) (see, J. Infect Dis. 2015 , 211 , 394) DENV-2 New Guinea serially passaged in mouse brain at 1x10 ⁵ PFU/mouse C (NGC-N) was intraperitoneally infused with 30 μL of PBS into the right hemisphere of the brain. Mice also received PBS or Compound III-28 (2.5 mg/kg) intraperitoneally during infection. As shown in FIG. 13, the survival rate is expressed as percent survival. The median survival time (T ₅₀ ) and P value were calculated (compared to PBS, log rank test). A single dose of Compound III-28, shown at 2.5 mg/kg, prolongs the survival of DENV-2 challenged mice, emphasizing the potential of the compounds to protect against several pathogenic human viruses. Example 13 : Compounds alleviate infection with Japanese encephalitis virus (JEV)

Human A549 cells were infected with JEV-eGFP reporter virus at MOI 5 for 24 h and treated with various concentrations (0, 1.0, 2.5 and 5.0 μM) of pyrrole compounds III-18 , 22 , 26 and 28 . The cells were fixed and processed for IFA. As shown in FIG. 14A of the immune fluorescence images, a compound to inhibit infection of JEV. Example 14 : Compounds reduce influenza H1N1 infection

Human A549 cells were infected with influenza A H1N1 virus at MOI 0.01 for 24 h and treated with various concentrations (0, 1.0, 2.5 and 5.0 μM) of pyrrole compounds III-18 , 22 , 26 and 28 . Cells were fixed and stained with anti-NP antibody for IFA. As shown in FIG. 14B of the immune fluorescence images, a compound to inhibit infection of H1N1 influenza. Example 15 : Compounds alleviate infection with Zika virus

Vero cells infected with Zika virus (MOI 0.1 and 5) were treated with the indicated dose of Compound III-28 . Cells were treated with yellow fever virus commonly used anti-E antibodies at 24 and 48 hours post-infection (hpi) for IFA. Nuclei were stained by DAPI and analyzed by ImageXpress Micro XL High Content Imaging System (Molecular Devices). The ICAM signal relative to the anti-Zika E protein is shown in each panel. definition

As used herein, an "alkyl" group includes both straight and branched chain alkyl groups having a plurality of carbon atoms (eg, 1 to 12, 1 to 10, 1 to 8, 1 to 6, or 1 to 4). Examples of the linear alkyl group include a group of a methyl group, an ethyl group, a n -propyl group, a n -butyl group, a n -pentyl group, a n -hexyl group, a n -heptyl group, and an n- octyl group. Examples of branched alkyl groups include, for example, isopropyl, isobutyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl. Representative substituted alkyl groups may be substituted one or more times by substituents such as those listed above, and include, without limitation, haloalkyl (eg, trifluoromethyl), hydroxyalkyl, sulfanyl, amine Alkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl or carboxyalkyl.

As used herein, an "alkoxy" group means a hydroxyl group (-OH) substituted with a bond of a carbon atom of a substituted or unsubstituted alkyl group with a hydrogen atom. Examples of the linear alkoxy group include, for example, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentyloxy group or a hexyloxy group. Examples of the branched alkoxy group include, for example, an isopropoxy group, a second butoxy group, a third butoxy group, an isopentyloxy group or an isohexyloxy group. Examples of the cycloalkoxy group include, for example, a cyclopropoxy group, a cyclobutoxy group, a cyclopentyloxy group or a cyclohexyloxy group. Representative substituted alkoxy groups can be substituted one or more times.

As used herein, a "cycloalkyl" group includes a single ring having from 3 to 12 carbon atoms (eg, from 3 to 10, from 3 to 8, or from 3 to 4, 5 or 6 carbon atoms) in each ring. , bicyclic or tricycloalkyl. Exemplary monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. The number of ring carbons of the cycloalkyl group may be 3 to 8, 3 to 7, 3 to 6, or 3 to 5. Bicyclic and tricyclic ring systems can include both bridged cycloalkyl and fused rings, such as bicyclo[2.1.1]hexane, adamantyl, decalinyl, and the like. The substituted cycloalkyl group may be substituted one or more times with non-hydrogen and non-carbon groups as defined above. The substituted cycloalkyl group may include a ring which may be substituted with a linear or branched alkyl group. A representative substituted cycloalkyl group may be monosubstituted or substituted more than once, for example a 2,2-, 2,3-, 2,4-, 2,5- or 2,6-disubstituted cyclohexyl group.

As used herein, "heterocycloalkyl" ring means an aromatic carbocyclic ring in which one or more ring carbon atoms are replaced by a heteroatom (eg, N, S or O). The non-aromatic heterocyclic ring may have 4, 5, 6, 7 or 8 ring atoms. Examples include oxazoline, thiazolinyl, oxazolidinyl, thiazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidine Base, piperidinyl, thiazolidinyl and the like.

As used herein, "aryl" group means a carbocyclic aromatic hydrocarbon. The aryl groups herein include monocyclic, bicyclic and tricyclic ring systems. The aryl group includes, for example, a phenyl group, a decyl group, a heptenyl group, a biphenyl group, a fluorenyl group, a phenanthryl group, a fluorenyl group, a fluorenyl group, an indanyl group, a pentenyl group, a naphthyl group, and the like, such as a phenyl group or a biphenyl group Base and naphthyl. The aryl group may contain, for example, 6 to 14, 6 to 12 or 6 to 10 ring carbons. In some embodiments, the aryl group can be phenyl or naphthyl. Although the phrase "aryl" may include a group containing a fused ring such as a fused aromatic-aliphatic ring system (eg, indanyl or tetrahydronaphthyl), unless specified as substituted or as appropriate Substituted, otherwise the "aryl" group does not include an aryl group to which one of the ring members is bonded to another group such as an alkyl group or a halo group. In contrast, a group such as a tolyl group may be referred to as a substituted aryl group. A representative substituted aryl group can be monosubstituted or substituted more than once. For example, mono-substituted aryl groups include, but are not limited to, 2-, 3-, 4-, 5- or 6-substituted phenyl or naphthyl groups which may be substituted with substituents such as those described above.

As used herein, "aralkyl" means an alkyl group wherein the hydrogen or carbon bond of the alkyl group is replaced by a bond to an aryl group. In some embodiments, an aralkyl group contains 7 to 16 carbon atoms, 7 to 14 carbon atoms, or 7 to 10 carbon atoms. The substituted aralkyl group may be substituted at the alkyl, aryl or alkyl and aryl groups of the group. Representative aralkyl groups include, for example, benzyl and phenethyl and fused (cycloalkylaryl)alkyl groups such as 4-indanylethyl. The substituted aralkyl group may be substituted one or more times.

As used herein, "heteroaryl" group means a carbocyclic aromatic ring wherein one or more ring carbon atoms are replaced by a heteroatom (eg, N, S or O). Heteroaryl groups may include, for example, imidazolyl, isoimidazolyl, thienyl, furyl, pyridyl, pyrimidinyl, pyranyl, pyrazolyl, pyrrolyl, pyridyl Base, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl and tetrazolyl. Heteroaryl also includes fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or a heteroaryl ring is fused to one or more other heteroaryl rings. Examples of the heteroaryl group may include benzothienyl, benzofuranyl, fluorenyl, quinolyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, benzene And imidazolyl, quinolyl, isoquinolyl and isodecyl.

Groups described herein having two or more attachment points (e.g., divalent, trivalent, or multivalent) within the compounds of the present technology can be identified by the use of the suffix "ene." For example, a divalent alkyl group may be an alkyl group, a divalent aryl group may be an aryl group, a divalent heteroaryl group may be a heteroaryl group or the like. In particular, certain polymers may be described by using the suffix "ene" in conjunction with the terminology describing polymer repeating units.

As used herein, "optionally substituted" means a compound or group that may be substituted or unsubstituted. The term "substituted" refers to an organic group (eg, an alkyl group) which may be replaced by a bond to a non-hydrogen or non-carbon atom with a bond of one or more hydrogen atoms contained therein. Substituted groups also include groups in which one or more bonds to a carbon or hydrogen atom may be replaced by one or more bonds (including double or triple bonds) with a hetero atom. Unless otherwise stated, a substituent may be substituted with one or more substituents. In some embodiments, a substituent may be substituted with 1, 2, 3, 4, 5 or 6 substituents.

Examples of the substituent include: halogen (F, Cl, Br, and I); a hydroxyl group; an alkoxy group, an alkenyloxy group, an aryloxy group, an aralkyloxy group, a heterocyclic oxy group, and a heterocyclic alkoxy group; a carbonyl group ( Oxyl); carboxy; ester; polyamine; hydrazine; hydroxylamine; alkoxyamine; aralkyloxyamine; fluorenyl; sulfide; hydrazine; hydrazine; sulfonyl; sulfonamide; amine; N-oxide;肼;醯肼;腙; azide; guanamine; urea; hydrazine; hydrazine; enamine; quinone imine; isocyanate; isothiocyanate; cyanate; thiocyanate; imine; Or nitrile. A "all" substituted compound or group is a compound or group in which all or substantially all of the substitutable positions are substituted with the indicated substituents. For example, 1,6-diiodoperfluorohexane is a compound of the formula C ₆ F ₁₂ I ₂ in which all substitutable hydrogen atoms have been replaced by fluorine atoms.

In particular, suitable substituents for alkyl, cycloalkyl, heterocycloalkyl or aryl ring carbons are those which do not substantially interfere with the activity of the disclosed compounds. Examples include -OH, halogen (-Br, -, -I, and -F), -OR ^A , -O(CO)R ^A , -(CO)R ^A , -CN, -NO ₂ , -CO ₂ H, -SO ₃ H, -NH ₂ , -NHR ^A , -N(R ^A R ^B ), -(CO)OR ^A , -(CO)H, -CONH ₂ , -CONHR ^A , -CON(R ^A R ^B ), -NHCOR ^A , -NRCOR ^A , -NHCONH ₂ , -NHCONR ^A H, -NHCON(R ^A R ^B ), -NR ^C CONH ₂ , -NR ^C CONR ^A H, -NR ^C CON(R ^A R ^B ), -C(=NH)-NH ₂ , -C(=NH)-NHR ^A , -C(=NH)–N(R ^A R ^B ), -C(=NR ^C )–NH ₂ , -C (=NR ^C )–NHR ^A , -C(=NR ^C )–N(R ^A R ^B ), —NH–C(=NH)–NH ₂ , —NH–C(=NH)–NHR ^A ,- NH–C(=NH)–N(R ^A R ^B ), —NH–C(=NR ^C )–NH ₂ , —NH–C(=NR ^C )–NHR ^A , —NH–C(=NR ^C )–N(R ^A R ^B ), NR ^D H–C(=NH)–NH ₂ , —NR ^D —C(=NH)–NHR ^A , —NR ^D —C(=NH)–N(R ^A R ^B ), -NR ^D -C(=NR ^C )NH ₂ , -NR ^D -C(=NR ^C )–NHR ^A , -NR ^D —C(=NR ^C )–N(R ^A R ^B ), -NHNH ₂ , -NHNHR ^A , -NHR ^A R ^B , -SO ₂ NH ₂ , -SO ₂ NHR ^A , -SO ₂ NR ^A R ^B , -CH=CHR ^A , -CH=CR ^A R ^B , -CR ^{C = CR A R B, -CR} C = CHR A, -CR C = CR B, -CCR A, -SH, -SO k R A (k lines 0 1 or 2) and -NH-C (= NH) -NH 2. Each of R ^A to R ^D may independently be an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aryl or substituted aryl such as alkyl, benzyl or aryl. Further, -NR ^A R ^D together may form a substituted or unsubstituted non-aromatic heterocyclic group. The non-aromatic heterocyclic group, benzyl group or aryl group may also have an aliphatic or substituted aliphatic group as a substituent. The substituted aliphatic group may also have a non-aromatic heterocyclic ring, a substituted non-aromatic heterocyclic ring, a benzyl group, a substituted benzyl group, an aryl group or a substituted aryl group as a substituent. The substituted aliphatic, non-aromatic heterocyclic group, substituted aryl group or substituted benzyl group may have more than one substituent.

Heteroaryl ring nitrogen atoms having three covalent bonds to other heteroaryl ring atoms, suitable substituents can include -OH and C ₁ to C ₁₀ alkoxy. A substituted heteroaryl ring nitrogen atom having three covalent bonds with other heteroaryl ring atoms is positively charged, which can be balanced by anions such as chlorides, bromides, formates, acetates, and the like. )balance. Examples of other suitable counter anions can include the counter anions present in the pharmaceutically acceptable salts.

Suitable substituents for a heteroaryl ring nitrogen atom having two covalent bonds with other heteroaryl ring atoms include alkyl groups, substituted alkyl groups (including haloalkyl groups), phenyl groups, substituted phenyl groups, S(O) ₂ -(alkyl), -S(O) ₂ -NH(alkyl), -S(O) ₂ -NH(alkyl) ₂ and the like.

Also included are pharmaceutically acceptable salts of the compounds described herein. Compounds having sufficient basic functionalities disclosed herein can be reacted with any of a number of organic or inorganic acids to form salts. Likewise, compounds disclosed herein having sufficient acidic functional groups can react with any of a number of organic or inorganic bases to form salts. Acids commonly used to form acid addition salts from compounds having a basic group may include inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like; and organic acids such as p-toluenesulfonic acid, Methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid and the like. Examples of such salts may include sulfates, pyrosulfates, hydrogen sulfates, sulfites, bisulfites, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides. , bromide, iodide, acetate, propionate, citrate, octoate, acrylate, formate, isobutyrate, hexanoate, heptanoate, propiolate, oxalate, Malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-diate, caproic acid-1,6-diate , benzoate, chlorobenzoate, methyl benzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonic acid Salt, xylene sulfonate, phenyl acetate, phenylpropionate, phenylbutyrate, citrate, lactate, γ-hydroxybutyrate, glycolate, tartrate, methanesulfonate , propane sulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like. Base addition salts include those derived from inorganic bases such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates and the like. Such bases used to prepare the salts of the compounds may include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, and the like.

An "effective amount" is an amount of a compound that achieves a beneficial clinical result when a compound is administered to a subject who will be suffering from the fungus. "Beneficial clinical outcome" may include one or more of the following: a decrease in the number of fungal cells in the subject; a decrease in the rate of fungal growth in the subject; a decrease in fungal metabolism or consumption of the subject's body resources; , toxins, proteins, peptides, and other biomolecules associated with infection with fungal infections in the fungus of the subject; fungal, allergic, toxic, disfiguring, or other effects of the fungus on the subject are reduced; The severity of the symptoms associated with the fungus is reduced and/or the life or health of the subject is increased.

The exact amount of compound administered to a subject can depend on the species, life cycle, and process of the fungal infection. The precise amount of the compound administered to the subject may also depend on the characteristics of the subject, such as general health, age, sex, weight, and tolerance to the drug. The skilled person can determine the appropriate dosage based on these and other factors. The effective amount of the disclosed compound typically ranges between about 1 mg/mm ² /day and about 10 g/mm ² /day, preferably between 10 mg/mm ² /day and about 5 g/mm ² /day. between.

The disclosed compounds and pharmaceutical compositions can be administered by any suitable route, including, for example, oral tablets, pills, gel capsules, lozenges or suspensions; by parenteral administration. Parenteral administration can include, for example, systemic administration, such as by intramuscular, intravenous, subcutaneous, or intraperitoneal injection. The compounds can also be administered, for example, orally (e.g., diet), topically, in the form of creams, sprays, patches, and the like; by inhalation (e.g., intrabronchial, intranasal, or oral inhalation aerosol formulation) , by intranasal drops and the like; by absorption through mucous membranes (eg, tissues such as the mouth, nose, rectum, vagina, and the like), via, for example, creams, lozenges, sprays, drops, suppositories And similar) to the administration; depot preparation; coatings on sutures, bandages, medical equipment and the like. In some embodiments, oral or parenteral administration is an exemplary mode of administration.

The disclosed compounds can be administered to a subject together with an acceptable pharmaceutical carrier as part of a pharmaceutical composition for treating the fungal infection. The formulation of the compound to be administered may vary depending on the route of administration and the vehicle to be administered (for example, a solution for injection, a capsule or tablet for ingestion, and the like). Suitable pharmaceutical carriers can contain inert ingredients that do not interact with the compound. Standard pharmaceutical formulation techniques can be employed, such as those described in Remington's Pharmaceutical Sciences, 22nd Edition, Mack Publishing Company, Easton, PA, 2012. Suitable pharmaceutical carriers for parenteral administration may include, for example, sterile water, physiological saline, bacteriostatic saline (e.g., saline containing about 0.9% mg/ml benzyl alcohol, and the like), phosphate buffered saline. , Hank's solution, Ringer's lactate and the like. Methods for encapsulating compositions, such as in hard gelatin or cyclodextrin coatings, or tabletting compositions are known in the art (Baker, et al., "Controlled Release of Biological Active Agents," John Wiley and Sons, New York, 1986).

A "subject" can be any animal subject suffering from an infection with the fungus, for example, the subject can be a mammal, bird, marsupial, fish or amphibious animal. For example, the subject can be a mammal, such as a human. Subjects may also be domesticated or wild animals that require veterinary treatment, such as companion animals (eg, dogs, cats, and the like), farm animals (eg, cows, sheep, pigs, horses, and the like), laboratory animals (eg, , rats, mice, guinea pigs and the like), birds, fish, marsupials and the like.

In the case where the term "include" or "including" is used in the context of this specification or the patent application, it is intended to be similar to the term "comprising", such as when used as a transitional term in the scope of the patent application. Understanding the term is as inclusive. In addition, where the term "or" is used (eg, A or B), it is intended to mean "A or B or both." When the applicant intends to indicate "only A or B and not both", then "only A or B but not both" will be used. Therefore, the use of the term "or" herein is intended to be inclusive, rather than exclusive. See, Bryan A. Garner, A Dictionary of Modern Legal Usage 624 (2nd ed. 1995). In addition, in the case where the terms "in" or "into" are used in the specification or the scope of the patent application, it is intended to mean "on" (on ) or "to". Where the term "selectively" is used in the specification or the scope of the claims, it is intended to refer to the conditions of the component in which the user of the device can activate or deactivate the group as needed or desired for use in the device. The characteristics or functions of the points. Where the term "operably linked" is used in the context of the specification or patent application, it is intended to mean that the identified components are connected in a manner that performs the specified function. Where the term "substantially" is used in the context of this specification or the patent application, it is intended to mean that the identified component has a relationship or quality indicative of the degree of error that would be acceptable in the subject matter.

The singular forms "a", "an", "the" and "the" are used in the plural. For example, reference to "a compound" can include a mixture of two or more compounds, as well as a single compound.

As used herein, the term "about" in conjunction with a number is intended to include the numeral ± 10%. In other words, "about 10" can mean 9 to 11. When the term "about" is used in relation to a number as an integer, the term "about" can mean a number ± 10%, or a number ± 5, ± 4, ± 3, ± 2, or ± 1.

As used herein, the terms "optional" and "optionally" mean that the circumstances described subsequently may or may not occur, so the description includes the circumstances at the time of the occurrence and when the situation does not occur. The situation.

In addition, where the features or aspects of the present disclosure are described in terms of a Markush group, those skilled in the art will recognize that the present disclosure is therefore described in terms of any individual member or subgroup of the Markush group members. . It will be understood by those skilled in the art that the scope of the disclosure and the scope of the invention and the scope of the invention. Any of the listed ranges can be readily identified as being sufficient to describe the same range and capable of decomposing the same range into at least equal half, one-third, one-fourth, one-fifth, one-tenth, and the like. By. As a non-limiting example, the ranges discussed herein can be readily broken down into the lower third, the middle third, and the upper third and the like. Those skilled in the art will also appreciate that all languages, such as "as many as", "at least", "greater than", and "less than", are inclusive of the recited number, and are intended to be subsequently decomposed into the range of sub-ranges discussed above. Ultimately, those skilled in the art will understand that the scope includes individual members. For example, a group having 1 to 3 members refers to a group having 1, 2, or 3 members. Similarly, a group having 1 to 5 members refers to a group having 1, 2, 3, 4, or 5 members, and the like. Although various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art.

As described above, the present application has been described by way of example, and the embodiments are not described in detail, but the scope of the appended claims is not limited or limited in any way. To this detail. Additional advantages and modifications will be apparent to those skilled in the art having the benefit of this disclosure. Therefore, in a broader aspect, the application is not limited to the details, the illustrative examples shown, or any of the devices mentioned. The details, examples, and devices may be departed from the spirit and scope of the general inventive concept.

The drawings incorporated in and constitute a part of this specification are in the

Figure 1A depicts a series of disclosed compounds by the chemical structure including a pyrrolyl group.

Figure 1B depicts a series of disclosed compounds by the chemical structure including a pyrrolyl group.

Figure 1C depicts a series of disclosed compounds by the chemical structure including pyrrolyl groups.

Figure 1D depicts a series of disclosed compounds by the chemical structure including a pyrrolyl group.

Figure 2A depicts a series of disclosed compounds by a chemical structure comprising a sulfhydryl group.

Figure 2B depicts a series of disclosed compounds by the chemical structure including a sulfhydryl group.

Figure 2C depicts a series of disclosed compounds by a chemical structure comprising a sulfhydryl group.

Figure 3 depicts a series of disclosed compounds by chemical structure including carbazolyl or pyridyl groups.

Figure 4A depicts a series of disclosed compounds by a chemical structure comprising an imidazolyl group.

Figure 4B depicts a series of disclosed compounds by the chemical structure including the imidazolyl group.

Figure 4C depicts a series of disclosed compounds by chemical structure including an imidazole group.

Figure 5A depicts the synthetic scheme for a compound having a pyrrolyl group (e.g., the pyrrole compounds of Figures 1A , 1B , 1C, and 1D ).

Figure 5B depicts a synthetic scheme for a compound having a biphenyl group (e.g., the compounds of Figures 1A , 1B , 1C, and 1D ).

Figure 6 depicts the synthetic scheme for a compound having an imidazolyl group (e.g., the compounds of Figures 4A , 4B, and 4C ).

Figure 7A depicts a synthetic scheme for a compound having a pyridyl group (e.g., the pyridine compound of Figure 3 ).

Figure 7B depicts a synthetic scheme for a compound having a naphthyl group (e.g., the naphthalene compound of Figures 1A , 1B , 1C, and 1D ).

Figure 7C depicts the synthetic scheme for a compound having a thiol group (e.g., a ruthenium compound of Figures 2A , 2B, and 2C ).

Figure 7D depicts a synthetic scheme for a compound having a carbazolyl group (e.g., the carbazole compound of Figure 3 ).

Figure 8A is a luminescence map of DENV-2-GFP infected host cells in the presence of varying amounts of the depicted pyrrole compound compared to the DMSO control.

Figure 8B is a luminescence map of DENV-2-GFP infected host cells in the presence of varying amounts of the depicted pyrrole and pyridine compounds compared to the DMSO control.

Figure 8C is a fluorescence map of DENV-2-GFP infected host cells in the presence of varying amounts of the depicted pyrrole compound compared to the DMSO control.

Figure 8D is a fluorescence map of DENV-2-GFP infected host cells in the presence of varying amounts of the depicted pyrrole compound compared to the DMSO control.

Figure 9A is a fluorescence diagram of DENV-2-GFP infected host cells in the presence of varying amounts of the depicted imidazole compound compared to the DMSO control.

Figure 9B is a fluorescence map of DENV-2-GFP infected host cells in the presence of varying amounts of the depicted imidazole compound compared to the DMSO control.

Figure 10A is a collection of immunofluorescent images of the anti-dengue effects of four representative pyrrole compounds indicating concentrations.

Figure 10B is a graph showing the inhibition versus concentration of representatively disclosed pyrrole and pyrazole compounds for dengue-infected host cells.

Figure 11A is a collection of immunofluorescence images of anti-dengue effects of human glial cells CHME3 cells against DENV2-eGFP, based on the concentration of four representative azole compounds.

Figure 11B is a collection of graphs of various concentrations of representative azole compounds showing anti-dengue effects of human mononuclear ball THP-1 cells with DC-SIGN overexpression (for DENV2-eGFP).

Figure 11C is a collection of graphs of various concentrations of representative azole compounds showing anti-dengue effects of human mononuclear THP-1 cells with DC-SIGN overexpression (for DENV2-eGFP).

Figure 11D is a collection of graphs of various concentrations of representative azole compounds showing anti-dengue effects of human mononuclear THP-1 cells with DC-SIGN overexpression (for DENV2-eGFP).

Figure 11E is a collection of graphs of various concentrations of representative azole compounds showing anti-dengue effects of human mononuclear THP-1 cells with DC-SIGN overexpression (for DENV2-eGFP).

Figure 12A is a collection of immunofluorescence images (anti-DENV antibody staining) of representative pyrrole compounds against dengue fever in human microglial cells CHME3 cells infected with various dengue strains: DENV-1 (Hawaii strain) DENV-2 (PL046 strain), DENV-3 (H087 strain) and DENV-4 (H241 strain).

Figure 12B is a collection of immunofluorescence images (anti-DENV antibody/DAPI staining) of representative pyrrole compounds against dengue fever in human microglial cells CHME3 cells infected with various dengue strains: DENV-1 (Hawaii Line), DENV-2 (PL046 strain), DENV-3 (H087 strain) and DENV-4 (H241 strain).

Figure 13 is a graph showing the anti-dengue activity in vivo in a mouse model of a representative azole compound as a percentage of survival over a period of days after infection.

Figure 14A is a collection of immunofluorescence images showing the effects of various concentrations of representative azole compounds on various concentrations of Japanese encephalitis virus infection (JEV-eGFP reporter virus) in human A549 cells.

Figure 14B is a collection of immunofluorescence images showing the effect of various concentrations of representative azole compounds on various concentrations of influenza H1N1 virus infection (influenza H1N1 α-NA) in human A549 cells.

Figure 15 is a collection of immunofluorescence images showing the effect of representative compounds at various concentrations on Vero cells infected with various concentrations of Zika virus.

Claims (86)

An antiviral treatment method comprising: providing a subject afflicted with or at risk of infection with the virus; administering a compound to the subject in an amount effective to reduce the viral infection in the subject, the compound Expressed by structural formula (I) : (I) And a pharmaceutically acceptable salt thereof, wherein: R ¹ is H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro; R ² H, And R ³ is: sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl, β-aminocarbonyl, γ-aminocarbonyl, α-β- a saturated carbonyl, hydrazine or urea; or an aniline nitrogen of the formula (I) , R ² and R ³ together form an optionally substituted heterocyclic group; and the Ar is composed of 1, 2, 3 or 4 rings, as the case may be. a substituted aryl or heteroaryl group, one or more of the ring-bonded ring and the fused ring; Het- based heteroaryl group containing a first ring, the heteroaryl group containing five or six nitrogen a heteroaryl group, the first ring optionally fused to one or more of the second ring and the third ring to form a bicyclic ring consisting of 8, 9, 10, 11, 12 or 13 ring atoms or a tricyclic heteroaryl group, wherein R ¹ and benzene ring A are bonded to the first ring, and Ar is bonded to the first ring, the second ring or the third ring; the limitation is that when the compound is 2 - amino - N - [4- [5- phenanthrene-2-yl-3- (trifluoromethyl) pyrazol-1-yl] phenyl] ethanone In the case of an amine, the virus is not one of the following: Ebola, Marburg, Reisal fever, Hepatitis A, Hepatitis B, serotype 5 adenovirus, Coxsackie virus B4, typhoid, mumps , measles, rubella, respiratory fusion virus a, respiratory fusion virus b, cytomegalovirus, influenza A and influenza B. The subject is infected with the virus according to the method of claim 1, wherein the method comprises administering to the subject an amount effective to reduce one or more symptoms of the viral infection in the subject. The subject is at risk of the viral infection, as in the method of claim 1, wherein the method comprises administering to the subject the compound in an amount effective to reduce the viral infection in the subject. The method of claim 1, wherein the subject comprises a cell capable of expressing one of: GRP78, BiP, and HSPA5; and the cells are infected by the virus or at risk of infection by the virus; And the compound effectively modulates one of the following: GRP78, BiP and HSPA5, which effectively alleviate the viral infection of the cells. For example, in the method of claim 1, the administration is one or more of the following: oral administration, intraperitoneal administration, intravenous administration, and intranasal administration. As in the method of claim 1, the amount of the composition administered to the subject is between about 1 mg and about 100 mg per kg of body weight of the subject. The method of claim 1, wherein the method comprises administering to the subject a dose in a range of mg/kg between one or more of the following: 1 and 5, 1 and 10, 1 and 15, 5 and 10, 5 and 15, and 5 and 20. The method of claim 1, wherein the amount of the composition administered to the subject is administered in a dose of one or more of the following: a single dose, a daily dose, a weekly dose, a monthly dose, and Annual dose. For example, in the method of claim 1, the virus belongs to one of the following: adenoviridae; genus genus; hepatic deoxyribonucleic acid; herpesviridae; paramyxoviridae; small ribonucleic acid Virology; chlamydia; and filamentous virus. For example, in the method of claim 1, the virus is one of the following: adenovirus; rysal fever virus; hepatitis B virus; cytomegalovirus; influenza A virus; measles virus; rubella virus; mumps Virus; respiratory fusion virus; Coxsackie virus; hepatitis A virus; typhoid; and rubella virus. For example, in the method of claim 1, the virus belongs to the yellow fever virus family. The method of claim 1, wherein the virus is one of the following: Zika virus, dengue virus, and Japanese encephalitis virus. The virus is a dengue virus having one of the following serotypes: DENV1, DENV2, DENV3, DENV4, and DENV5, as in the method of claim 12. The virus is a dengue virus having one of the following strains: DENV1 Hawaii, DENV2 PL046, DENV3 H087, and DENV4 H241, as in the method of claim 12. For example, in the method of claim 1, the virus belongs to the class of orthomyxovirus. The method of claim 1, wherein the virus is an influenza virus. As for the method of claim 1, the virus is influenza H1N1. The method of claim 1, further comprising co-administering an antiviral agent to the subject. The method of claim 1, further comprising co-administering a phosphodiesterase inhibitor to the subject. The method of claim 1, wherein the compound is represented by structural formula (II) : (II) Wherein: R ¹ is a C ₁ -C ₄ alkyl group or a C ₁ -C ₄ haloalkyl group; an Ar phenanthryl group, an anthracenyl group, a biphenyl group, a phenyl group or a naphthyl group, and Ar is optionally subjected to the following Substituted by one or more: halogen, C ₁ -C ₄ haloalkyl, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy, nitrile and nitro; R ² H, and R ³ is SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)C(CH _{3 2} NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O) CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH [CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ Or R ² , R ³ and the aniline nitrogen of formula (II) are formed together: Wherein R ⁴ and R ⁵ are each independently: H, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl or C ₁ -C ₆ haloalkyl; and n is an integer from 1 to 6. The method of claim 20, wherein the compound is represented by structural formula (III) : (III) . Wherein: R ¹ is CF ₃ ; Ar is phenanthryl, anthracenyl, biphenylyl, phenyl or naphthyl; and Ar is optionally halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ haloalkyl substituted; and Ar is 2-phenanthryl, 3-phenanthryl, 9-fluorenyl, 4-biphenylyl, 4-(4'-CF ₃ )-biphenyl, 4- (3',5'-Dimethyl)-biphenyl, 4-(3',5'-dimethoxy)-biphenyl, phenyl, 1-(4-CF ₃ )-phenyl, 1-naphthyl or 2-naphthyl; and R ² is H, and R ³ is SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C (=O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C (= O) CH (CH 3) NH (CH 3), C (= O) CH [CH 2 CH (CH 3) 2] NH (CH 3), C (= O) CH (CH 2 Ph) NH (CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (III) are formed together: . The method of claim 21, wherein the compound is: 2-amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrole- 1-yl)phenyl)acetamidine ( III-1 ); 2-amino- N- (4-(2-(phenanthr-3-yl)-4-(trifluoromethyl)-1 H -pyrrole -1-yl)phenyl)acetamidine ( III-2 ); 2-amino- N- (4-(2-(naphthalen-2-yl)-4-(trifluoromethyl)-1 H - Pyrrol-1-yl)phenyl)acetamidine ( III-3 ); 2-amino- N- (4-(2-(naphthalen-1-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamidine ( III-4 ); 2-amino- N- (4-(4-(trifluoromethyl)-2-(4-(trifluoromethyl)) Phenyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-5 ); N -(4-(2-([1,1'-biphenyl]-4-yl)-) 4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2-aminoacetamide ( III-6 ); 2-amino- N- (4-(4-(3) Fluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-7 ); 2-Amino- N- (4-(2-(3',5'-dimethyl-[1,1'-biphenyl]-4-yl)-4-(trifluoro) Methyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-8 ); 2-amino- N- (4-(2-(3',5'-dimethoxy-) [1,1'-biphenyl] -4-yl) -4- (trifluoromethyl) -1 H - pyrazol 1-yl) phenyl) acetyl amine (III-9); 2- (methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) - 1 H - pyrrol-1-yl) phenyl) acetyl amine (III-10); 2- (methylamino) - N - (4- (2- ( naphthalen-2-yl) -4- (trifluoromethyl methyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-11); 2- (methylamino) - N - (4- (2- ( naphthalen-1-yl) -4 -(Trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-12 ); N -(4-(2-([1,1'-biphenyl]-4) -yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2-(methylamino)acetamide ( III-13 ); N- (4-(2- (3',5'-Dimethyl-[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2 -(methylamino)acetamide ( III-14 ); N- (4-(2-(3',5'-dimethoxy-[1,1'-biphenyl]-4-yl) 4-(Trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2-(methylamino)acetamide ( III-15 ); 2-(dimethylamino) -N -(4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamide ( III-16 ); 2-(dimethyl yl amino) - N - (4- (2- ( naphthalen-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-17) ( S )-2-Amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl ) Phenyl) -3-phenyl-propan-acyl amines (III-18); (S ) -2- ( methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (C fluoromethyl) -1 H - pyrrol-1-yl) phenyl) -3-phenyl-propan-acyl amines (III-19); (S ) -2- ( methylamino) - N - (4- (2 -(naphthalen-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-3-phenylpropanamide ( III-20 ); ( R )-2- (dimethylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) -3-phenyl Propylamine ( III-21 ); ( R )-2-Amino-4-methyl- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H - pyrrol-1-yl) phenyl) pentyl Amides (III-22); (R ) -4- methyl-2- (methylamino) - N - (4- (2- ( 2-phenanthrene -4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)pentanylamine ( III-23 ); ( S )-4-methyl-2-(methylamino) -N -(4-(2-(naphthalen-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)pentanylamine ( III-24 ); ( R )-2 -amino-3-methyl- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)butanamine ( III-25); (R) -2- amino-3-methyl - N - (4- (2- (naphthalen-2-yl) -4- (trifluoromethyl) -1 H - pyrrole -1 - yl) phenyl) butan Amides (III-26); (R ) -2- ( methyl group) - N - (4- (2- ( phenanthrene-2-yl) 4-(Trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)propanamine ( III-27 ); 2-amino-2-methyl- N- (4-(2-( Phenylidene-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)propanamine ( III-28 ); 2-amino-2-methyl- N- ( 4-(2-(naphthalen-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)propanamine ( III-29 ); 1-amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)cyclopropane-1-carboxamide ( III-30 ); -amino- N- (4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)cyclopropane-1-carboxamide ( III-31 ); N -(4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)) )-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)propynylamine ( III-32 ); N,N -dimethyl-1- (1-(4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-1 H -1,2,3-triazole 4-yl)methylamine ( III-33 ); 1-(1-(4-(2-(蒽-9-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl) Phenyl)-1 H -1,2,3-triazol-4-yl) -N,N -dimethylmethylamine ( III-34 ); N,N -dimethyl-1-(1-( 4- (4- (trifluoromethyl) -2- (4 '- (trifluoromethyl) - [1,1'-biphenyl] -4-yl) -1 H - pyrrol-1-yl) Yl) -1 H -1,2,3- triazol-4-yl) methylamine (III-35); N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl -1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-36 ); N- (4-(2-(phenanthr-3-yl)-4-(trifluoromethyl)- 1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-37 ); N -(4-(2-(蒽-9-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-38 ); or N- (4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-)- [1,1'-Biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-39 ). The method of claim 1, wherein the compound is represented by the formula (IV) : (IV) Wherein: R ¹ is C ₁ -C ₄ alkyl or C ₁ -C ₄ haloalkyl; Ar is phenanthryl, fluorenyl, biphenyl, phenyl, naphthyl, pyridyl or pyrrolyl, and Ar In the case of halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkyl, nitrile or SO ₂ -C ₁ -C ₄ alkyl; R ² is H, and R ³ is SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C (=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N (CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (IV) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. The method of claim 23, wherein the compound is represented by the structural formula (V) : (V) Wherein: R ¹ is C ₁ -C ₄ alkyl or C ₁ -C ₄ haloalkyl; Ar is 1-(4-CF ₃ )-phenyl, 1-(4-CN)-phenyl, 1- (4-Me)-phenyl, 5-(2-CF ₃ )-pyridyl, 1-(4-SO ₂ Me)-phenyl, 9-fluorenyl, 1-(4-OMe)-phenyl, 1-(4-F)-phenyl, 1-(4- t Bu)-phenyl, 1-(4-Et)-phenyl, 1-(4- i Pr)-phenyl or N- Me- 3-pyrrolyl; R ² is H, and R ³ is C(=O)CH ₂ NH ₂ , SO ₂ NH ₂ , C(=O)C(CH ₃ ) ₂ NH ₂ , C(=O)C( Cyclopropyl)NH ₂ , C(=O)(CH ₂ ) ₂ NH ₂ , C(=O)CH(NH ₂ )(4-imidazole), SO ₂ N(CH ₃ ) ₂ , C(=O) CH ₂ NH(CH ₃ ); or R ² , R ³ and the nitrogen of formula (V) are formed together: . The method of claim 24, wherein the compound is: 2-amino- N- (4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -吲哚-1-yl)phenyl)acetamidamine ( V-1 ); 2-amino- N- (4-(3-isopropyl-6-(4-(methylsulfonyl)phenyl)) -1 H -Indol-1-yl)phenyl)acetamidamine ( V-2 ); 3-(1-(4-(2-aminoethylamino)phenyl)-6-(4- (trifluoromethyl)phenyl)-1 H -indol-3-yl) -N -methylpropanamide ( V-3 ); N- (4-(3-isopropyl-6-(4) -(Trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)-2-(methylamino)acetamide ( V-4 ); ( S )-2-amino- 2- (1 H - imidazol-4-yl) - N - (4- (3- isopropyl-6- (4- (trifluoromethyl) phenyl) -1 H - indol-1-yl) Phenyl)acetamide ( V-5 ); 2-amino- N- (4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -indole- 1-yl)phenyl)-2-methylpropanamide ( V-6 ); 1-amino- N- (4-(3-isopropyl-6-(4-(trifluoromethyl))benzene yl) -1 H - indol-1-yl) phenyl) cyclopropane-1-acyl-amine (V-7); 3- amino - N - (4- (3- isopropyl-6- ( 4-(trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)propanamine ( V-8 ); 1-(1-(4-(3-isopropyl-6) -(4-(trifluoromethyl)phenyl)-1 H -吲哚- 1-yl)phenyl)-1 H -1,2,3-triazol-4-yl) -N,N -dimethylmethylamine ( V-9 ); N- (4-(3-isopropyl) 5-(4-(trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-10 ); N -(4-(6-( 4-cyanophenyl)-3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-11 ); N- (4-(3-isopropyl)- 6-(p-tolyl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-12 ); N- (4-(3-isopropyl-6-(p-tolyl) ) -1 H - indol-1-yl) phenyl) sulfonylurea dimethylamino amine (V-13); N - (4- (6- (4- ( tert-butyl) phenyl) - 3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-14 ); N -(4-(6-(4-ethylphenyl)-3-) Propyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-15 ); N- (4-(3-isopropyl-6-(4-isopropylphenyl)) -1 H - indol-1-yl) phenyl) sulfonamide group Amides (V-16); N - (4- (3- isopropyl-6- (4-methoxyphenyl) -1 H -Indol-1-yl)phenyl)aminosulfonamide ( V-17 ); N- (4-(6-(4-fluorophenyl)-3-isopropyl-1 H -indole -1-yl)phenyl)aminosulfonamide ( V-18) ; N- (4-(3-isopropyl-6-(4-(methylsulfonyl)phenyl)-1 H -吲哚-1-yl)phenyl)aminosulfonamide ( V-19 N- (4-(6-(蒽-9-yl)-3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-20 ); N - (4-(3-Isopropyl-6-(6-(trifluoromethyl)pyridin-3-yl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-21 Or N- (4-(3-isopropyl-6-(1-methyl-1 H -pyrrol-3-yl)-1 H -indol-1-yl)phenyl)aminosulfonate Amine ( V-22 ). The method of claim 1, wherein the compound is represented by the formula (VI) : (V) Wherein: R ¹ is C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl or C ₁ -C ₄ haloalkyl; Ar phenanthryl, anthracenyl, biphenylyl, phenyl or naphthyl, And Ar is optionally substituted by haloalkyl; R ² is H, and R ³ is SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C( =O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C (=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ ,C (=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH( CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (V) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. The method of claim 26, wherein the compound is represented by the formula (VII) : (VII) Wherein: R ¹ is CF ₃ or cyclopropyl; Ar is CF ₃ -phenyl; and R ² is H, and R ³ is C(=O)CH ₂ NH ₂ or SO ₂ NH ₂ . The method of claim 27, wherein the compound is: 2-amino- N- (4-(3-(trifluoromethyl)-6-(4-(trifluoromethyl)phenyl)- 1 H -carbazol-1-yl)phenyl)acetamidine ( VII-1 ); 2-amino- N- (4-(3-cyclopropyl-6-(4-(trifluoromethyl)) Phenyl)-1 H -carbazol-1-yl)phenyl)acetamidine ( VII-2 ); N- (4-(3-cyclopropyl-6-(4-(trifluoromethyl))benzene -1 H -carbazol-1-yl)phenyl)aminosulfonamide ( VII-3 ); or N- (4-(3-(trifluoromethyl)-6-(4-(three) Fluoromethyl)phenyl)-1 H -indazol-1-yl)phenyl)aminosulfonamide ( VII-4 ). The method of claim 1, wherein the compound is represented by the formula (VIII) : (VIII) Wherein: R ¹ is C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl or C ₁ -C ₄ haloalkyl; Ar phenanthryl, anthracenyl, biphenylyl, phenyl or naphthyl, And Ar is optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ haloalkyl; R ² is H, and R ³ is SO ₂ NH ₂ , C ( =O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ ) CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH( CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (VIII) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. The method of claim 29, wherein the compound is represented by the structural formula (IX) : (IX) Wherein: R ¹ is CF ₃ ; Ar is phenanthryl; and R ² is H, and R ³ is C(=O)CH ₂ NH ₂ or SO ₂ NH ₂ . The method of claim 12, wherein the compound is: 2-amino-N-(4-(6-(phenanthr-2-yl)-4-(trifluoromethyl)pyridin-2-yl) Phenyl)acetamide ( IX-1) ; or N- (4-(6-(phenanthr-2-yl)-4-(trifluoromethyl)pyridin-2-yl)phenyl)aminosulfonate Amine ( IX-2) . The method of claim 1, wherein the compound is represented by the structural formula (X) : (X) Wherein: R ¹ is C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl or C ₁ -C ₄ haloalkyl; Ar phenanthryl, anthracenyl, biphenylyl, phenyl or naphthyl, And Ar is optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ haloalkyl; and R ² is H, and R ³ is SO ₂ NH ₂ , C (=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _{2 ,} C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH (CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (X) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. The method of claim 32, wherein the compound is represented by the structural formula (XI) : (XI) , Wherein: R ¹ based CF _3; Ar-based anthracenyl, phenanthrenyl, CF ₃ - biphenyl, CF ₃ - phenyl Br- or phenyl; R ² lines H, and R ³ lines SO ₂ NH _2, C (=O)CH ₂ NH ₂ , C(=O)CH ₂ NH(CH ₃ ), C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH[CH(CH ₃ ) ₂ ]NH(CH ₃ ); or, or R ² , R ³ and the aniline nitrogen of formula (XI) are formed together: . The method of claim 33, wherein the compound is: 2-amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -imidazole- 1-yl)phenyl)acetamidine ( XI-1 ); 2-amino- N- (4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[ 1,1'-biphenyl]-4-yl)-1 H -imidazol-1-yl)phenyl)acetamidamine ( XI-2 ); 2-amino- N- (4-(2-( 4-bromophenyl)-4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)acetamidamine ( XI-3 ); 2-amino- N- (4-(4- (trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)-1 H -imidazol-1-yl)phenyl)acetamidamine ( XI-4 ); 2-(dimethylamine N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)acetamidamine ( XI-5 ); - (methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - imidazol-1-yl) phenyl) acetyl amine (XI -6); (S) -4- methyl-2- (methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - imidazol-1-yl) phenyl) pentyl Amides (XI-7); (R ) -3- methyl-2- (methylamino) - N - (4- (2- ( 2-phenanthrene -4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)butanamine ( XI-8 ); N,N -dimethyl-1-(1-(4-(2) - (phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - imidazol-1 ) Phenyl) -1 H -1,2,3- triazol-4-yl) methanamine (XI-9); N - (4- (2- ( 9-yl) -4- (trifluoromethyl Methyl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-10 ); N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl) ) -1 H - imidazol-1-yl) phenyl) sulfonamide group Amides (XI-11); N - (4- (4- ( trifluoromethyl) -2- (4- (trifluoromethyl Phenyl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-12 ); N -(4-(4-(trifluoromethyl)-2-(4'-( Trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-13 ); ( S )-2 -amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)-3-phenylpropanamide ( XI -14 ); N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)propynylamine ( XI-15 ); 2-Amino- N- (4-(2-(3',5'-dimethyl-[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1H -imidazol-1-yl)phenyl)acetamidine ( XI-16 ); 2-amino- N- (4-(2-(3',5'-dimethoxy-[1,1'-- Biphenyl]-4-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)acetamidamine ( XI-17 ); 2-amino- N- (4-( 2- (naphthalen-2-yl) -4- (trifluoromethyl) lH-imidazol-1-yl) phenyl) acetyl amine (XI-18); 2- amine - N - (4- (2- (naphthalen-1-yl) -4- (trifluoromethyl) lH-imidazol-1-yl) phenyl) acetyl amine (XI-19); 2- amine - N -(4-(2-(3',5'-bis(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1H -imidazol-1-yl)phenyl)acetamidine ( XI-20 ); or N- (4-(2-(3',5'-bis(trifluoromethyl)-[1,1'-linked Phenyl]-4-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)-2-(methylamino)acetamide ( XI-21 ). The method of claim 1, wherein the compound is represented by the structural formula (XII) : (XII) Wherein R ¹ is C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl, C ₁ -C ₄ haloalkyl or alkylalkylamine optionally alkylated; Ar phenanthryl, fluorenyl, Biphenyl, phenyl or naphthyl, and Ar is optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ haloalkyl; and R ² is H, And R ³ R ² ' is H, and R ³ ' is sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazine, α-aminocarbonyl other than glycine, β- An aminocarbonyl group, a γ-aminocarbonyl group, or an α-β-unsaturated carbonyl group; or R ² , R ³ and an aniline nitrogen of the formula (XII) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. The method of claim 35, wherein the compound is represented by the structural formula (XIII) : (XIII) Wherein R ¹ is CH ₂ CH ₂ C(=O)NHCH ₃ ; Ar is optionally substituted by halogen or C ₁ -C ₄ haloalkyl; and R ² is H, and R ³ is SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ NH(CH ₃ ), C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)CH[CH ₂ CH (CH ₃ ) ₂ ]NH(CH ₃ ) or C(=O)CH[CH(CH ₃ ) ₂ ]NH(CH ₃ ). The method of claim 36, wherein the compound is 3-(1-(4-(2-aminoethylguanidino)phenyl)-5-(4'-(trifluoromethyl)-[ 1,1'-Biphenyl]-4-yl)-1 H -pyrazol-3-yl) -N -methylpropanamide ( XIII-1 ). For example, in the method of claim 1, wherein Het is one of the following: pyrrole, imidazole, triazole, tetrazole, oxazole, thiazole, hydrazine, oxazole, benzimidazole, benzoxazole, Benzothiazole, carbazole, quinoline, isoquinoline, quin Porphyrin, quinazoline, pyridine, pyridyl , pyrimidine and three . The method of claim 1, wherein R ¹ is H, C ₁ -C ₄ alkyl, C ₃ -C ₆ cycloalkyl, C ₁ -C ₄ haloalkyl, C ₃ -C ₆ halocycloalkane Base, halogen, nitrile, alkyl decylamine or nitro group. The method of claim 1, wherein R ¹ is CF ₃ , isopropyl, cyclopropyl or —(CH ₂ ) ₂ C(O)NH(CH ₃ ). The method of claim 1, wherein R ² is H, and: R ³ is SO ₂ NH ₂ , SO ₂ NH(CH ₃ ), SO ₂ N(CH ₃ ) ₂ , S(=O)-C ₁ -C ₄ alkylamine, SO ₂ -C ₁ -C ₄ alkylamine, C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)CH ₂ NH(CH ₃ ), C(=O)(CH ₂ ) ₂ NH ₂ , C(=O)(CH ₂ ) ₃ NH ₂ , C(=O)C(CH ₃ ) ₂ NH ₂ , C(= O) CH(NH ₂ )(4-imidazole), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C (=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)C(cyclopropyl)NH ₂ , C(=O)C≡CH or C(=O)CHCH ₂ ; or the aniline nitrogen of formula (I) to which R ³ and R ³ are bonded together represent a guanamine-bonded: glycine, alanine, Serine, threonine, cysteine, valine, leucine, isoleucine, methionine, valine, phenylalanine, tyrosine, tryptophan, aspartate , glutamic acid, aspartame, glutamine, histidine, lysine or arginine. The method of claim 1, wherein the compound is represented by the structural formula (XIV) : (XIV) Wherein R ⁴ and R ⁵ are each independently H, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl or C ₁ -C ₆ haloalkyl; and n is an integer from 1 to 6. The method of claim 1, wherein R ² , R ³ and the aniline nitrogen of formula (I) together form an optionally substituted triazole or tetrazole. The method of claim 43, wherein the triazole is substituted with an alkylamine group. The method according to Claim 1 patentable scope, wherein Ar Department of optionally substituted: phenyl, pyridyl, pyrazolyl Base, pyrimidinyl, naphthyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, biphenyl, bipyridyl, phenanthryl, morpholinyl, fluorenyl, fused tetraphenyl, propylene naphthyl, anthracenyl, Base, acridine group, pheno , carbazolyl, fluorenyl, dibenzofuran, fluorenyl, oxazolyl, benzimidazolyl, benzoxazolyl, benzofuranyl, fluorenyl, pyrrolyl, imidazolyl, pyrazolyl , triazolyl or tetrazolyl. The method of claim 1, wherein the Ar is replaced by one or more of the following: C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, C ₁ -C ₆ haloalkyl , C ₃ -C ₆ halocycloalkyl, nitrile, C ₁ -C ₆ alkyl hydrazine, alkyl fluorene, C ₁ -C ₆ O-alkyl, O-phenyl, C ₁ -C ₆ NH-alkane , C ₂ -C ₁₂ N-alkyl ₂ , hydroxy, NH ₂ , halogen, meta-dioxole, dioxolane, NO ₂ , aldehyde, C ₂ -C ₇ alkyl or aryl ketones, C ₂ -C ₇ alkyl or aryl esters, C ₂ -C ₇ alkyl acyl or aryl amine, guanidine, amidine, N-OH amidine, urea, acyl imines, oximes, hydrazones, and acyl hydrazide. The method according to Claim 1 patentable scope, wherein Ar is optionally substituted in one or more of the following: methyl, ethyl, isopropyl, t-butyl, CF _3, CN, methoxy, S (O) ₂ -C ₁ -C ₄ alkyl, Br and F. The method of claim 1, wherein the compound is represented by the structural formula (I') : (I') Wherein R ¹ ' is trifluoromethyl; Ar' is 2-phenanthryl; R ² ' is H, and R ³ ' is one of the following: CONH ₂ , C(=NH)NH ₂ , C(= O) CH ₂ NH ₂ , CH ₂ C(=O)NH ₂ , C(=O)-(p-phenylene)-SO ₂ NH ₂ , C(=O)CH ₂ NHC(=NH)NH ₂ and C(=O)CH ₂ NHCO-phenyl, the virus is not one of the following: Ebola, Marburg, Reisar fever, Hepatitis A, Hepatitis B, serotype 5 adenovirus, Coxsackie Virus B4, typhus, mumps, measles, rubella, respiratory fusion virus a, respiratory fusion virus b, cytomegalovirus, influenza A and influenza B. For example, in the method of claim 1, the limitation is that when the virus is one of the following: Ebola, Marburg, Reiser fever, Hepatitis A, Hepatitis B, serotype 5 adenovirus, Coxsackie virus B4, typhus, mumps, measles, rubella, respiratory fusion virus a, respiratory fusion virus b, cytomegalovirus, influenza A and influenza B, the compound is composed of structural formula (I') Represents: (I') Wherein: R ¹ ' is H, cycloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro; Ar' is optionally substituted and is one of the following: fused tetraphenyl, propylene Naphthalene, sulfhydryl, Phenyl, morphinyl, acridinyl, phenanthrene Base, carbazolyl, dibenzofuranyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, bipyridyl, pyridyl, pyridyl , Pyrimidinyl, indolyl, benzoimidazolyl, benzoxazolyl, benzofuranyl and indenyl group; R ² 'system H, and R ^3' amine based sulfonylureas, sulfinyl, alkylated Amino hydrazine, alkylamino hydrazide, α-aminocarbonyl other than glycine, β-aminocarbonyl, γ-aminocarbonyl, or α-β-unsaturated carbonyl; or R ² ' , R The aniline nitrogen of ³ ' and formula (I') together form an optionally substituted heterocyclic group. A compound represented by the formula (I) : (I) And a pharmaceutically acceptable salt thereof, wherein: R ¹ is H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro; R ² H, And R ³ is: sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl, β-aminocarbonyl, γ-aminocarbonyl, α-β- a saturated carbonyl, hydrazine or urea; or an aniline nitrogen of the formula (I) , R ² and R ³ together form an optionally substituted heterocyclic group; and the Ar is composed of 1, 2, 3 or 4 rings, as the case may be. a substituted aryl or heteroaryl group, one or more of the ring-bonded ring and the fused ring; Het- based heteroaryl group containing a first ring, the heteroaryl group containing five or six nitrogen a heteroaryl group, the first ring optionally fused to one or more of the second ring and the third ring to form a bicyclic ring consisting of 8, 9, 10, 11, 12 or 13 ring atoms or a tricyclic heteroaryl group, wherein R ¹ and benzene ring A are bonded to the first ring, and Ar is bonded to the first ring, the second ring or the third ring; the limitation is that when the compound is as follows When expressed: (I') One or more of the following: R ¹ ' is H, cycloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro; Ar' is optionally substituted and is one of the following : thick tetraphenyl, propylene naphthalene, fluorenyl, Phenyl, morphinyl, acridinyl, phenanthrene Base, carbazolyl, dibenzofuranyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, bipyridyl, pyridyl, pyridyl , Pyrimidinyl, indolyl, benzimidazolyl, benzoxazolyl, benzofuranyl and indenyl group; R ² 'system H, and R ^3' amine based sulfonylureas, sulfinyl, alkylated Amino hydrazine, alkylamino hydrazide, α-aminocarbonyl other than glycine, β-aminocarbonyl, γ-aminocarbonyl, or α-β-unsaturated carbonyl; or structural formula (I' ) of the aniline nitrogen, R ² and R ³ form an optionally substituted heterocyclic group of. A compound of claim 50, wherein the compound is represented by structural formula (II) : (II) Wherein: R ¹ is a C ₁ -C ₄ alkyl group or a C ₁ -C ₄ haloalkyl group; an Ar phenanthryl group, an anthracenyl group, a biphenyl group, a phenyl group or a naphthyl group, and Ar is optionally subjected to the following Substituted by one or more: halogen, C ₁ -C ₄ haloalkyl, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy, nitrile and nitro; R ² H, and R ³ is SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)C(CH _{3 2} NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O) CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH [CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ Or R ² , R ³ and the aniline nitrogen of formula (II) are formed together: Wherein R ⁴ and R ⁵ are each independently: H, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl or C ₁ -C ₆ haloalkyl; and n is an integer from 1 to 6. A compound of claim 51, wherein the compound is represented by structural formula (III) : (III) . Wherein: R ¹ is CF ₃ ; Ar is phenanthryl, anthracenyl, biphenylyl, phenyl or naphthyl; and Ar is optionally halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ haloalkyl substituted; and Ar is 2-phenanthryl, 3-phenanthryl, 9-fluorenyl, 4-biphenylyl, 4-(4'-CF ₃ )-biphenyl, 4- (3',5'-Dimethyl)-biphenyl, 4-(3',5'-dimethoxy)-biphenyl, phenyl, 1-(4-CF ₃ )-phenyl, 1-naphthyl or 2-naphthyl; and R ² is H, and R ³ is SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C (=O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C (= O) CH (CH 3) NH (CH 3), C (= O) CH [CH 2 CH (CH 3) 2] NH (CH 3), C (= O) CH (CH 2 Ph) NH (CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (III) are formed together: . A compound according to claim 52, wherein the compound is: 2-amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrole- 1-yl)phenyl)acetamidine ( III-1 ); 2-amino- N- (4-(2-(phenanthr-3-yl)-4-(trifluoromethyl)-1 H -pyrrole -1-yl)phenyl)acetamidine ( III-2 ); 2-amino- N- (4-(2-(naphthalen-2-yl)-4-(trifluoromethyl)-1 H - Pyrrol-1-yl)phenyl)acetamidine ( III-3 ); 2-amino- N- (4-(2-(naphthalen-1-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamidine ( III-4 ); 2-amino- N- (4-(4-(trifluoromethyl)-2-(4-(trifluoromethyl)) Phenyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-5 ); N -(4-(2-([1,1'-biphenyl]-4-yl)-) 4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2-aminoacetamide ( III-6 ); 2-amino- N- (4-(4-(3) Fluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-7 ); 2-Amino- N- (4-(2-(3',5'-dimethyl-[1,1'-biphenyl]-4-yl)-4-(trifluoro) methyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-8); 2- amino - N - (4- (2- ( 3 ', 5'- dimethoxy - [1,1'-biphenyl] -4-yl) -4- (trifluoromethyl) -1 H - Slightly-1-yl) phenyl) acetyl amine (III-9); 2- (methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-10); 2- (methylamino) - N - (4- (2- ( naphthalen-2-yl) -4- (C fluoromethyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-11); 2- (methylamino) - N - (4- (2- ( naphthalen-1-yl) - 4-(Trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-12 ); N -(4-(2-([1,1'-biphenyl]-) 4-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2-(methylamino)acetamide ( III-13 ); N -(4-(2 -(3',5'-Dimethyl-[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)- 2-(methylamino)acetamide ( III-14 ); N- (4-(2-(3',5'-dimethoxy-[1,1'-biphenyl]-4-yl) -4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2-(methylamino)acetamide ( III-15 ); 2-(dimethylamino)- N - (4- (2- (phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-16); 2- (two methylamino) - N - (4- (2- ( naphthalen-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-17 ( S )-2-Amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrole-1- Yl) phenyl) -3-phenyl-propan-acyl amines (III-18); (S ) -2- ( methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- ( trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) -3-phenyl-propan-acyl amines (III-19); (S ) -2- ( methylamino) - N - (4- ( 2-(naphthalen-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-3-phenylpropanamine ( III-20 ); ( R )-2 - (dimethylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) -3- phenyl Propionamide ( III-21 ); ( R )-2-amino-4-methyl- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H - pyrrol-1-yl) phenyl) pentyl Amides (III-22); (R ) -4- methyl-2- (methylamino) - N - (4- (2- ( phenanthren-2 4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)pentanylamine ( III-23 ); ( S )-4-methyl-2-(methylamino)- N - (4- (2- (naphthalen-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) pentyl Amides (III-24); (R ) - 2-amino-3-methyl- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)butanamine ( III-25 ); ( R )-2-Amino-3-methyl- N- (4-(2-(naphthalen-2-yl)-4-(trifluoromethyl)-1 H -pyrrole- 1- yl) phenyl) butan Amides (III-26); (R ) -2- ( methylamino) - N - (4- (2- ( phenanthren-2 ) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) propan-acyl amine (III-27); 2- amino-2-methyl - N - (4- (2- (phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)propanamine ( III-28 ); 2-amino-2-methyl- N- (4-(2-(naphthalen-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)propanamine ( III-29 ); 1-amino- N -(4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)cyclopropane-1-carboxamide ( III-30 ); 1-amino- N- (4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)cyclopropane-1-carboxamide ( III-31 ); N- (4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl) -[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)propynylamine ( III-32 ); N,N -dimethyl-1 -(1-(4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-1 H -1,2,3-tri Iazol-4-yl)methylamine ( III-33 ); 1-(1-(4-(2-(蒽-9-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl) Phenyl)-1 H -1,2,3-triazol-4-yl) -N,N -dimethylmethylamine ( III-34 ); N,N -dimethyl-1-(1- (4-(4-(Trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl) Phenyl)-1 H -1,2,3-triazol-4-yl)methylamine ( III-35 ); N -(4-(2-(phenanthr-2-yl)-4-(trifluoro) Methyl)-1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-36 ); N- (4-(2-(phenanthr-3-yl)-4-(trifluoromethyl) -1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-37 ); N- (4-(2-(蒽-9-yl)-4-(trifluoromethyl)- 1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-38 ); or N -(4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)) ) - [1,1'-biphenyl] -4-yl) -1 H - pyrrol-1-yl) phenyl) sulfonamide group Amides (III-39). A compound of claim 50, wherein the compound is represented by structural formula (IV) : (IV) Wherein: R ¹ is C ₁ -C ₄ alkyl or C ₁ -C ₄ haloalkyl; Ar is phenanthryl, fluorenyl, biphenyl, phenyl, naphthyl, pyridyl or pyrrolyl, and Ar In the case of halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkyl, nitrile or SO ₂ -C ₁ -C ₄ alkyl; R ² is H, and R ³ is SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C (=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N (CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (IV) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. A compound of claim 54, wherein the compound is represented by structural formula (V) : (V) Wherein: R ¹ is C ₁ -C ₄ alkyl or C ₁ -C ₄ haloalkyl; Ar is 1-(4-CF ₃ )-phenyl, 1-(4-CN)-phenyl, 1- (4-Me)-phenyl, 5-(2-CF ₃ )-pyridyl, 1-(4-SO ₂ Me)-phenyl, 9-fluorenyl, 1-(4-OMe)-phenyl, 1-(4-F)-phenyl, 1-(4- t Bu)-phenyl, 1-(4-Et)-phenyl, 1-(4- i Pr)-phenyl or N- Me- 3-pyrrolyl; R ² is H, and R ³ is C(=O)CH ₂ NH ₂ , SO ₂ NH ₂ , C(=O)C(CH ₃ ) ₂ NH ₂ , C(=O)C( Cyclopropyl)NH ₂ , C(=O)(CH ₂ ) ₂ NH ₂ , C(=O)CH(NH ₂ )(4-imidazole), SO ₂ N(CH ₃ ) ₂ , C(=O) CH ₂ NH(CH ₃ ); or R ² , R ³ and the nitrogen of formula (V) are formed together: . A compound according to claim 55, wherein the compound is: 2-amino- N- (4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -吲哚-1-yl)phenyl)acetamidamine ( V-1 ); 2-amino- N- (4-(3-isopropyl-6-(4-(methylsulfonyl)phenyl)) -1 H -Indol-1-yl)phenyl)acetamidamine ( V-2 ); 3-(1-(4-(2-aminoethylamino)phenyl)-6-(4- (trifluoromethyl)phenyl)-1 H -indol-3-yl) -N -methylpropanamide ( V-3 ); N- (4-(3-isopropyl-6-(4) -(Trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)-2-(methylamino)acetamide ( V-4 ); ( S )-2-amino- 2- (1 H - imidazol-4-yl) - N - (4- (3- isopropyl-6- (4- (trifluoromethyl) phenyl) -1 H - indol-1-yl) Phenyl)acetamide ( V-5 ); 2-amino- N- (4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -indole- 1-yl)phenyl)-2-methylpropanamide ( V-6 ); 1-amino- N- (4-(3-isopropyl-6-(4-(trifluoromethyl))benzene yl) -1 H - indol-1-yl) phenyl) cyclopropane-1-acyl-amine (V-7); 3- amino - N - (4- (3- isopropyl-6- ( 4-(trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)propanamine ( V-8 ); 1-(1-(4-(3-isopropyl-6) - (4- (trifluoromethyl) phenyl) -1 H - indazole 1-yl) phenyl) -1 H -1,2,3- triazol-4-yl) - N, N - dimethylmethanamine (V-9); N - (4- (3- iso Propyl-6-(4-(trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-10 ); N -(4-(6- (4-cyanophenyl)-3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-11 ); N- (4-(3-isopropyl) -6-(p-tolyl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-12 ); N- (4-(3-isopropyl-6-(p-toluene) (1) H -indol-1-yl)phenyl)dimethylaminosulfonamide ( V-13 ); N- (4-(6-(4-(t-butyl)phenyl) 3-isopropyl- 1H -indol-1-yl)phenyl)aminosulfonamide ( V-14 ); N- (4-(6-(4-ethylphenyl)-3- Isopropyl- 1H -indol-1-yl)phenyl)aminosulfonamide ( V-15 ); N- (4-(3-isopropyl-6-(4-isopropylphenyl) -1 H -Indol-1-yl)phenyl)aminosulfonamide ( V-16 ); N- (4-(3-isopropyl-6-(4-methoxyphenyl)- 1 H -Indol-1-yl)phenyl)aminosulfonamide ( V-17 ); N -(4-(6-(4-fluorophenyl)-3-isopropyl-1 H -indole哚-1-yl)phenyl)aminosulfonamide ( V-18) ; N -(4-(3-isopropyl-6-(4-(methylsulfonyl)phenyl)-1 H -吲哚-1-yl)phenyl)aminosulfonamide ( V -19 ); N- (4-(6-(蒽-9-yl)-3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-20 ); N- (4-(3-isopropyl-6-(6-(trifluoromethyl)pyridin-3-yl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V -21 ); or N -(4-(3-isopropyl-6-(1-methyl-1 H -pyrrol-3-yl)-1 H -indol-1-yl)phenyl)amino Sulfonamide ( V-22 ). A compound of claim 50, wherein the compound is represented by structural formula (VI) : (V) Wherein: R ¹ is C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl or C ₁ -C ₄ haloalkyl; Ar phenanthryl, anthracenyl, biphenylyl, phenyl or naphthyl, And Ar is optionally substituted by haloalkyl; R ² is H, and R ³ is SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C( =O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C (=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ ,C (=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH( CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (V) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. A compound of claim 57, wherein the compound is represented by structural formula (VII) : (VII) Wherein: R ¹ is CF ₃ or cyclopropyl; Ar is CF ₃ -phenyl; and R ² is H, and R ³ is C(=O)CH ₂ NH ₂ or SO ₂ NH ₂ . A compound according to claim 58 wherein the compound is: 2-amino- N- (4-(3-(trifluoromethyl)-6-(4-(trifluoromethyl)phenyl)- 1 H -carbazol-1-yl)phenyl)acetamidine ( VII-1 ); 2-amino- N- (4-(3-cyclopropyl-6-(4-(trifluoromethyl)) Phenyl)-1 H -carbazol-1-yl)phenyl)acetamidine ( VII-2 ); N- (4-(3-cyclopropyl-6-(4-(trifluoromethyl))benzene -1 H -carbazol-1-yl)phenyl)aminosulfonamide ( VII-3 ); or N- (4-(3-(trifluoromethyl)-6-(4-(three) trifluoromethyl) phenyl) -1 H - indazol-1-yl) phenyl) sulfonamide group Amides (VII-4). A compound of claim 50, wherein the compound is represented by structural formula (VIII) : (VIII) Wherein: R ¹ is C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl or C ₁ -C ₄ haloalkyl; Ar phenanthryl, anthracenyl, biphenylyl, phenyl or naphthyl, And Ar is optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ haloalkyl; R ² is H, and R ³ is SO ₂ NH ₂ , C ( =O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _2, , C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ ) CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH( CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (VIII) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. A compound of claim 60, wherein the compound is represented by structural formula (IX) : (IX) Wherein: R ¹ is CF ₃ ; Ar is phenanthryl; and R ² is H, and R ³ is C(=O)CH ₂ NH ₂ or SO ₂ NH ₂ . A compound according to claim 61, wherein the compound is: 2-amino-N-(4-(6-(phenanthr-2-yl)-4-(trifluoromethyl)pyridin-2-yl) Phenyl)acetamide ( IX-1) ; or N- (4-(6-(phenanthr-2-yl)-4-(trifluoromethyl)pyridin-2-yl)phenyl)aminosulfonate Amine ( IX-2) . The compound of claim 50, wherein the compound is represented by the structural formula (X) : (X) Wherein: R ¹ is C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl or C ₁ -C ₄ haloalkyl; Ar phenanthryl, anthracenyl, biphenylyl, phenyl or naphthyl, And Ar is optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ haloalkyl; and R ² is H, and R ³ is SO ₂ NH ₂ , C (=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)C(cyclopropyl)NH ₂ , C(=O)C(CH ₃ ) ₂ NH _{2 ,} C(=O)C≡CH, C(=O)CH ₂ NH(CH ₃ ), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ CH ₂ CH(CH ₃ ) ₂ , C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)CH[CH ₂ CH (CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ ; or R ² , R ³ and the aniline nitrogen of formula (X) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. A compound of claim 63, wherein the compound is represented by structural formula (XI) : (XI) , Wherein: R ¹ based CF _3; Ar-based anthracenyl, phenanthrenyl, CF ₃ - biphenyl, CF ₃ - phenyl Br- or phenyl; R ² lines H, and R ³ lines SO ₂ NH _2, C (=O)CH ₂ NH ₂ , C(=O)CH ₂ NH(CH ₃ ), C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH[CH(CH ₃ ) ₂ ]NH(CH ₃ ); or, or R ² , R ³ and the aniline nitrogen of formula (XI) are formed together: . A compound according to claim 64, wherein the compound is: 2-amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -imidazole- 1-yl)phenyl)acetamidine ( XI-1 ); 2-amino- N- (4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[ 1,1'-biphenyl]-4-yl)-1 H -imidazol-1-yl)phenyl)acetamidamine ( XI-2 ); 2-amino- N- (4-(2-( 4-bromophenyl)-4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)acetamidamine ( XI-3 ); 2-amino- N- (4-(4- (trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)-1 H -imidazol-1-yl)phenyl)acetamidamine ( XI-4 ); 2-(dimethylamine N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)acetamidamine ( XI-5 ); - (methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - imidazol-1-yl) phenyl) acetyl amine (XI -6); (S) -4- methyl-2- (methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - imidazol-1-yl) phenyl) pentyl Amides (XI-7); (R ) -3- methyl-2- (methylamino) - N - (4- (2- ( 2-phenanthrene -4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)butanamine ( XI-8 ); N,N -dimethyl-1-(1-(4-(2) -(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -imidazole-1 -yl)phenyl)-1 H -1,2,3-triazol-4-yl)methylamine ( XI-9 ); N -(4-(2-(蒽-9-yl)-4-( Trifluoromethyl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-10 ); N -(4-(2-(phenanthr-2-yl)-4-(trifluoro) Methyl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-11 ); N -(4-(4-(trifluoromethyl)-2-(4-(trifluoro)) Methyl)phenyl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-12 ); N- (4-(4-(trifluoromethyl)-2-(4') -(Trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-13 ); ( S ) 2-amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)-3-phenylpropanamide ( XI-14 ); N -(4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)propynylamine ( XI-15 2-amino- N- (4-(2-(3',5'-dimethyl-[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl) -1H-imidazol-1-yl)phenyl)acetamidine ( XI-16 ); 2-amino- N- (4-(2-(3',5'-dimethoxy-[1,1 '-Biphenyl]-4-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)acetamidamine ( XI-17 ); 2-amino- N- (4 - (2- (naphthalen-2-yl) -4- (trifluoromethyl) lH-imidazol-1-yl) phenyl) acetyl amine (XI-18); 2- Yl - N - (4- (2- (naphthalen-1-yl) -4- (trifluoromethyl) lH-imidazol-1-yl) phenyl) acetyl amine (XI-19); 2- amine yl - N - (4- (2- ( 3 ', 5'- bis (trifluoromethyl) - [1,1'-biphenyl] -4-yl) -4- (trifluoromethyl) - 1H-imidazol-1-yl)phenyl)acetamidine ( XI-20 ); N- (4-(2-(3',5'-bis(trifluoromethyl)-[1,1'-linked Phenyl]-4-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)-2-(methylamino)acetamide ( XI-21 ). A compound of claim 50, wherein the compound is represented by structural formula (XII) : (XII) Wherein R ¹ is C ₁ -C ₄ alkyl, C ₂ -C ₆ cycloalkyl, C ₁ -C ₄ haloalkyl or alkylalkylamine optionally alkylated; Ar phenanthryl, fluorenyl, Biphenyl, phenyl or naphthyl, and Ar is optionally substituted by halogen, C ₁ -C ₄ alkyl, C ₁ -C ₄ alkoxy or C ₁ -C ₄ haloalkyl; and R ² is H, And R ³ R ² ' is H, and R ³ ' is sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazine, α-aminocarbonyl other than glycine, β- An aminocarbonyl group, a γ-aminocarbonyl group, or an α-β-unsaturated carbonyl group; or R ² , R ³ and an aniline nitrogen of the formula (XII) are formed together: Wherein R ⁴ and R ^{5 are} optionally H or C ₁ -C ₄ alkyl. A compound of claim 66, wherein the compound is represented by structural formula (XIII) : (XIII) Wherein R ¹ is CH ₂ CH ₂ C(=O)NHCH ₃ ; Ar is optionally substituted by halogen or C ₁ -C ₄ haloalkyl; and R ² is H, and R ³ is SO ₂ NH ₂ , C(=O)CH ₂ NH ₂ , C(=O)CH ₂ NH(CH ₃ ), C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)CH[CH ₂ CH (CH ₃ ) ₂ ]NH(CH ₃ ) or C(=O)CH[CH(CH ₃ ) ₂ ]NH(CH ₃ ). A compound according to claim 67, wherein the compound is 3-(1-(4-(2-aminoethylamino)phenyl)-5-(4'-(trifluoromethyl)-[ 1,1'-Biphenyl]-4-yl)-1 H -pyrazol-3-yl) -N -methylpropanamide ( XIII-1 ). Such as the compound of claim 50, wherein Het is one of the following: pyrrole, imidazole, triazole, tetrazole, oxazole, thiazole, hydrazine, oxazole, benzimidazole, benzoxazole, Benzothiazole, carbazole, quinoline, isoquinoline, quin Porphyrin, quinazoline, pyridine, pyridyl , pyrimidine and three . A compound according to claim 50, wherein R ¹ is H, C ₁ -C ₄ alkyl, C ₃ -C ₆ cycloalkyl, C ₁ -C ₄ haloalkyl, C ₃ -C ₆ halocycloalkane Base, halogen, nitrile, alkyl decylamine or nitro group. A compound according to claim 50, wherein R ¹ is CF ₃ , isopropyl, cyclopropyl or —(CH ₂ ) ₂ C(O)NH(CH ₃ ). A compound according to claim 50, wherein R ² is H, and: R ³ is SO ₂ NH ₂ , SO ₂ NH(CH ₃ ), SO ₂ N(CH ₃ ) ₂ , S(=O)-C ₁ -C ₄ alkylamine, SO ₂ -C ₁ -C ₄ alkylamine, C(=O)CH ₂ NH ₂ , C(=O)CH ₂ N(CH ₃ ) ₂ , C(=O)CH _{2 NH (CH 3), C} (= O) (CH 2) 2 NH 2, C (= O) (CH 2) 3 NH 2, C (= O) C (CH 3) 2 NH 2, C (= O) CH(NH ₂ )(4-imidazole), C(=O)CH(NH ₂ )CH(CH ₃ ) ₂ , C(=O)CH(NH ₂ )CH ₂ CH(CH ₃ ) ₂ , C (=O)CH[CH ₂ CH(CH ₃ ) ₂ ]NH(CH ₃ ), C(=O)CH(CH ₂ Ph)NH ₂ , C(=O)CH(CH ₂ Ph)NH(CH ₃ ), C(=O)CH(CH ₂ Ph)N(CH ₃ ) ₂ , C(=O)CH(CH ₃ )NH(CH ₃ ), C(=O)C(cyclopropyl)NH ₂ , C(=O)C≡CH or C(=O)CHCH ₂ ; or the aniline nitrogen of the formula (I) to which R ³ and R ³ are bonded together represent a guanamine-bonded: glycine, alanine , serine, threonine, cysteine, valine, leucine, isoleucine, methionine, valine, phenylalanine, tyrosine, tryptophan, aspartame Acid, glutamic acid, aspartame, glutamine, histidine, lysine or arginine. A compound of claim 50, wherein the compound is represented by structural formula (XIV) : (XIV) Wherein R ⁴ and R ⁵ are each independently H, C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl or C ₁ -C ₆ haloalkyl; and n is an integer from 1 to 6. A compound according to claim 50, wherein R ² , R ³ and the aniline nitrogen of formula (I) together form an optionally substituted triazole or tetrazole. A compound of claim 74, wherein the triazole is substituted with an alkylamine group. For example, the compound of claim 50, wherein Ar is substituted as appropriate: phenyl, pyridyl, pyridyl Base, pyrimidinyl, naphthyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, biphenyl, bipyridyl, phenanthryl, morpholinyl, fluorenyl, fused tetraphenyl, propylene naphthyl, anthracenyl, Base, acridine group, pheno , carbazolyl, fluorenyl, dibenzofuran, fluorenyl, oxazolyl, benzimidazolyl, benzoxazolyl, benzofuranyl, fluorenyl, pyrrolyl, imidazolyl, pyrazolyl , triazolyl or tetrazolyl. A compound according to claim 50, wherein Ar is optionally substituted by one or more of the following: C ₁ -C ₆ alkyl, C ₃ -C ₆ cycloalkyl, C ₁ -C ₆ haloalkyl , C ₃ -C ₆ halocycloalkyl, nitrile, C ₁ -C ₆ alkyl hydrazine, alkyl fluorene, C ₁ -C ₆ O-alkyl, O-phenyl, C ₁ -C ₆ NH-alkane , C ₂ -C ₁₂ N-alkyl ₂ , hydroxy, NH ₂ , halogen, meta-dioxole, dioxolane, NO ₂ , aldehyde, C ₂ -C ₇ alkyl or aryl Ketone, C ₂ -C ₇ alkyl or aryl ester, C ₂ -C ₇ alkyl or aryl decylamine, hydrazine, hydrazine, N-OH hydrazine, urea, quinone imine, hydrazine, hydrazine and hydrazine. The compound of the patented scope 50, wherein Ar is optionally substituted in one or more of the following: methyl, ethyl, isopropyl, t-butyl, CF _3, CN, methoxy, S (O) ₂ -C ₁ -C ₄ alkyl, Br and F. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier or excipient; and a compound represented by structural formula (I) : (I) And a pharmaceutically acceptable salt thereof, wherein: R ¹ is H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro; R ² H, And R ³ is: sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl, β-aminocarbonyl, γ-aminocarbonyl, α-β- a saturated carbonyl, hydrazine or urea; or an aniline nitrogen of the formula (I) , R ² and R ³ together form an optionally substituted heterocyclic group; and the Ar is composed of 1, 2, 3 or 4 rings, as the case may be. a substituted aryl or heteroaryl group, one or more of the ring-bonded ring and the fused ring; Het- based heteroaryl group containing a first ring, the heteroaryl group containing five or six nitrogen a heteroaryl group, the first ring optionally fused to one or more of the second ring and the third ring to form a bicyclic ring consisting of 8, 9, 10, 11, 12 or 13 ring atoms or a tricyclic heteroaryl group, wherein R ¹ and benzene ring A are bonded to the first ring, and Ar is bonded to the first ring, the second ring or the third ring; the limitation is that when the compound is as follows When expressed: (I') One or more of the following: R ¹ ' is H, cycloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro; Ar' is optionally substituted and is one of the following : thick tetraphenyl, propylene naphthalene, fluorenyl, Phenyl, morphinyl, acridinyl, phenanthrene Base, carbazolyl, dibenzofuranyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, bipyridyl, pyridyl, pyridyl , Pyrimidinyl, indolyl, benzimidazolyl, benzoxazolyl, benzofuranyl and indenyl group; R ² 'system H, and R ^3' amine based sulfonylureas, sulfinyl, alkylated Amino hydrazine, alkylamino hydrazide, α-aminocarbonyl other than glycine, β-aminocarbonyl, γ-aminocarbonyl, or α-β-unsaturated carbonyl; or structural formula (I' ) of the aniline nitrogen, R ² and R ³ form an optionally substituted heterocyclic group of. The pharmaceutical composition of claim 79, which further comprises an antiviral agent. The pharmaceutical composition of claim 79, further comprising a phosphodiesterase inhibitor. The pharmaceutical composition of claim 79, wherein the compound is III-1 to III-39 , V-1 to V-22 , VII-1 to VII-4 , IX-1 , IX-2 , XI- 1 to XI-21 or XIII-1 : 2-amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrole-1 -yl)phenyl)acetamide ( III-1 ); 2-amino- N- (4-(2-(phenanthr-3-yl)-4-(trifluoromethyl)-1 H -pyrrole- 1-yl)phenyl)acetamidine ( III-2 ); 2-amino- N- (4-(2-(naphthalen-2-yl)-4-(trifluoromethyl)-1 H -pyrrole -1-yl)phenyl)acetamidine ( III-3 ); 2-amino- N- (4-(2-(naphthalen-1-yl)-4-(trifluoromethyl)-1 H - Pyrrol-1-yl)phenyl)acetamidine ( III-4 ); 2-amino- N- (4-(4-(trifluoromethyl)-2-(4-(trifluoromethyl)benzene) -1 H -pyrrol-1-yl)phenyl)acetamidamine ( III-5 ); N- (4-(2-([1,1'-biphenyl]-4-yl)-4) -(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2-aminoacetamide ( III-6 ); 2-amino- N- (4-(4-(trifluoro) Methyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)acetamide ( III -7 ); 2-amino- N- (4-(2-(3',5'-dimethyl-[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl) Base)-1 H -pyrrol-1-yl)phenyl Ethylamine ( III-8 ); 2-amino- N- (4-(2-(3',5'-dimethoxy-[1,1'-biphenyl]-4-yl) 4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-9); 2- (methylamino) - N - (4- (2- ( Philippines - 2- yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-10); 2- (methylamino) - N - (4- (2 - (naphthalen-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) acetyl amine (III-11); 2- (methylamino) - N - ( 4-(2-(naphthalen-1-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)acetamidamine (III-12); N -(4-(2 -([1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2-(methylamino)acetamide ( III-13 ); N -(4-(2-(3',5'-Dimethyl-[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)- 1 H -pyrrol-1-yl)phenyl)-2-(methylamino)acetamide ( III-14 ); N -(4-(2-(3',5'-dimethoxy-[ 1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-2-(methylamino)acetamide ( III- 15); 2- (dimethylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) as acetamide (III-16); 2- (dimethylamino) - N - (4- (2- ( naphthalen-2-yl) -4- (trifluoromethyl) -1 H - pyrazol 1-yl) phenyl) acetyl amine (III-17); (S ) -2- amino - N - (4- (2- (phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) -3-phenyl-propan-acyl amines (III-18); (S ) -2- ( methylamino) - N - (4- (2- ( Philippines - 2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-3-phenylpropanamide ( III-19 ); ( S )-2-(methylamino) ) - N - (4- (2- ( naphthalen-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) -3-phenyl-propan Amides (Ill 20); (R) -2- (dimethylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl Phenyl)-3-phenylpropanamide ( III-21 ); ( R )-2-amino-4-methyl- N- (4-(2-(phenanthr-2-yl)-4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) pentyl Amides (III-22); (R ) -4- methyl-2- (methylamino) - N - (4- (2-(phenan-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)pentanylamine ( III-23 ); ( S )-4-methyl- 2- (methylamino) - N - (4- (2- ( naphthalen-2-yl) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) pentyl Amides (III - ( R )-2-amino-3-methyl- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrole-1- yl) phenyl) butan Amides (III-25); (R ) -2- amino-3-methyl - N - (4- (2- (naphthalen-2 ) -4- (trifluoromethyl) -1 H - pyrrol-1-yl) phenyl) butan Amides (III-26); (R ) -2- ( methylamino) - N - (4- ( 2-(phenanthrene-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)propanamine ( III-27 ); 2-amino-2-methyl- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)propanamine ( III-28 ); 2-amino group -2-methyl- N- (4-(2-(naphthalen-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)propanamide ( III-29 1-amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)cyclopropane-1-yl Indoleamine ( III-30 ); 1-amino- N- (4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl) ]-4-yl)-1 H -pyrrol-1-yl)phenyl)cyclopropane-1-carboxamide ( III-31 ); N- (4-(4-(trifluoromethyl)-2- (4'-(Trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)propynylamine ( III-32 ); N ,N -Dimethyl-1-(1-(4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)-1 H -1,2,3-triazol-4-yl)methylamine ( III-33 ); 1-(1-(4-(2-(蒽-9-yl)-4-(trifluoromethyl)-) 1 H -pyrrol-1-yl)phenyl)-1 H -1,2,3-triazol-4-yl) -N,N -dimethylmethylamine ( III-34 ) ; N,N -Dimethyl-1-(1-(4-(4-(trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]] 4-yl)-1 H -pyrrol-1-yl)phenyl)-1 H -1,2,3-triazol-4-yl)methylamine ( III-35 ); N -(4-(2 -(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-36 ); N -(4-(2-( Phenanthren-3-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-37 ); N -(4-(2-(蒽- 9-yl)-4-(trifluoromethyl)-1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III-38 ); N- (4-(4-(trifluoromethyl) )-2-(4'-(Trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -pyrrol-1-yl)phenyl)aminosulfonamide ( III -39 ); 2-amino- N- (4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl) Indoleamine ( V-1 ); 2-amino- N- (4-(3-isopropyl-6-(4-(methylsulfonyl)phenyl)-1 H -indol-1-yl) Phenyl)acetamide ( V-2 ); 3-(1-(4-(2-aminoethylamino)phenyl)-6-(4-(trifluoromethyl)phenyl)-1 H -Indol-3-yl) -N -methylpropanamide ( V-3 ); N- (4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)- 1 H -indol-1-yl)phenyl)-2-(methylamino)acetamide ( V-4 ); ( S )-2-amino-2-(1) H - imidazol-4-yl) - N - (4- (3- isopropyl-6- (4- (trifluoromethyl) phenyl) -1 H - indol-1-yl) phenyl) acetate Indoleamine ( V-5 ); 2-amino- N- (4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -indol-1-yl) Phenyl)-2-methylpropanamide ( V-6 ); 1-amino- N- (4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -Indol-1-yl)phenyl)cyclopropane-1-carboxamide ( V-7 ); 3-amino- N- (4-(3-isopropyl-6-(4-(III) Fluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)propanamine ( V-8 ); 1-(1-(4-(3-isopropyl-6-(4-) (trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)-1 H -1,2,3-triazol-4-yl) -N,N -dimethylmethylamine ( V-9 ); N- (4-(3-isopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -indol-1-yl)phenyl)aminosulfonate Amine ( V-10 ); N- (4-(6-(4-cyanophenyl)-3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V -11 ); N- (4-(3-isopropyl-6-(p-tolyl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-12 ); N - (4-(3-isopropyl-6-(p-tolyl)-1 H -indol-1-yl)phenyl)dimethylaminosulfonamide ( V-13 ); N -(4- (6-(4-(Tert-butyl)phenyl)-3-isopropyl-1 H -indol-1-yl Phenyl)aminosulfonamide ( V-14 ); N- (4-(6-(4-ethylphenyl)-3-isopropyl-1 H -indol-1-yl)phenyl Aminosulfonamide ( V-15 ); N- (4-(3-isopropyl-6-(4-isopropylphenyl)-1 H -indol-1-yl)phenyl)amine Sulfosamine ( V-16 ); N- (4-(3-isopropyl-6-(4-methoxyphenyl)-1 H -indol-1-yl)phenyl)aminosulfonate Indoleamine ( V-17 ); N- (4-(6-(4-fluorophenyl)-3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V -18) ; N -(4-(3-isopropyl-6-(4-(methylsulfonyl)phenyl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-19 ); N- (4-(6-(蒽-9-yl)-3-isopropyl-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-20) N- (4-(3-isopropyl-6-(6-(trifluoromethyl)pyridin-3-yl)-1 H -indol-1-yl)phenyl)aminosulfonamide ( V-21 ); N- (4-(3-isopropyl-6-(1-methyl-1 H -pyrrol-3-yl)-1 H -indol-1-yl)phenyl)amine Sulfonamide ( V-22 ); 2-amino- N- (4-(3-(trifluoromethyl)-6-(4-(trifluoromethyl)phenyl)-1 H -carbazole -1-yl)phenyl)acetamidine ( VII-1 ); 2-amino- N- (4-(3-cyclopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -carbazol-1-yl)phenyl)acetamidamine ( VII-2 ); N- (4-(3-cyclopropyl-6-(4-(trifluoromethyl)phenyl)-1 H -indazol-1-yl)phenyl)aminosulfonamide ( VII-3 ) N- (4-(3-(trifluoromethyl)-6-(4-(trifluoromethyl)phenyl)-1 H -indazol-1-yl)phenyl)aminosulfonamide VII-4 ); 2-Amino-N-(4-(6-(phenanthr-2-yl)-4-(trifluoromethyl)pyridin-2-yl)phenyl)acetamide ( IX-1) ); N - (4- (6- ( phenanthrene-2-yl) -4- (trifluoromethyl) pyridin-2-yl) phenyl) sulfonamide group Amides (IX-2); 2- amine - N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)acetamide ( XI-1 ); 2-amine yl - N - (4- (4- (trifluoromethyl) -2- (4 '- (trifluoromethyl) - [1,1'-biphenyl] -4-yl) -1 H - imidazole -1-yl)phenyl)acetamidine ( XI-2 ); 2-amino- N- (4-(2-(4-bromophenyl)-4-(trifluoromethyl)-1 H - Imidazol-1-yl)phenyl)acetamidine ( XI-3 ); 2-amino- N- (4-(4-(trifluoromethyl)-2-(4-(trifluoromethyl)benzene) yl) -1 H - imidazol-1-yl) phenyl) acetyl amine (XI-4); 2- (dimethylamino) - N - (4- (2- ( phenanthrene-2-yl) - 4-(Trifluoromethyl)-1 H -imidazol-1-yl)phenyl)acetamidamine ( XI-5 ); 2-(methylamino)- N -(4-(2-(phenanthrene)- 2- yl) -4- (trifluoromethyl) -1 H - imidazol-1-yl) phenyl) acetyl amine (XI-6) (S) -4- methyl-2- (methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl) -1 H - imidazol-1 yl) phenyl) pentyl Amides (XI-7); (R ) -3- methyl-2- (methylamino) - N - (4- (2- ( phenanthrene-2-yl) -4- (trifluoromethyl)-1 H -imidazol-1-yl)phenyl)butanamine ( XI-8 ); N,N -dimethyl-1-(1-(4-(2-(phenanthrene)- 2-yl)-4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)-1 H -1,2,3-triazol-4-yl)methylamine ( XI-9 ) N- (4-(2-(蒽-9-yl)-4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-10 ); N -(4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-11 ); N -( 4-(4-(Trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)-1 H -imidazol-1-yl)phenyl)aminosulfonamide ( XI-12 ); N- (4-(4-(Trifluoromethyl)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1 H -imidazole-1 -yl)phenyl)aminosulfonamide ( XI-13 ); ( S )-2-amino- N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)) -1H-imidazol-1-yl)phenyl)-3-phenylpropanamide ( XI-14 ); N- (4-(2-(phenanthr-2-yl)-4-(trifluoromethyl)) -1H-imidazol-1-yl)phenyl)propynylamine ( XI-15 ); 2-amino- N- (4-(2-(3',5'-dimethyl-[1 ,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)acetamidamine ( XI-16 ); 2-amino- N- (4-(2-(3',5'-Dimethoxy-[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl Phenyl)acetamide ( XI-17 ); 2-amino- N- (4-(2-(naphthalen-2-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl) Phenyl)acetamide ( XI-18 ); 2-amino- N- (4-(2-(naphthalen-1-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl Phenyl)acetamide ( XI-19 ); 2-amino- N- (4-(2-(3',5'-bis(trifluoromethyl)-[1,1'-biphenyl) ]-4-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)acetamidamine ( XI-20 ); N- (4-(2-(3',5') -Bis(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl)phenyl)-2-(A Ethylamino)acetamide ( XI-21 ); or 3-(1-(4-(2-aminoethylamino)phenyl)-5-(4'-(trifluoromethyl)-[ 1,1'-Biphenyl]-4-yl)-1 H -pyrazol-3-yl) -N -methylpropanamide ( XIII-1 ). The pharmaceutical composition of claim 79, which comprises a compound according to any one of claims 50 to 78. A kit comprising: instructions for guiding a user: providing a subject at risk of or at risk of infection with the virus; and administering to the subject an amount effective to reduce the viral infection in the subject The compound is administered; the compound, which is represented by the structural formula (I) : (I) And a pharmaceutically acceptable salt thereof, wherein: R ¹ is H, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro; R ² H, And R ³ is: sulfonamide, sulfinamide, alkylamino hydrazine, alkylamino hydrazide, α-aminocarbonyl, β-aminocarbonyl, γ-aminocarbonyl, α-β- a saturated carbonyl, hydrazine or urea; or an aniline nitrogen of the formula (I) , R ² and R ³ together form an optionally substituted heterocyclic group; and the Ar is composed of 1, 2, 3 or 4 rings, as the case may be. a substituted aryl or heteroaryl group, one or more of the ring-bonded ring and the fused ring; Het- based heteroaryl group containing a first ring, the heteroaryl group containing five or six nitrogen a heteroaryl group, the first ring optionally fused to one or more of the second ring and the third ring to form a bicyclic ring consisting of 8, 9, 10, 11, 12 or 13 ring atoms or a tricyclic heteroaryl group, wherein R ¹ and benzene ring A are bonded to the first ring, and Ar is bonded to the first ring, the second ring or the third ring; the limitation is that when the compound is as follows When expressed: (I') One or more of the following: R ¹ ' is H, cycloalkyl, halocycloalkyl, halogen, nitrile, alkyl decylamine or nitro; Ar' is optionally substituted and is one of the following : thick tetraphenyl, propylene naphthalene, fluorenyl, Phenyl, morphinyl, acridinyl, phenanthrene Base, carbazolyl, dibenzofuranyl, quinolyl, isoquinolinyl, quin Lolinyl, quinazolinyl, bipyridyl, pyridyl, pyridyl , Pyrimidinyl, indolyl, benzimidazolyl, benzoxazolyl, benzofuranyl and indenyl group; R ² 'system H, and R ^3' amine based sulfonylureas, sulfinyl, alkylated Amino hydrazine, alkylamino hydrazide, α-aminocarbonyl other than glycine, β-aminocarbonyl, γ-aminocarbonyl, or α-β-unsaturated carbonyl; or structural formula (I' ) of the aniline nitrogen, R ² and R ³ form an optionally substituted heterocyclic group of. In the case of the kit of claim 84, the specification instructs the user to perform the method of any one of claims 1 to 49. The kit of claim 84, which comprises a compound according to any one of claims 50 to 78, or a pharmaceutical composition according to any one of claims 79 to 83.